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Histone demethylases are involved in transcriptional regulation and have recently been 
implicated in human diseases including cancer. KDM5B belongs to the KDM5 family of 
histone demethylases, which catalyse the removal of the methyl group from the active 
tri-methyl mark, H3K4me3, thereby regulating transcription. KDM5B was first identified 
in our lab as being downregulated when HER2 was inhibited by Trastuzumab 
(Herceptin). KDM5B is widely expressed in breast cancer and other cancers, where it 
may act by repressing genes such as Caveolin1 (CAV1). Recent studies have implicated 
KDM5 proteins in resistance to targeted therapies and so considerable effort is being 
employed to develop KDM5 small molecule inhibitors. A role for KDM5B in mammary 
gland development has also been demonstrated. In the mouse model lacking 
demethylase activity (DARID mouse), KDM5B has been shown to repress CAV1 in the 
mid-pregnant mammary gland. Thus, suggesting similar pathways operate in the normal 
and malignant mammary gland.  
This PhD aimed to further understand the role of KDM5B in breast cancer and in the 
normal mammary gland. The first aim was to generate KDM5B knockout (KO) breast 
cancer cell line models using CRISPR-Cas9 technology and investigate the effect of this 
modulation on gene expression, proliferation and drug resistance. The second aim was 
to investigate the extent of CAV1 downregulation by KDM5B in breast cancer and, 
identify the cell types where this downregulation may occur in the developing mammary 
gland. 
KDM5B KO cell lines were generated in two HER2+ breast cancer cell lines, BT-474 and 
SKBr3. KDM5B KO significantly reduced cell proliferation of SKBr3, but not BT-474 cells 
in cell viability assays. Treatment of KDM5B KO cells with Herceptin and Lapatinib, 
showed increased sensitivity to Herceptin in BT-474. There was no significant increase 
in sensitivity to Lapatinib in the KDM5B KO cells. Microarray gene expression analysis 
in the SKBr3 KDM5B KO was used to elucidate targets of KDM5B and revealed the early 
response gene EGR1, in addition to CAV1 and MYC, to be amongst the top upregulated 
genes. Surprisingly, CAV1 was not upregulated in BT-474 KO cells. 
Immunohistochemistry analysis showed co-localisation of CAV1 and KDM5B in the 
myoepithelial and stromal cells, in the mid-pregnant mouse mammary gland.  
The data demonstrate a cell phenotype dependent role for the function of KDM5B and 
the importance of pre-clinical investigations for potential therapeutic targets. These cell 
line models can be used to identify novel mechanisms through which KDM5B promotes 
cancer progression and drug resistance in breast cancer. This will in turn enable 
interrogation of these mechanisms for the development of novel therapies. 
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BRSM1                   Breast	cancer	metastasis	suppressor	1		




Cas                           CRISPR	associated		
CAV1                     Caveolin-1		
Cba                        Chicken	beta	actin		
ccRCC                      Clear	cell	renal	carcinoma		
CDK                               Cyclin	dependent	kinase		
cDNA                        Complementary	DNA	
CGI                          CpG	Islands		
CHD4                      Chromodomain	helicase	DNA	binding	protein	4		
ChIP                      Chromatin	immunoprecipitation		
CN                           Copy	number		
COC                      Combined	oral	contraceptives		
CRISPR              Clustered,	regularly	interspaced,	short	palindromic	repeat	
CRPC                    Castration	resistant	prostate	cancer		
crRNA                       CRISPR	RNA		
CSD                       Caveolin	scaffolding	domain		
Ct                             Cycle	threshold		
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CTSZ                     Cathepsin	Z		
	  
D  
DCIS                      Ductal	carcinoma	in	situ		
DMEM                    Dulbecco’s	Modified	Eagle’s	Medium		
DMSO                    Dimethyl	sulfoxide		
DNMT                DNA	methyltransferase	
DOTL                     DOT1-like		
Dri                           Dead	ringer		
DSB                       Double	strand	break		
	  
E  
ECL                      Enhanced	chemiluminescence		
EGF                     Epidermal	growth	factor		
EGFR                   EGF	receptor		
EGR1                   Early	growth	response	gene	1		
ER                       Estrogen	receptor		
ESC                     Embryonic	stem	cell		
ET                         Endocrine	therapy		
	  
F  
F                          Forward	
FACS                 Fluorescence-activated	cell	sorting		
FAD                    Flavine	adenine	dinucleotide		
FBS                     Fetal	Bovine	Serum		
FDR                    False	discovery	rate		
FI                        Fluorescent	intensity		
	  
G  
GE                    Gene	expression	
GFP                 Green	fluorescent	protein		
GO                   Gene	Ontology	




HCC                 Hepatocellular	carcinoma		
HCl                Hydrochloric	acid		
HDACi             Histone	deacetylase	inhibitor	
HDAC            Histone	deacetylase	
HDR                Homology	directed	repair		
HER2             Human	epidermal	growth	factor	receptor	2		
HR                   Homologous	recombination		





IDAA              Indel	detection	by	amplicon	analysis		
IGF-1R           Insulin	like	growth	factor	1	receptor		
	  
J  
JAK2              Janus	kinase	2		
JARID            Jumonji	AT-rich	interactive	domain		
JmjC               Jumonji	C		
JmjN               N-terminal	Jumonji		
	  
K  
KD                 Knockdown		
KDM         Lysine	demethylase	
KMT        Lysine	methyltransferase	
KO                 Knockout			
	  
L  
LB                   Lysogeny	broth		
LCN2              Lipocalin	2		
Lid                  Little	imaginal	disk	
LSD                Lysine	specific	demethylase		
LumA              Luminal	A			
LumB              Luminal	B		
	  
M  
MAPK             Mitogen	activated	protein	kinase		
MBD                Methyl-CpG	binding	domain		
MEC        Mammary	epithelial	cell	
MEF2               Myocyte	enhancer	factor	2		
mESC             Mouse	embryonic	stem	cell		
METABRIC      Molecular	Taxonomy	of	Breast	Cancer	International	Consortium			
miRNA             MicroRNA	
mRNA             Messenger	RNA		
mTOR            Mammalian	target	of	rapamycin		
MTT             Thiazolyl	blue	tetrazolium	bromide		
	  
N  
NaN3                          Sodium	Azide	
NaOAc              Sodium	acetate	
NaOH                Sodium	hydroxide	
NF-kB              Nuclear	factor–kB		
NHEJ               Non-homologous	end	joining		
NHSBSP         National	Health	Service	breast	screening	programme		
NK                   Natural	killer		
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NMD                 Nonsense-mediated	decay		
Nt                     Nucleotide		
NuRD               Nucleosome	remodelling	and	deacetylase		
	  
O  
OD                 Optical	density		
OSCC            Oral	squamous	cell	carcinoma		
	  
P  
PAM                 Protospacer	adjacent	motif			
PAM50              Prediction	analysis	of	microarray	50		
PARP                Poly	(ADP-ribose)	polymerase		
PAX-9                Paired	box	9		
PBS                   Phosphate	buffered	saline		
PD-1                  Programmed	cell	death-1		
PDL-1               Programmed	death	ligand	1		
PHD                  Plant	homeodomain		
pHER2               Phosphorylated	HER2		
PI3K                  Phosphoinositide	3-kinase		
PIK3CA             Phosphatidylinositol-4,5-bisphosphate	3-Kinase	Catalytic	Subunit	
Alpha		
PLCg1               Phospholipase	C	gamma	1		
PMSF                Phenylmethylsulfonyl	fluoride		
PR                    Progesterone	receptor		
pRb                   Retinoblastoma	binding	protein		
PRC2                Polycomb	repressive	complex	2		
Prl                     Prolactin		
Prl-R                 Prolactin	receptor		
PRMT             Protein	arginine	methyltransferase		
pSTAT5             Phosphorylated	STAT5		
PTEN                 Phosphatase	and	tensin	homolog		
PTM                 Post-translational	modification		
 	
Q	  
qRT-PCR          quantitative	reverse	transcriptase	polymerase	chain	reaction	 
 	
R	  
R                       Reverse	 
RA                      Retinoic	acid		
RIN                    RNA	integrity	number		
RNAi                 RNA	interference		
RPMI                  Roswell	Park	Memorial	Institute	1640		
 	
S	  
SAM                       S-adenosylmethionine 
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SDS-PAGE             Sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis		
SERM                   Selective	estrogen	modulator		
SET                         SU(VAR)3-9,	Enhancer	of	zeste	and	Trithorax		
sgRNA                     Single	guide	RNA		
shRNA                     short	hairpin	RNA		
SLC40A1                Solute	carrier	family	40	member	1		
SNP                          Single	Nucleotide	Polymorphism		
SOC                         Super	optimal	broth	with	catabolite	repression		
STAT                        Signal	transducers	and	activators	of	transcription		
SWIRM                   SWI3,	RSC8	and	Moira	
 	
T	  
T-DM1          Trastuzumab	emtansine	 
TALEN      Transcription	activator-like	effector	nucleases		
TBS              Tris-buffered	saline	
TBST            Tris-buffered	saline/Tween		
TCGA          The	Cancer	Genome	Atlas		
TEB              Triton	Extraction	buffer		
TET             Ten-eleven	translocation		
TFAP2C        Transcription	factor	AP-2	gamma			
TGFb            Transforming	growth	factor-beta	
TN                 Triple	negative		
TNBC           Triple	negative	breast	cancer		
TNC             Tenascin	C		
 	
U 	
UK             United	Kingdom		
UNG         	 Uracil-DNA	glycosylase	 
UPR          Unfolded	protein	response	 
 	
W 	
WT            Wild-type		
	  
Z  









































1.1 The normal mammary gland: steroid hormones in 
development and tumorigenesis 
The adult breast is made up of branched, tree-like structures of ducts that are lined by 
two layers of epithelial cells and surrounded by fibroblasts and adipose tissue (reviewed 
by 1). The lobules, also known as terminal ductal lobular unit (TDLU), are the milk-
producing component of the breast. Maturation of lobules from alveolar buds into 
secretory sacs known as alveoli, occurs after menarche and becomes fully developed 
during pregnancy, when they expand in preparation for lactation. The lobules involute 
after lactation, resembling those in the non-pregnant gland, although the number of 
alveoli per lobule may increase over those seen before pregnancy. Alveoli consist of an 
inner layer of luminal epithelial and an outer basal, myoepithelial cell layer which contacts 
the basement membrane. Proliferation of epithelial cells occurs mainly in the luminal 
cells of the non-pregnant gland. Histopathologically, epithelial hyperplasia and 
carcinoma of the breast arise from the lobules.  
During normal human mammary gland development, the ovarian steroids estrogen and 
progesterone, play a crucial role 2. These hormones act through nuclear receptors found 
predominantly on female reproductive tissues, to exert their function. The estrogen 
receptor (ER) and progesterone receptor (PR) are found on luminal epithelial cells 3, 
where they regulate expression of specific genes when bound to their ligands. Discovery 
of a second ER gene 4, led to renaming the classic ER protein as ERa and the new 
receptor as ERb. In the normal breast, ERa expression is restricted to luminal epithelial 
cells, whereas ERb is more widely expressed, as it is also expressed in the myoepithelial, 
endothelial, stromal cells and lymphocytes 5. PR also has two isoforms namely PRA and 
PRB 6. Although both PRA and PRB are expressed at the same level and in the same 
cells 7, PRB appears to be the active PR 6.  
In the premenopausal breast, steroid hormones promote proliferation of approximately 
5% epithelial cells, which surprisingly do not express the gene encoding ER (ESRA)8. 
These cells are instead adjacent or in close proximity to cells that express ESRA, thus 
suggesting that proliferation of ERa-negative (ERa-) cells occurs through paracrine 
factors secreted by ERa-positive (ERa+) cells, in response to estrogen  (reviewed by 1). 
Indeed, several studies have reported that steroid receptor synthesis in the mammary 
epithelium is dissociated from cell proliferation 9–11. This dissociation is however 
dysregulated in the early stages of breast tumorigenesis, as observed by increased 
proliferating ERa+ cells 12, which are dependent on estrogen for their growth 12.  
Contrastingly, expression of ERb decreases in the transition from normal to malignant 
cells and correlates with reduced proliferation and pathological grade 13. ERb  expression 
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has been observed in approximately 70% of invasive breast cancers 14,15 and a subset 
of these tumours also express ERa 15. ERb is also expressed in a subset of ER- breast 
cancers 15, which are usually characterised by overexpression of genes encoding growth 
factor receptors such as human epidermal growth factor receptor 2 (HER2) 16. The role 
of ERb in ERa+ breast cancers however, has not yet been determined. ERb exerts an 
anti-proliferative function in ERa+ breast cancer cells 17 and is believed to negatively 
regulate ERa signalling. The exact role of ERb in breast cancer however, remains 
unclear. Currently, clinical decisions are based solely on expression of ERa, which is 
also the targeted receptor in breast cancer therapies.  
Alterations in PRA and PRB during breast tumorigenesis have also been observed, 
where PRA is the predominantly expressed isoform in atypical ductal hyperplasia, ductal 
carcinoma in situ (DCIS) and invasive tumours 7. PR expression is generally associated 






















1.2 Breast Cancer  
	
1.2.1 Epidemiology 
Breast cancer is the most common cancer and leading cause of cancer death in women 
worldwide, with an estimated 1.7 million cases and 521,900 deaths reported in 2012 19,20. 
In the United Kingdom (UK), breast cancer is the most common cancer and the second 
leading cause of cancer death in women, with 54,833 cases and 11,360 deaths reported 
in 2014 (Fig 1.1 and 1.2) 21. Of the total breast cancer cases in UK (2014), 389 (around 
1%) were reported in males. It is estimated that 1 in 8 women and 1 in 870 men, will be 
diagnosed with breast cancer in their lifetime. Although breast cancer incidence has 
increased since the early 1990s, mortality rates have decreased over time 22. This is 
mainly attributed to advances in medicine which have led to early detection of the 
disease and better treatment strategies, as discussed below. 	
 
 
Figure 1.1: Twenty most common cancers, UK (2014). Breast cancer is the most common 
cancer in UK. 
 


























Figure 1.2: Ten most common causes of cancer death in females, UK (2014). Breast cancer 
is the second most common cause of cancer death in females. 
 
 
1.2.2 Risk factors 
Breast cancer is mostly diagnosed in older age groups, with 48% of diagnoses occurring 
in women aged 65 and over 21. Less than 10% of breast cancers are attributed to an 
inherited genetic mutation, whilst the majority are attributed to reproductive, lifestyle and 
environmental factors. These risk factors are summarised in Table 1.1 and show their 
associate relative risk 23. Relative risk indicates the risk for an individual who is positive 
for a factor versus who is negative for that same factor. A relative risk of 1 denotes no 


































      Table 1.1: Risk factors associated with Breast Cancer 
*It has been suggested that these relative risks may overestimate the true risk associated with 
germline mutations in BRCA genes as they are subject to ascertainment bias38. 
 
Risk Factor Category at risk Comparison 
category 
Relative Risk 
Age 24 Women aged 65 and 
over 
Women aged less 
than 65  
5.8 
Reproductive Factors    
Age of menarche 25 Menses before age 
12  
Menses after age 
15  
1.3 





Age of first birth 27,28 Nulliparous or first 
child after 30 years 





   
Alcohol consumption 29 2 drinks/day Non-drinker 1.2 
Body Mass Index 30 80th percentile, age 
55 
20th percentile 1.2 
Radiation exposure 31,32 Receiving radiation 










Genetic Factors    
Family history 33 First degree relative 
at ³50 years with 
postmenopausal 
breast cancer 





relative with breast 
cancer 
 
Two first degree 
relative with breast 
cancer 
No first or second 
degree relative with 
breast cancer 
No first or second 
degree relative with 
breast cancer 
No first or second 
degree relative with 
breast cancer 
No first or second 












Genetic mutations 34 Women aged <40 
years who are 
heterozygous for 
BRCA1 





for BRCA1 at age 
<40 
Not heterozygous 





Exogenous hormones    
Hormone replacement 
therapy with estrogen and 
progesterone 35 
Current user for at 
least 5 years 
Never used 1.3 
Past history of breast 
cancer 36,37 
Previous history of 
invasive breast 
carcinoma 





1.2.3 Breast Cancer screening  
Population based screening of breast cancer is carried out using mammography. 
Mammography involves taking two radiographs of each breast to detect changes in 
breast tissue 39. In England, the National Health Service breast screening programme 
(NHSBSP) offers free breast screening for women aged 50-70, every three years 40. 
Women at a higher risk of developing breast cancer are however screened at an earlier 
age. Approximately 1300 lives are saved per year, as a result of mammography 
screening 41. 
 
1.2.4 Histological and Molecular classification of Breast Cancer 
For many years, breast cancer was considered a single disease with diverse 
histopathological features and a range of clinical behaviours. It was later determined that 
breast cancer could be divided into two groups, according to expression of ER. 
Traditionally, treatment strategies were based on clinicopathological features that had 
prognostic value such as, histological type, histological grade, lymph node metastasis 
and expression of predictive markers (ER, PR and HER2) (reviewed by 42). Advances in 
gene expression analysis using high throughput platforms, have demonstrated that 
breast cancer is a heterogeneous disease consisting of multiple subtypes with distinct 
histological patterns, biological features and clinical outcome 43,44.  
Perou and colleagues were the first to demonstrate that breast cancer can be classified 
into distinct molecular subtypes43. The authors revealed that ER+ and ER- breast 
cancers are molecularly distinct tumours, based on their expression of an ‘intrinsic gene 
subset’. Furthermore, clustering analysis identified four distinct molecular breast cancer 
subtypes namely luminal, HER2-positive (HER2+), basal-like and normal-like. Using a 
larger cohort, Sorlie and colleagues later confirmed this classification and found that the 
luminal subtype could be further divided into 2 groups namely luminal A and luminal B44 
(Table 1.2). The luminal subtype corresponds to ER+ tumours and their division into two 
subgroups is based on expression of proliferation-related genes. The HER2+ subtype 
consists of tumours that have HER2 amplification and generally express low levels of 
ER. HER2+ tumours that also express ER are classified under the luminal B subtype. 
Basal-like breast cancers are characterised by the absence or low levels of ER and ER 
related genes including PR, general lack of HER2 overexpression (i.e. triple negative), 
high expression of proliferation related genes and genes associated with basal epithelial 
cells (e.g. cytokeratin 5/6 and 17). The normal-like subtype was found to express high 
levels of genes associated with adipose tissue and normal breast tissue. Recent studies 
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have however demonstrated that tumours classified under the normal-like subtype, may 
be an artefact of having a high proportion of normal tissue in the tumour specimen 45.  
These molecular subtypes have also been shown to be clinically relevant, as observed 
by better disease-free and overall survival of luminal A tumours in comparison to the 
other subtypes 44. Luminal B tumours have an intermediate outcome, whereas basal-like 
and HER2+ subtypes displayed the shortest survival times (Table 1.2). To further 
evaluate the prognostic value of these ‘intrinsic subtypes’, a study by Parker and 
colleagues, developed a 50-gene prognostic model for node negative breast cancer, 
using the intrinsic subtypes and clinical information 45. The assay was termed ‘prediction 
analysis of microarray 50 (PAM 50)’, and demonstrated that intrinsic subtypes can be 
used to predict efficacy to neoadjuvant chemotherapy. Further validation is however still 
required before this assay can be used in the clinic.  
 




Basal-like ER-, PR-, HER2+/- Poor 
Luminal A ER+, PR+/-, HER2- Good 
Luminal B ER+, PR+/-, HER2+/- Intermediate 
HER2+ ER+/-, PR-, HER2+ Poor 
Normal-like ER+/-, PR+/-, HER2- Intermediate 
 
More recently, in an effort to further define breast cancer subtypes, an integrated analysis 
using genomic and transcriptomic data from 2000 breast tumours was used46. Through 
joint clustering of copy number and gene expression data, the authors identified 10 
integrative clusters/subgroups labelled as ‘IntClust 1-10’. These 10 subgroups were 
defined by their copy number profiles and showed distinct clinical outcomes. Surprisingly, 
a subgroup of ER+ tumours (IntClust 2) was found to be high risk, since they displayed 
poor clinical outcome. This work revealed novel subgroups and demonstrated the effect 
of copy number aberrations on gene expression, in breast cancer.  
Gene expression profiling has also been used to develop breast cancer prognostic 
signatures. These prognostic signatures are used to predict clinical outcome of individual 
patients and to identify patients requiring adjuvant chemotherapy. A prognostic signature 
that is currently approved in the NHS, is Oncotype DX. Oncotype Dx is a quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR)-based assay, that 
measures expression of 21 genes associated with ER and HER2 signalling and cell 
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proliferation 47. It is the most widely used assay for prognosis and prediction analysis, 
and has been suggested as a decision-making tool for adjuvant chemotherapy in ER 
positive, lymph node negative and HER2 negative early breast cancer 48. 
 
1.2.5 Breast Cancer Treatment  
The main standard treatments for breast cancer include, surgery, radiotherapy, 
chemotherapy, hormone/endocrine therapy and targeted therapy 49. Currently, breast 
cancer patients are often given a combination of standard treatments, as well as optional 
complementary treatments that range from acupuncture to diet management. Surgery 
and radiotherapy are used mainly to remove the primary breast tumour and any 
surrounding cancerous tissue. Chemotherapy and targeted therapies on the other hand, 
reduce tumour burden and also prevent, control or treat cancer metastasis and/or 
resistance (reviewed by 50). Hormone and targeted therapies are discussed in more 
detail below.  
 
1.2.5.1 Endocrine/Hormone therapy 
The majority of breast cancers (approximately 70%) are ER+ and so constitute the 
largest clinical group 43. Since these cancers are driven by the hormone estrogen, ER+ 
breast cancers are normally treated with endocrine therapy (ET) which can be given in 
the neo-adjuvant, adjuvant and metastatic setting. ET include selective estrogen 
modulators (SERMs) and aromatase inhibitors. Tamoxifen was the first SERM to be 
approved for the adjuvant treatment of ER+ breast cancer, and has reduced breast 
cancer recurrence by approximately 40-50% in women with early breast cancer 51. 
Overall, the use of Tamoxifen has reduced the yearly breast cancer mortality rate by one 
third 51. Tamoxifen has also been approved for the prevention of breast cancer in high 
risk pre-and post-menopausal women 52. Another SERM, Raloxifene has also been 
approved as a preventive treatment for post-menopausal women with osteoporosis or 
women at high risk of invasive breast cancer 53. Although Raloxifene is not as effective 
as Tamoxifen in preventing invasive breast cancer, it has fewer side effects and so might 
be preferred by some patients. Aromatase inhibitors such as anastrozole, exemestane 




1.2.5.2 Targeted therapies 
	
1.2.5.2.1 PARP inhibitors 
Breast cancers that lack overexpression of HER2, ER and PR are referred to as triple 
negative breast cancer (TNBC). Approximately 20% of breast cancers are of the TNBC 
subtype 54, of which around 75% are characteristic of the basal-like molecular subtype 
55. TNBC represents the most aggressive phenotype of breast cancer 44,55 and currently, 
specific targeted therapies to TNBC are unavailable. Standard treatment for TNBC 
patients is chemotherapy, particularly anthracycline and taxanes (reviewed by 56).   
Although genetic predisposition to TNBC has not been widely studied, the frequency of 
TNBC in BRCA1 and BRCA2 mutation carriers was found to be 57% and 23%, 
respectively 57. Approximately 20% of TNBC cases harbour BRCA1 (15.6%) or BRCA2 
mutations (3.9%) 58. BRCA-related breast cancers are often characterised by genomic 
instability and an aberrant homologous recombination DNA repair pathway 59. Targeting 
these aberrations using agents such as Poly (ADP-ribose) polymerase (PARP) 
inhibitors, are potential therapeutic strategies. PARP enzymes are involved in single 
strand break DNA repair. Inactivation of the BRCA1 and/or BRCA2 genes allows for DNA 
repair via PARP enzymes, and so presents a mechanism through which cancer cells can 
continue to grow 60. Blocking PARP enzymes in BRCA1/2 mutated cells, blocks the only 
functioning DNA repair pathway and so results in tumour cell death, due to synthetic 
lethality 60. PARP inhibitors for the treatment of BRCA1 mutation carriers are currently 
being investigated in clinical trials (NCT00516373) and indeed Olaparib has been 
approved by the FDA and NICE for the treatment of advanced Ovarian cancer patients 
with germline BRCA mutations 61.  
 
1.2.5.2.2 Immunotherapy 
Breast cancer was considered a non-immunogenic disease for many years. Recently 
however, the HER2 and TNBC subtypes have been shown to be characterised by an 
immune infiltrate. The aim of immunotherapy is to activate the immune response so it 
recognises tumours as foreign entities, eventually killing them. Expression of 
programmed death ligand 1 (PDL-1) has been observed in breast cancer clinical 
samples, particularly in TNBC tumours and cell lines 62,63. PDL-1 is a ligand for the 
immune checkpoint receptor, programmed cell death-1 (PD-1) found on T cells, which 
negatively regulates their function, preventing autoimmunity and inflammatory response 
64. Thus, blocking PD-1 and PDL-1, should enhance antibody function in cancer patients. 
Currently, there are several clinical trials that are investigating the efficacy of inhibiting 
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the PD-1/PDL-1 axis with specific antibodies, for treatment of TNBC and HER2+ breast 
cancer (reviewed by 65,66). Several other immunotherapy modalities  are also currently 
being evaluated for their efficacy (reviewed by 66). 
 
1.2.5.2.3 HER2 targeted therapies 
Amplification of HER2 is observed in approximately 20% of breast carcinomas  and is 
associated with increased disease progression and poor prognosis67. HER2 is a 
transmembrane tyrosine kinase belonging to the EGF receptor (EGFR/HER) family 
(reviewed by 68). This family constitutes of four members (EGFR/HER1, HER2, HER3 
and HER4), which stimulate various signalling pathways (Fig 1.3). Of these four 
members, HER2 has a unique feature, in that it does not have a known ligand. HER2 is 
the favoured dimerization partner of the other EGFR/HER family members, with robust 
signalling activity observed between EGFR/HER2 and HER2/HER3 heterodimers. HER2 
can also form homodimers, which become functional upon overexpression of HER2.  
The first drug that was approved by the FDA for the treatment of HER2+ breast cancers 
was the monoclonal antibody, Trastuzumab (Herceptin)69,70. Although Herceptin 
treatment improved overall survival of HER2+ breast cancer patients with advanced 
disease, a subset of patients did not respond to treatment. Furthermore, most of the 
patients who initially responded, later acquired resistance 69,70. This therefore led to 
development of additional approaches of targeting HER2 which have included: 
development of antibodies that bind to different sites of HER2 compared to Herceptin 
such as Pertuzumab 71; HER2 tyrosine kinase inhibitors such as Lapatinib 72; and 
antibody-drug conjugates such as Trastuzumab emtansine (T-DM1) 73. Currently, five 
drugs have been approved for the treatment of HER2+ breast cancer: Trastuzumab 
(Herceptin), Pertuzumab, Trastuzumab emtansine (T-DM1), Lapatinib and Neratinib (Fig 
1.3). These HER2 targeted therapies are discussed below. 
 
1.2.5.2.3.1 Trastuzumab (Herceptin) 
Herceptin is a monoclonal antibody that binds to the extracellular domain IV of HER2 74. 
Herceptin is currently administered in combination with chemotherapy in the adjuvant 
setting, to early stage HER2+ breast cancer patients, for one year 49. This treatment 
regimen has proven to be beneficial, since it has resulted in 40% fewer cancer 
recurrences and 34% fewer deaths 75. Herceptin is also administered in combination with 
Pertuzumab and the chemotherapeutic agent docetaxel, in the neoadjuvant setting, for 
patients with advanced or early stage HER2+ breast cancer 49,76.  
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Different modes of action have been suggested for Herceptin which include suppression 
of downstream mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling pathways 77,78, blocking 
ligand-independent HER2/HER3 heterodimerization 78 and antibody-dependent cellular 
cytotoxicity (ADCC) through engaging natural killer (NK) cells 79,80.  
 
1.2.5.2.3.2 Trastuzumab emtansine (T-DM1) 
T-DM1 is an antibody-drug conjugate where Trastuzumab is linked with the microtubule 
toxin, emtansine. Upon binding to HER2, the conjugate is internalized and emtansine is 
released into the cell, leading to cell death 81. T-DM1 is used for the treatment of 
advanced HER2+ breast cancer 82,83.  
 
1.2.5.2.3.3 Pertuzumab  
Pertuzumab is a monoclonal antibody that binds to the extracellular domain II of HER2, 
therefore inhibiting HER2 dimerization with other HER proteins, particularly HER3 71. Like 
Herceptin, Pertuzumab also activates ADCC with equivalent efficacy, resulting in cell 
death 84. As aforementioned, Pertuzumab is administered in the neo-adjuvant setting, in 
combination with Herceptin and docetaxel in advanced and early stage HER2+ breast 






Figure 1.3: HER2 signalling pathway and targeted therapies. The human epidermal growth 
factor (EGF) receptor family (HER1, HER2, HER3, HER4), are receptor tyrosine kinases involved 
in signalling pathways that lead to biological processes such as cell cycle control and proliferation. 
The HER proteins are made up of an extracellular binding domain, a transmembrane domain and 
an intracellular tyrosine kinase domain (with the exception of HER3 which has no kinase activity). 
Upon binding of a ligand to the extracellular binding domain of a HER receptor, the receptor forms 
homodimers or heterodimers with other HER family members. HER2 is the only receptor that 
does not have a ligand and is the preferential dimerization partner of the other members of the 
HER family. Homo-and hetero-dimerization results in phosphorylation of the tyrosine kinase 
domain therefore activating downstream signalling pathways including the PI3K-AKT-mTOR and 
the MAPK (also known as RAS-RAF-MEK-ERK) pathways. These pathways are involved in cell 
cycle control, proliferation and apoptosis. Current HER2 targeted therapies for the treatment of 
HER2+ breast cancer includes: A) Trastuzumab, a monoclonal antibody that binds to extracellular 
domain IV of the HER2 receptor. Different modes of action of Trastuzumab have been suggested 
including inhibiting downstream signalling pathways such as PI3K/AKT pathway. B) T-DM1, an 
antibody-drug conjugate consisting of Trastuzumab and DM1(the highly potent antimitotic drug, 
emantansine), binds to the extracellular domain of HER2 and allowing for delivery of DM1 to the 
cell. C) Pertuzumab, a monoclonal antibody that binds to extracellular domain II of HER2 thereby 
inhibiting dimerization of HER2 with other HER family members, especially with HER3. D) 
Lapatinib is a dual tyrosine kinase inhibitor targeting HER1 and HER2 and has been shown to 




Lapatinib is a dual EGFR and HER2 tyrosine kinase inhibitor, used for the treatment of 
metastatic HER2+ breast cancer 49. Lapatinib has been shown to inhibit the activation of 
MAPK, PI3K-AKT and phospholipase C gamma 1 (PLCg1) pathways due to reduced 
phosphorylation of the targeted receptors 72, thus resulting in reduced cell proliferation, 
metastasis, migration and increased apoptosis. Lapatinib is usually given in combination 
with the chemotherapy agent capecitabine, to breast cancer patients who have 
previously been treated with Herceptin, anthracycline and taxane 85,86. Furthermore, 




































of  hormone receptor positive and HER2+ metastatic breast cancer 87. Combination of 
Lapatinib and Herceptin has also been shown to be more beneficial than single agents, 
in the neoadjuvant setting 88.  
 
1.2.5.2.3.5 Neratinib 
Neratinib is a pan-tyrosine kinase inhibitor of the EGFR/HER family, that binds to their 
kinase domain therefore inhibiting downstream signalling 89. In a phase III trial, HER2+ 
breast cancer patients that received Neratinib for 12 months following chemotherapy and 
Herceptin-based adjuvant therapy, showed improved 2-year invasive disease-free 
survival, compared to patients who did not receive Neratinib treatment 90. The results of 
this study, have led to Neratinib being approved by the FDA for treatment of early stage 
HER2+ breast cancer, following Herceptin-based adjuvant therapy 91.  
 
1.2.5.3 Mechanisms of resistance in HER2 targeted therapies 
Studies in this project were based on the HER2+ breast cancer subtype. Therefore, the 
mechanisms of resistance to HER2 targeted therapy will be discussed below.  
Although HER2 targeted therapies have improved patient survival, most patients acquire 
resistance or exhibit primary resistance to these therapies. Various mechanisms of 
resistance have been proposed which can be classified as factors associated with either 
HER2 receptor level or components of downstream signalling pathways. Recent studies 
have also shown a role for epigenetics in promoting resistance of HER2+ breast cancers.  
 
1.2.5.3.1 HER2 receptor  
Mutation of HER2 results in a truncated protein, p95HER2, that lacks the extracellular 
domain binds and so is unable to bind to Trastuzumab 92. The p95HER2 protein arises 
through extracellular domain shedding by a metalloprotease e.g. ADAM10 or by 
alternative translation of HER2 mRNA 93.  Expression of p95HER2 protein has been 
associated with Trastuzumab resistance 94,95. Since this protein still has constitutive 
kinase activity, HER2+ breast cancer cells expressing p95HER2 have been shown to be 
sensitive to the HER2 tyrosine kinase inhibitors Lapatinib 94.  
A HER2 splice variant (HER2D16 ) has been reported in breast cancer cell lines 96 and 
breast tumours 97. HER2D16 is characterised by a 16-amino acid exon that is deleted in 
the extracellular domain 96. The deleted exon was found to contain two cysteine residues 
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that were critical for HER2 transformation activity 96. HER2D16 expression is tumour 
specific and has been shown to confer Trastuzumab resistance in breast cancer cell lines 
98. These functions of HER2D16 were found to be mediated by Src kinase, since 
treatment with the tyrosine kinase inhibitor, dasatinib, inactivated Src, destabilised 
HER2D16 and inhibited tumorigenecity 98. A phase II clinical trial of dasatinib in advanced 
HER2+ and/or hormone receptor breast cancer patients however, only found one out of 
24 HER2+ patients previously treated with anti-HER2 therapies, showing a partial 
response 99.  
Hsp90 is a chaperone protein that activates several oncoproteins including HER2 100. 
Inhibition of Hsp90 has been shown to reduce the anti-tumour activity of Trastuzumab 
resistant and Trastuzumab sensitive xenografts and could potentially be a novel 
therapeutic strategy for the treatment of HER2+ breast cancers 101,102.  
Loss of HER2 amplification following neoadjuvant Herceptin-based therapy has also 
been observed in patients with residual disease 103 and so may contribute to resistance.  
 
1.2.5.3.2 Downstream signalling pathways 
Activation of the PI3K/AKT pathway due to decreased phosphatase and tensin homolog 
(PTEN) expression and oncogenic mutations in phosphatidylinositol-4,5-bisphosphate 3-
Kinase Catalytic Subunit Alpha (PIK3CA), have been associated with Herceptin 
resistance in breast cancer cell lines and tumours 104. Similarly, loss of PTEN and 
PIK3CA mutations also confer Lapatinib resistance in breast cancer cell lines and 
xenograft models 105. A later study showed that inhibition of HER2 using Lapatinib 
conferred resistance in breast cancer xenograft models and patients, through 
upregulation of ER and the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) 106. 
Interestingly, the authors showed that 18% of tumours treated with Lapatinib in the 
neoadjuvant setting converted from ER- to ER+, thus providing an ER-dependent 
mechanism for survival.  
Crosstalk between HER2 and insulin like growth factor 1 receptor (IGF-1R), has also 
been shown to promote Herceptin resistance, since inhibition of IGF-1R kinase activity 
led to decreased HER2 phosphorylation in resistant cells and re-sensitised these cells 
to Herceptin 107. Additionally, Herceptin resistant breast cancer cells overexpress HER 
activating ligands, which lead to increased expression of EGFR and HER3 receptors. 
These receptors in turn form heterodimers with HER2, which are not inhibited with 
Herceptin, and so provide a mechanism for resistance through EGFR or HER3 signalling 
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pathways 108. This corresponds to a report showing that inhibition of HER2 reactivates 
HER3 in HER2+ breast cancer cell lines 109. 
 
1.2.5.3.3 A role for Epigenetics in resistance to HER2 targeted therapies  
Various epigenetic proteins have been implicated in resistance to HER2 targeted 
therapies. microRNAs (miRNAs) have been shown to confer resistance to HER2 
targeted therapies through various mechanisms including targeting PTEN and triggering 
nuclear factor–kB (NF-kB) signalling that in turn activates PI3K pathway 110. 
Hypermethylation of transforming-growth factor b1 (TGFb1), B- cell lymphoma 6 (BCL6), 
p53-regulated DNA replication inhibitor (KILLIN) and cathepsin Z (CTSZ) genes, were 
shown to be predictive biomarkers of Herceptin resistance in HER2+ breast cancer cells, 
since treatment with a demethylating agent restored their expression to similar levels 
with Herceptin sensitive cells 111. Histone deacetylases have also been implicated in 
resistance to HER2 targeted therapy. This is demonstrated by treatment of HER2+ 
breast cancer cells with histone deacetylase inhibitors (HDACi) increasing sensitivity to 
Herceptin and lapatinib 112,113, as well as, overcoming Herceptin resistance112. 
Overexpression of histone demethylases (e.g. KDM5 family of histone demethylases) 
have also recently been shown to promote resistance of HER2+ breast cancer cells to 













1.3 Epigenetics and gene expression 
Transcription is a fundamentally important process involving transfer of genetic 
information from DNA to messenger RNA (mRNA). Although this genetic material is the 
same in all cells of an organism, different cell types differ in their gene expression 
patterns, owing to their specific functions. For this reason, transcription is tightly 
regulated to ensure maintenance of gene expression patterns during mitotic cell division. 
This maintenance of gene expression patterns over many cell divisions, occurs through 
inherited information that is not encoded in the DNA sequence, and is known as 
epigenetic information (reviewed by 116).  
Epigenetics therefore describes heritable gene expression changes that occur without 
alterations in the DNA sequence. An additional definition of epigenetics however does 
not include the requirement for heritability. For instance, the US National Institute of 
Health roadmap epigenomics project (http://www.roadmapepigenomics.org) states that 
‘epigenetics refers to both heritable changes in gene activity and expression (in the 
progeny of cells or of individuals) and also stable, long-term, alterations in the 
transcriptional potential of a cell that are not necessarily heritable’. Regardless of 
definition, epigenetic processes that alter gene expression patterns are DNA 
methylation, post-translational modification (PTM) of histone proteins, chromatin 
remodelling and RNA based mechanisms 116. Collectively, epigenetic modifications are 
referred to as the ‘epigenome’. Since the epigenome plays an important role during 
cellular processes such as development and differentiation, inadequate maintenance 
can lead to development of diseases including cancer. Therefore, understanding 
molecular mechanisms driving epigenetic changes in cancer is imperative for the 
development of novel cancer therapies. This PhD thesis is based on a histone protein 
modification enzyme, and so this epigenetic process will be the focus of the discussions 
below. 
 
1.3.1 Histone proteins and regulation of gene expression  
Transcription in eukaryotic cells takes place in chromatin. Chromatin is a complex made 
up of histone proteins and DNA. The basic unit of chromatin is the nucleosome which 
consists of 147 bp of DNA wrapped around an octamer of two copies of each of the four 
core histone proteins (H2A, H2B,H3 and H4) 117,118 (Fig 1.4). Nucleosomes are separated 
by a linker DNA of 10-60bp which associates with a linker histone, H1 117,118. The core 
histones H3 and H4 contain amino-terminal tails that protrude from the nucleosome core 
and undergo PTM at specific amino acid residues. These histone PTM include: 
• Phosphorylation (at serine and threonine residues) 
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• Acetylation (at lysine side chains) 
• Methylation (at lysine and arginine residues) 
• Ubiquitination (at lysine residues) 
• Sumoylation (at lysine residues) 
• ADP ribosylation (at glutamic acid residues)  
Of these histone PTMs, the best characterised are methylation, phosphorylation and 
acetylation 116. Histone PTMs are carried out by specific enzymes known as ‘writers’ and 
are inherited through cell division (reviewed by 119) (Fig 1.4). This epigenetic information 
encoded within histone tails can be read by proteins known as ‘readers’, which in turn 
use this information to alter chromatin structure, thereby regulating transcription (Fig 
1.4). Additionally, there are enzymes that remove these modifications and are so known 
as ‘erasers’ (Fig 1.4). Aberrations in these histone modification factors (writers, readers 
and erases) can contribute to development of diseases such as cancer. This PhD thesis, 
investigates the role of a specific eraser protein (histone lysine demethylase 5B 
(KDM5B)) in breast cancer, and so this group of proteins will be discussed below.  
 
Figure 1.4: Epigenetic modifications in chromatin. The nucleosome, which is the basic unit of 
chromatin consists of a 147 bp of DNA sequence wrapped around an octamer of two copies of 
each of the four core histone proteins (H2A, H2B, H3 and H4). Epigenetic modifications (yellow 
circles) on DNA and histones regulate chromatin accessibility to transcription machinery. These 
epigenetic marks are established by ‘writers’ such as histone lysine methyltransferases (KMT), 
histone acetyltransferases (HATs) and DNA methyltransferases (DNMTs). The marks are in turn 
interpreted by ‘readers’. Epigenetic modifications are reversible, a process mediated by a group 
of enzymes known as ‘erasers’ which include histone demethylases (KDMs), histone 
deacetylases (HDACs) and by the ten-eleven translocation (TET) family of 5-methylcytosine 
oxidases. Epigenetic proteins are important in regulating transcription and establishing and 






1.3.2 Histone methylation  
Histone methylation plays important roles in cellular processes such as transcription and 
genomic stability. Histones can become methylated on arginine or lysine residues by 
enzymes known as histone methyltransferases, which are responsible for catalysing this 
modification (reviewed by 121). These proteins catalyse methylation by adding methyl 
groups to histones using the methyl donor S-adenosylmethionine (SAM). There are three 
families of histone methyltransferases namely protein arginine methyltransferases 
(PRMTs) 122–126 and histone lysine methyltransferases (KMTs) which are divided into two 
groups: SU(VAR)3-9, Enhancer of zeste and Trithorax (SET)-domain methyltransferases 
127,128 and the non-SET domain proteins DOT1 and DOT1-like (DOT1L) 129,130.  
Histones can become mono (me1)-, di (me2)- or tri (me3)- methylated on specific lysine 
residues in histone H3 and H4 proteins, whereas arginine residues can become 
monomethylated (me1), symmetrically dimethylated (me2s) or asymmetrically 
dimethylated (me2a) 131. These modified histones have been shown to associate with 
different chromatin states thereby regulating transcription for example; H3K4me3, 
H3K36me3 and H3K79me3 are associated with active transcription, whereas H3K9me3 
and H3K27me3 are associated with gene silencing 132,133.  
 
1.3.3 Histone demethylases 
Prior to the discovery of lysine specific demethylase 1 (LSD1) 134, histone methylation 
was considered an irreversible epigenetic modification, believed to only be erased upon 
histone exchange or DNA replication. Subsequent studies identified a second family of 
LSD demethylases containing a Jumonji C (JmjC) domain 135–137. Consequently, 
demethylating enzymes of most methylated lysines have now been characterized 138, 
showing histone lysine methylation as a dynamic process regulating individual genes 
through recruitment of methyltransferases and demethylases.  
 
1.3.3.1 	The LSD family of histone demethylases 
LSD1 belongs to the LSD family of histone demethylases which is composed of two 
members: LSD1 (also known as KDM1A, AOF2, BHC110 or KIAA0601) 134 and LSD2 
(also known as KDM1B or AOF1) 139. The LSD proteins contain an amine oxidase-like 
domain (AOL) of catalytic activity and a SWIRM (SWI3, RSC8 and Moira) domain, found 
only in chromatin associated proteins 119. LSD enzymes can only catalyse the 
demethylation of me1 and me2 but not me3 on lysine residues, via an oxidation 
mechanism involving the flavine adenine dinucleotide (FAD) cofactor 140.  
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1.3.3.2 The JmjC domain containing histone demethylases 
The JmjC family contains a catalytic Jumonji domain, present in 32 human proteins, 22 
of which are histone demethylases (Table 1.3) 141. Clustering of these proteins based on 
homology and structural similarities, divides them into seven subfamilies. The catalytic 
mechanism of these enzymes involves an oxidative reaction that requires two cofactors: 
Fe(II) and a-ketoglutarate. This reaction forms an oxoferryl (Fe(iv)=O) intermediate that 
hydrolyxylates the methyl group resulting in an unstable carbinolamine that breaks down, 
to form an unmethylated peptide and formaldehyde (Fig 1.5) 142. This mechanism allows 
JmjC demethylases to demethylate all three methylation states (me1, me2 and me3) on 
histone lysines at H3K4, H3K9, H3K27 and H3K36 135,137,143–146. A prominent group 
among the JmjC histone demethylases, is the KDM5 (JARID1) protein family, whose 
members are involved in development, transcriptional regulation, genomic instability and 
have recently been implicated in progression and drug resistance of numerous cancers.  
 
	
Figure 1.5: The catalytic mechanism of JmjC domain containing histone demethylases. 
This mechanism involves an oxidative reaction that is dependent on Fe(II) and a-ketoglutarate 
co-factors. The KDM5 family specifically demethylate H3K4me3/me2.  
 
1.4 KDM5 histone demethylases 
The KDM5 (also known as Jumonji AT-rich interactive domain (JARID1)) family of 
histone demethylases consist of four members: KDM5A (JARID1A/RBP2), KDM5B 
(JARID1B/PLU-1), KDM5C (JARID1C/SMCX) and KDM5D (JARID1D/SMCY). Single 
orthologues of the KDM5 family exist across species including Drosophila melanogaster 
(Little imaginal disks (Lid)) 147, Caenorhabditis elegans (RBR-2) and Saccharomyces 
cerevisiae (Jhd2p/Yjr119Cp) 148, where they have similar functions as transcriptional 
regulators and chromatin modifiers.  
KDM5 proteins are capable of catalysing the demethylation of di- and tri-methyl 


















of target genes 146,149–151. KDM5A and KDM5B have also been shown to catalyse the 
demethylation of the mono-methylated mark at the same site (H3K4me1), in vivo 145,146. 
Table 1.3: Protein domain and histone substrate of the JmjC histone demethylases  
 
 
** This is not an exhaustive list of aliases. *The PHD3 of KDM5A and KDM5B bind to H3K4me3 
substrate. Modified image from 152. 
 
1.4.1 Structural organisation of KDM5 histone demethylases 
KDM5 histone demethylases have a highly conserved multi-domain structure consisting 
of an N-terminal Jumonji (JmjN) domain, an AT-rich interactive (ARID) domain, a JmjC 












1.6). Despite the conserved sequence homology, the KDM5 proteins have distinct 
structural features, in that KDM5A and KDM5B have two PHD fingers in their C-terminal 
region, whereas KDM5C and KDM5D only have one PHD finger in this region (Fig 1.6).  
 
Among the Jumonji domain containing histone demethylases, the KDM5 family is unique 
in that, their catalytic domain is separated into two subunits (JmjN and JmjC) by insertion 
of the ARID and PHD1 domains (Table 1.3). However, Horton and colleagues have 
shown using a crystal structure, that the two Jumonji subunits (JmjN and JmjC) are linked 
through internal folding, and together with the C-terminal region of the C5HC2 zinc finger 
domain are required for enzymatic activity153. The ARID domain was first identified in the 
mouse B cell specific transcription factor, Bright 154 and the Dead ringer protein (Dri) of 
Drosophila melanogaster 155, as a domain that bound AT-rich sequences. In KDM5B, the 
ARID domain was also found to bind to a GCACA/C consensus sequence 156,157. PHD1 
and PHD3 fingers (numbering of PHD fingers starts from N terminal side of the protein) 
are required for histone tail recognition. PHD1 domain of KDM5A and KDM5B bind to 
unmethylated H3K4 histone tail (H3K4me0) 158,159. In KDM5A, binding of PHD1 to 
H3K4me0 stimulates demethylation of the adjacent H3K4me3 mark, suggesting a model 
for spreading demethylation on chromatin through a positive feedback mechanism 
between the reader and catalytic domains 158. PHD3 of KDM5A and KDM5B specifically 
binds to H3K4me3/me2 marks 159,160. Conservation of structural domains is evident 
amongst the KDM5 homologs present in Drosophila melanogaster (Lid), Caenorhabditis 
elegans (RBR-2) and Saccharomyces cerevisiae (Jhd2p/Yjr119Cp) as observed by 




Figure 1.6: Domain structure of JARID1 histone demethylases. The domain structure of 
KDM5 proteins are conserved across species and consist of a JmjN, ARID, JmjC and C5HC2-
zinc finger, and 2-3 PHD finger domains with the exception of the yeast, which only has one PHD 
finger and does not have a C5HC2 zinc-finger domain. JmjN: N-terminal Jumonji, ARID: AT-rich 





















1.4.2 KDM5 Histone Demethylase Function  
The following section will discuss the function of KDM5A, KDM5C and KDM5D in normal 
development and cancer. The functions of KDM5B will be discussed separately in 
section 1.5. 
 
1.4.2.1 KDM5 proteins in normal development 
KDM5A, was first identified as a retinoblastoma binding protein (pRb) in a cDNA 
expression library 161. A later report showed that KDM5A together with the transcription 
factor E2F4, enhanced Rb’s transcriptional repression of target genes, during embryonic 
stem cell (ESC) differentiation 162. Significantly, KDM5A-/- mice are viable and fertile but 
display behavioural abnormalities 145. Surprisingly, deletion of KDM5A did not alter global 
H3K4me3 levels in mouse embryonic fibroblasts 145, probably due to redundancy of the 
other KDM5 proteins. During embryogenesis both KDM5A and KDM5B demethylate 
broad H3K4me3 domains found in mouse oocytes, which is required for normal 
activation of the zygotic genome and is important for early embryonic development 163. 
 
KDM5C, encoded by the SMCX gene located on the X chromosome, was identified as 
an X-linked gene which during embryogenesis, is able to escape X-inactivation 164. In 
human adult tissue, KDM5C shows strong expression in the brain, lung and skeletal 
muscle; and a moderate to low expression in the pancreas and heart 165. Mutations, as 
well as loss of function of KDM5C are associated with X-linked mental retardation 165,166. 
In mice, KDM5C null mutations were found to be embryonic lethal 167.  
 
KDM5D, encoded by the SMCY gene is only expressed in males being located on the Y 
chromosome, and was reported to be a candidate for the male specific minor 
histocompatibility antigen H-Y 168. KDM5D is moderately expressed in the brain, 
pancreas, skeletal muscle and lung 165 and in spermatogenesis. KDM5D is the least 
studied member of the KDM5 family. 
 
1.4.2.2 KDM5 proteins in Cancer 
KDM5A is overexpressed in gastric and cervical cancer cells, and its depletion leads to 
senescence and growth arrest, possibly due to increased expression of cyclin dependent 
kinase (CDK) inhibitors such as p21 169. Amplification of KDM5A has been reported in 
breast and head and neck cancers170,171. In breast cancer, in vivo studies have shown 
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that KDM5A promotes metastasis to the lungs, through positively regulating metastasis 
related genes such as tenascin C (TNC) 172. Additionally, increased expression of 
KDM5A was found to promote cell proliferation of basal breast cancer cell lines, possibly 
through repressing CDK inhibitors and apoptosis related genes 170. An oncogenic 
translocation between PHD3 of KDM5A and nucleoporin-98 (NUP98), has been shown 
to induce acute myelogenous leukemia (AML) in mice, thereby demonstrating a role of 
KDM5A in oncogenesis of AML 160.  
 
KDM5C acts in a complex with the viral protein E2 to suppress the expression of viral 
oncoproteins E6 and E7 in human papilloma virus-associated cancers 173. In clear cell 
renal carcinoma (ccRCC) 3% of tumours were found to harbour truncating KDM5C 
mutations 174, which can trigger genomic instability 175. On the other hand, 
overexpression of KDM5C has been observed in hepatocellular carcinoma cells, where 
it promotes migration, invasion and metastasis by repressing the bone morphogenetic 
protein 7 (BMP7) 176. KDM5C also promotes cell migration, metastasis and invasion in 
breast cancer by repressing the breast cancer metastasis suppressor 1 (BRSM1) 177. In 
prostate cancer, KDM5C knockdown was found to inhibit proliferation of prostate cancer 
cells 178. Furthermore, nuclear expression of KDM5C was associated with reduced 
prostate-specific antigen relapse free survival, and was proposed to be a prognostic 
marker 178.  
KDM5D was initially reported by Perinchery and colleagues as a gene associated with 
prostate cancer, since it’s deletion was observed in 52% of cases179. Recently, KDM5D 
was shown to be mutated or frequently deleted in metastatic prostate cancer, and that 
low levels were associated with poor prognosis180. Moreover, KDM5D suppresses 
invasion of prostate cancer cells both in vivo and in vitro, by repressing expression of 
invasion associated genes, through its enzymatic activity180. Another study has shown 
that KDM5D physically interacts with the androgen receptor (AR) in the nucleus, and 
regulates AR signalling by repressing AR target genes 181. Similar to KDM5C, KDM5D 
has also been implicated in ccRCC as it was found to be downregulated due to loss of 
chromosome Y 182. Further analysis showed that KDM5D reduced cell viability of renal 






KDM5B is a 176kDa protein encoded by a gene located on chromosome 1q32.1. KDM5B 
was first identified in a cDNA library screen as a gene whose expression was down-
regulated upon inhibition of the tyrosine kinase, HER2, with Herceptin 183. Following the 
identification of KDM5B, other splice variants have also been reported namely, RBP2-
H1 184 and RBP2-H1A 185. RPB2-H1 was identified as a gene whose expression was 
frequently down-regulated in melanoma 184. Although there is high homology between 
the cDNA sequences of these splice variants, RBP2-H1 contains an extra exon that 
encodes a region with strong homology to chromosomal ALU repeats 184. Among the 
splice variants, PLU-1 (KDM5B) is the most widely studied and most abundant in a panel 
of breast cancer and melanoma cell lines examined 186.  
 
1.5.1 KDM5B Expression 
In normal human adult tissues, high KDM5B mRNA expression is restricted to testis, with 
moderate expression in the placenta and ovary 183. Recently using an in-house antibody, 
we have shown expression of KDM5B on lymphoid cells within tonsil (Steven Catchpole 
personal communication). In the adult mouse, high KDM5b mRNA expression is 
restricted to testes with moderate expression in the ovary, prostate and eye 187. Analysis 
of KDM5b mRNA expression during the different stages of mouse mammary gland 
differentiation, showed that KDM5b is expressed in the virgin (non-pregnant) gland, 
increased during pregnancy, decreased at lactation and re-expressed at involution 187–
189. In the mouse embryo, KDM5b is expressed in ESCs 190,191, neural progenitors 192 and 
embryonic mammary bud187. 
 
1.5.2 The Function of KDM5B 
Consistent with the ability of KDM5 proteins to demethylate the active H3K4me3 mark, 
many studies have described them as transcriptional repressors, that act directly or in 
association with repressive complexes, to regulate gene expression. So far studies have 
demonstrated a role of KDM5B in biological processes such as, normal development, 
differentiation/cell fate, cell cycle, genome stability and mammary gland development.  
 
1.5.2.1 Normal development and differentiation 
KDM5B regulates H3K4 methylation marks close to promoters and enhancers of ESCs, 
thus affecting the balance between differentiation and self-renewal 193. Indeed, Dey and 
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colleagues demonstrated that KDM5B bound on promoters of cell fate modulators early 
growth response gene 1 (Egr1), p27 and BMI1, repressing their expression through its 
demethylase activity 190, thus enhancing cell proliferation. Furthermore, during ESC-self-
renewal KDM5B has been reported to  catalyse the demethylation of H3K4me3 on 
intragenic regions, thus repressing cryptic transcription during expression of self-renewal 
genes 191.  
The importance of KDM5b in regulating gene expression during early development is 
demonstrated by embryonic 188 and neonatal 194 lethality upon knockout of the gene, with 
the latter displaying neuronal defects such as disorganized cranial nerves, defective eye 
development and increased exencephaly 194. Zou and colleagues however, successfully 
developed a KDM5b-/- mouse strain that remained viable beyond the embryonic and 
neonatal stages195. This mouse strain however, displayed phenotypic defects such as, 
delayed mammary gland development, reduced mammary epithelial cell proliferation 
and premature mortality 195. The phenotype of the KOs from Zou and colleagues 
corresponded with those of a mouse strain with a deleted ΔARID domain (ΔARID mouse) 
that was developed in our laboratory 188. The ΔARID mice were viable and fertile but also 
displayed developmental abnormalities in the mammary gland such as delayed 
development of the terminal end bud and side branching in early pregnancy and at 
puberty 188. The differences observed in the KDM5b-/- mouse models may be related to 
colony maintenance, since different phenotypes were observed in mice with the same 
genetic background (C57BL/6).  
 
1.5.2.2 Mammary gland development  
KDM5B was found to be critical for the expression of mammary gland development 
regulators such as FOXA1, HER2, STAT5a and ESR1, since they were downregulated 
upon loss of KDM5B in mammary epithelial cells 195. In the ΔARID mouse mammary 
gland, decreased phosphorylated STAT5 196 and increased Caveolin-1 (CAV1) (Steven 
Catchpole personal communication), an inhibitor of phosphorylated STAT5 (pSTAT5), 
was observed at mid-pregnancy day 12.5.	Thus, showing the requirement of KDM5B in 
regulating the janus kinase 2 (JAK2)/signal transducers and activators of transcription 
5a (STAT5a) signalling pathway, during mammary gland development. Taken together 
with the observation that KDM5B interacts with ERa 188 and that loss of KDM5B reduces 
serum estrogen level 195, this demonstrates a role of KDM5B in luminal epithelial cell 
proliferation of the mammary gland. Thus, may explain the delayed side branching and 
terminal end bud in the mammary gland in KDM5b mouse models195188.  
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1.5.2.3 Cell cycle progression 
A role of KDM5B in positively regulating the cell cycle has been demonstrated. In ESCs, 
KDM5B was found to promote G1-S progression through direct repression of the growth 
arrest-promoting proteins Egr1 and p27190,197. Consistently, KDM5B was also found to 
promote G1-S progression in MCF-7 breast cancer cells,  as demonstrated by 
accumulation of cells at G1 phase and delay in cell cycle exit upon its knockdown 146. 
Scibetta and colleagues further showed that in breast cancer cells, KDM5B positively 
regulated genes involved in control of spindle checkpoint, chromatin condensation and 
G2/M checkpoint, therefore implicating it in cell cycle checkpoint regulation156.  
 
1.5.2.4 Genome stability 
KDM5B has been described as a key regulator of genome stability, since its depletion 
promoted DNA damage and sensitised osteosarcoma and breast cancer cells to 
genotoxic insult198. KDM5B was shown to be essential for the recruitment of Ku70 and 
BRCA1, to sites of DNA damage and subsequent repair of DNA double strand break 
(DSB) via non-homologous end joining (NHEJ) and homologous recombination (HR) 198. 
KDM5B demethylase activity was found to be important for its DSB repair function, since 
H3K4me3 demethylation by KDM5B triggered recruitment of BRCA1 to sites of DNA 
damage198. 
 
1.5.2.5 Interaction of KDM5B with other repressor proteins 
KDM5B interacts with the developmental transcription factors brain factor -1 (BF1) and 
paired box 9 (PAX-9), via their conserved sequence motif (Ala-X-Ala-Ala-X-Val-Pro-X4-
Val-Pro-X8-Pro) termed the VP motif in the transcription factors 199. KDM5B was found 
to act as a transcriptional co-repressor of BF-1 and PAX9 as co-expression of KDM5B 
with either transcription factors enhanced their repression activity 199. Since BF-1 is part 
of the Groucho repressive complex, the authors suggested that KDM5B may be involved 
in groucho-mediated transcriptional repression 199. Furthermore, since PAX-9 mRNA 
was found to be elevated in breast cancer, it is possible that the KDM5B-BF-1-PAX9 
interaction may be important in the development of breast cancer 186.  KDM5B also 
cooperates with the polycomb repressive complex 2 (PRC2) through the SUZ12 
component of PRC2, where it acts as a co-activator of retinoic acid (RA) signalling 200.  
An association between KDM5B and HDACs has been reported. KDM5B associates with 
HDAC4 by binding to the N-terminal half of HDAC4 which contains the myocyte enhancer 
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factor 2 (MEF2)-binding domain189. This interaction was found to be dependent on two 
PHD domains of KDM5B 189. KDM5B and HDAC4 were found to be co-expressed in the 
pregnant mouse mammary gland, as well as, in breast cancer, thus suggesting an 
important of KDM5B in these processes 189. Co-localisation of KDM5B with two catalytic 
subunits of the nucleosome remodelling and deacetylase (NuRD) complex: HDAC1 and 
chromodomain helicase DNA binding protein 4 (CHD4) has also been reported159. Since 
both subunits are important in regulating gene expression and chromatin remodelling, 
KDM5B may cooperate with HDAC1 and CHD4 in transcriptional repression. These 
interactions between KDM5B and different complexes/proteins may depend on the cell 
phenotype. 
 
1.5.3 KDM5B in Cancer 
Of the KDM5 proteins, the role of KDM5B in cancer progression is the most studied. 
Overexpression of KDM5B has been reported in various cancers including breast, 
melanoma, prostate and lung, where it has been regarded as an oncogene, as it 
appeared to be essential for the growth and survival of these cancers (reviewed by 201).  
 
1.5.3.1 Breast Cancer 
KDM5B has been most widely studied in breast cancer. Upon discovery of KDM5B as a 
gene regulated by HER2 signalling (See section 1.5), high expression of the gene was 
also reported in breast cancer tissue and cell lines 183. Knockdown of KDM5B in the MCF-
7 ER+ breast cancer cell line reduced cell proliferation, colony formation and tumour 
formation in a mouse mammary tumour model 146. It was later shown that KDM5B 
promoted estrogen dependent tumour growth of MCF-7 cells in immune suppressed 
mice188. Thus, these findings demonstrated the importance of KDM5B in the MCF-7 ER+ 
breast cancer cells. Indeed, KDM5B has been described as a ‘luminal lineage driving 
oncogene’ in breast cancer202. The authors showed that KDM5B was amplified and 
overexpressed in luminal breast cancers, and that KDM5B was enriched on promoters 
and enhancers of the luminal genes ER, GATA3, FOXA1 and TFAP2C in luminal cells 
202. Other KDM5B target genes in MCF-7 ER+ cells include BRCA1, CAV1 and 
metallothionein genes (MT1H, MT1F and MT1X), where KDM5B was shown to bind their 
promoters repressing their expression via its demethylase activity 146,156. Additionally, 
high KDM5B activity in ER+ tumours was associated with poor outcome and endocrine 
resistance 202, suggesting KDM5B as a potential therapeutic target in ER+ breast cancer.  
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In the triple negative breast cancer subtype, KDM5B expression was downregulated in 
both tumours and cell lines 159. Genome-wide gene expression analysis of MDA-MB-231 
cells, showed that KDM5B knockdown increased expression of genes involved in cell 
proliferation, migration and inflammatory response 159. Indeed, overexpression of 
KDM5B was shown to suppress migration and invasion of this cell line 159. This 
corresponds with findings showing suppression of metastasis and angiogenesis by 
KDM5B, in MDA-MB-231 cells203. Thus, in triple negative breast cancer cells KDM5B 
may have a different function which can lead to tumour inhibition.  
 
1.5.3.2 Melanoma 
A sub-population of slow-cycling melanoma cells were found to express high levels of 
KDM5B (KDM5Bhigh), which was required for their continuous growth 204. Depletion of 
KDM5B in KDM5Bhigh cells, initially accelerated tumour growth but was followed by 
exhaustion, suggesting that KDM5B confers a stem cell-like function in melanoma cells 
204. Thus, in melanoma cells, KDM5B seems to be required for the maintenance of 
continuous growth rather than initiation of tumours 204.  
 
1.5.3.3 Prostate Cancer 
Bioinformatics analysis using the Oncomine Cancer database revealed upregulation of 
KDM5B in prostate cancer, particularly in metastatic prostate cancer 205. KDM5B was 
shown to associate with and regulate the transcriptional activity of the androgen receptor 
205. Inhibiting the expression of KDM5B via binding of microRNA-29a in the 3’-
untranslated region of KDM5B, significantly reduced prostate cancer cell proliferation 
and induced apoptosis206.  
 
1.5.3.4 Other cancers 
Overexpression of KDM5B has been reported in bladder and lung cancer, where it was 
shown to promote proliferation, survival and/or invasion of these cells 207,208. In gastric 
cancer, KDM5B is upregulated and promotes cell growth and metastasis through 
activation of the AKT pathway209. Increased expression of KDM5B in hepatocellular 
carcinoma (HCC) correlated with tumour size and was associated with poor prognosis. 
Consistently, knockdown of KDM5B significantly suppressed HCC cell proliferation210. 
KDM5B knockdown in oral squamous cell carcinoma (OSCC) cells, reduced stemness, 
migration, invasion and increased radiation sensitivity 211. Similarly, silencing of KDM5B 
	 48	
in neuroblastoma cell lines downregulated Notch/Jaggged signalling, thus demonstrating 
that KDM5B promotes a stemness in these cell lines 212 
In general, it is evident that KDM5B is mostly upregulated in cancer where it acts to 
promote tumour progression. However, target gene identification analyses have also 
revealed a cell-type specific function of KDM5B, that needs to be considered when 
targeting KDM5B for cancer therapy.  
 
1.6 Genes regulated by KDM5B in the normal and malignant 
mammary gland: CAV1 
Genome-wide expression analysis performed to identify KDM5B target genes, revealed 
a number of genes that were either up- or down-regulated in  the ER+ breast cancer cell 
line, MCF-7 146,156,202. From the genes that are down-regulated by KDM5B, CAV1 is of 
particular interest in this project. Recent data from our laboratory using a mouse model 
lacking KDM5B demethylase activity, termed ΔARID, showed upregulation of CAV1 in 
the mid-pregnant mammary gland (Steven Catchpole personal communication). These 
findings suggest that KDM5B regulates CAV1 expression in the normal and malignant 
mammary gland, and so indicates that similar networks may be operative in normal and 
cancer cells. Therefore, the extent of CAV1 regulation by KDM5B needs to be studied 
further to understand its importance in normal development, as well as, in cancer. 
 
1.6.1 CAV1 
Caveolins, the main components of caveolae-enriched plasma membranes, are a protein 
family consisting of three proteins, caveolin 1, 2 and 3 213–215. Caveolin proteins organise 
and concentrate lipids (i.e. cholesterol and glycosphingolipids) 216–218 and signalling 
molecules 213 within caveolar membranes and are thought to act as scaffolding proteins. 
CAV1 is abundantly expressed in myoepithelial, endothelial, adipocytes and fibroblast 
cells 219,220 and is co-expressed with CAV2 214,221, whereas CAV3 is expressed in muscle 
cells215. CAV1 maps to chromosome 7q31.1, which is a fragile region that is frequently 
deleted in many cancers including breast cancer 222. Proteins that interact with CAV1 
such as EGFR, G protein and G-protein coupled receptors, HER2 and H-ras, bind to a 
cytoplasmic region of CAV1 that is proximal to the membrane, known as caveolin 
scaffolding domain (CSD) 213,223–225. Functionally, CAV1 is involved in controlling 
signalling, which can lead to effects on various cellular processes such as, cell growth226, 
lipid transport and signal transduction 227.  
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1.6.2 CAV1 in the normal mammary gland 
Documentation of CAV1 protein expression during mouse mammary gland development, 
showed that it  steadily declines during mid to late pregnancy remaining downregulated 
during lactation, only re-emerging during weaning and being restored to non-pregnant 
levels, at involution228.  
The JAK2/STAT5 pathway is required for alveologenesis (development of alveoli 
structures in the mammary gland) 229 and lactogenesis (milk production) 230, during 
pregnancy. Interestingly, a CAV1 knockout mouse model showed extensive proliferation 
of the mammary gland and hyperphosphorylation of STAT5a231. Therefore, CAV1 was 
characterised as a negative regulator of the Prl-R/JAK2/STA5a signalling pathway231. 
Indeed, in the ΔARID mouse, phosphorylated STAT5 was found to be downregulated 196 
and this correlated with upregulation of CAV1 (Steven Catchpole personal 
communication), in the mid-pregnant mammary gland.  
 
1.6.3 CAV1 in Breast Cancer 
In breast cancer, CAV1 expression is generally low232 in tumours that are hormone 
receptor positive (ER and PR) and express luminal cytokeratins 233. Thus, in these breast 
cancers, CAV1 may act as a tumour suppressor gene, since its overexpression in ER+ 
breast cancer cell lines, results in reduction of tumour growth234, migration and epidermal 
growth factor (EGF)-stimulated lamellipod extension235. Contrastingly, overexpression of 
CAV1 is often observed in aggressive breast cancers such as basal-like and triple 
negative breast cancers233,236. These differences in CAV1 expression in different 
subtypes of breast cancer, have been shown to be due to promoter methylation 237, 
thereby demonstrating epigenetic regulation of CAV1 expression in breast cancer. 
Nevertheless, CAV1 expression in breast cancer cells is not associated with patient 
survival238,239. However, recently CAV1 was identified as a marker for Herceptin 
resistance in HER2+ breast cancer 240,241. 
On the other hand, CAV1 expression in breast cancer stroma is associated with good 
clinical outcome. High CAV1 expression in breast cancer-associated fibroblasts, is 
associated with good clinical outcome 242. This also includes triple negative breast 
cancers, where stromal CAV1 expression predicts good overall survival238,239 and so is a 
prognostic marker238. Taken together, these findings suggest a multifaceted and cell-
type specific role of CAV1 in breast cancer.  
The studies from KDM5B KD in breast cancer cell lines such as MCF-7, indicate that 
KDM5B can normally downregulate CAV1 expression. Similarly, studies in the KDM5B 
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demethylase null mouse model also indicate that KDM5B can downregulate CAV1, in 
the normal mouse mammary gland. It will be important to know just how general the 
regulation of CAV1 by KDM5B is in different cell phenotypes, and this question will be 
addressed in this thesis in chapter 4, focusing on HER2 positive cell lines.  
 
1.7 KDM5 proteins in drug resistance 
The KDM5 proteins have been implicated in drug resistance of several cancers and are 
therefore potential therapeutic targets. During their investigations in modelling response 
to anti-cancer drugs, Sharma and colleagues observed a small subpopulation of 
reversible ‘drug tolerant’ cells that maintained viability 243. Using lung cancer cell lines, 
the authors investigated the underlying mechanisms of the reversibility of drug tolerant 
cells, and identified KDM5A as a gene that was upregulated in these cells. Indeed, 
knockdown of KDM5A in PC9 lung cancer cells significantly reduced the emergence of 
drug tolerant cells and likewise, transient expression of KDM5A in PC9 cells decreased 
sensitivity to anti-cancer drugs 243. Chronic drug exposure to a prostate cancer cell line 
also resulted in drug tolerant cells that had high expression of KDM5A 244. Amplification 
and increased expression of KDM5A in breast cancer, has also been shown to promote 
resistance to the EGFR inhibitor, erlotinib, since its knockdown significantly reduced the 
number of drug-tolerant cells170. A recent study by 245, demonstrated that expression of 
KDM5A was upregulated in gliobastoma resistant cells, and that inactivating or 
overexpressing KDM5A resulted in increased sensitivity or resistance, to the DNA 
alkylating agent temozolomide.  
Cytotoxic treatment of melanoma cells resulted in enrichment of therapy resistant cells 
that had high KDM5B expression 246. These observations were also seen in vivo, and it 
was demonstrated that knockdown of KDM5B increased sensitivity to anti-melanoma 
treatment 246. In neuroblastoma, KDM5B expression was found to correlate with 
sensitivity to chemotherapy, since cell lines with a higher KDM5B expression were more 
resistant to doxorubicin, etoposide and cisplatin 212. Indeed, KDM5B silencing led to 
increased sensitivity to cisplatin 212. KDM5D has recently been implicated in resistance 
of prostate cancer cell lines to docetaxel. RNA-seq analysis of two prostate cancer cell 
lines, identified KDM5D as a gene that mediated docetaxel sensitivity 181. Indeed, 
silencing KDM5D in a sensitive cell line led to docetaxel resistance. This corresponded 
to the observation that KDM5D was deleted in a castration resistant prostate cancer 
(CRPC) cell line, which was insensitive to docetaxel 181. The authors demonstrated that 




1.8 KDM5B as a target for cancer therapy 
Accumulating evidence showing dysregulated histone demethylases in human cancers, 
has led to the development of small molecule inhibitors that target the demethylase 
activity of these proteins, for anti-cancer therapy. As discussed herein, KDM5 
demethylases are upregulated in various cancers where they promote tumour growth 
and drug resistance. Thus, there have been major efforts within academia and industry 
to develop compounds targeting the demethylase activity of KDM5 proteins. To date, 
several KDM5 small molecule inhibitors have been reported however, some lack 
cytotoxicity or selectively between KDM4 and KDM5 histone demethylases114,115,247–256.  
Selective and potent KDM5 inhibitors that have been shown to prevent drug tolerance in 
various cancer cell lines include CPI-455 115, YUKA1 114, KDOAM-25 254 (Table 1.4). CPI-
455 is a pan-KDM5 inhibitor with a 200-fold selectivity for KDM5 enzymes over KDM4 
demethylases, and a >500-fold selectivity over other JmjC-containing demethylases. 
Treatment of lung, melanoma, colon and breast cancer cell lines with CPI-455 in 
combination with targeted therapies, reduced the number of drug tolerant cells 
demonstrating that the demethylase activity of KDM5 proteins is required for drug 
resistance 115. YUKA1 is a KDM5A and KDM5C inhibitor with an IC50 of 2.66µM and 
7.12µM for KDM5A and KDM5C respectively. An EGFR-mutant lung cancer cell line and 
a HER2+ breast cancer cell line treated with gefitinib and Herceptin respectively, in 
combination with YUKA1, reduced the number of drug tolerant cells 114. These findings 
also demonstrated that requirement of the demethylase activity of KDM5A/C in 
promoting drug resistance of these cell lines. KDOAM-25 is a pan-KDM5 inhibitor with 
potencies of <100nM for KDM5 enzymes, but has a higher potency for KDM5B (19nM). 
KDOAM-25 was shown to reduce cell proliferation of a multiple myeloma cell line 254. The 
authors did not investigate the effect of this inhibitor on drug tolerance. Recently, a 
potent, selective and orally bioavailable KDM5 inhibitor, that showed high potency for 
KDM5B (IC50 4.7nM) and KDM5C (IC50 65.5nM) in vivo, was developed247. This 
compound known as 48, can now be used to study KDM5 functions in vivo.  
Since KDM5 demethylases have been shown to downregulate tumour suppressor genes 
via their demethylase activity, the use of demethylase inhibitors can be viewed as a 
means of suppressing tumour growth 152. This therefore requires a comprehensive 
analysis of target genes for specific KDM5 enzymes. However, since member specific 
KDM5 demethylase inhibitors are currently unavailable, gene editing techniques such as 
CRISPR, can be used to identify genes regulated by individual KDM5 demethylases, and 
to further study their function in cancer cell lines 152.  
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Table 1.4: Small molecule inhibitors targeting KDM5 histone demethylases 
Inhibitor Specificity Effects 
CPI-455 115 Selectively inhibits demethylase 
activity of the four KDM5 proteins 
Prevents drug tolerance in 
multiple cancer cell line 




Selectively inhibits demethylase 
activity of KDM5A and KDM5C 
proteins 
Prevents drug tolerance in 




Selectively inhibits demethylase 
activity of KDM5B with a higher 
potency, than KDM5A and KDM5C 
proteins 
Inhibits cell growth of the 
MM1S multiple myeloma cell 
line 
48 
(Liang et al. 2016) 
Potent inhibitor to KDM5B and 
KDM5C 
Oral dosage given twice a day 
in mice shows unbound 
maximal plasma concentration 
(Cmax) >15-fold over its cell 
EC50 
 
1.9 Gene editing technologies in drug target validation  
According to data analysis from pharmaceutical companies, a major factor contributing 
to the failure of drug candidates at the late stages of clinical development, is lack of 
efficacy attributed to erroneous hypotheses about the linkage of the drug target to 
disease257.  Thus, the need to better understand the role of drug targets in disease 
biology is important, to ensure success during drug development. Genome editing 
technology has currently gained momentum as one of the methods to study gene 
function in human disease, since it allows precise modification of genes257.  
Genome editing using customized nucleases provides a system through which targeted 
deletions, insertions or specific sequence changes can be induced in organisms and cell 
types 258. The first step in genome editing is the creation of a DNA DSB at a desired 
genomic locus, followed by repair of the DSB via homology directed repair (HDR) or 
NHEJ 258. HDR is used for precise genome editing, where a DNA fragment with a 
complementary sequence to the target site is used to repair DSBs via homologous 
recombination 259. This DNA fragment can harbour any alteration, therefore allowing 
integration of any desired DNA sequence at the target site 259. NHEJ is an error-prone 
repair mechanism which introduces insertions or deletions (indels) of varying lengths 
which can cause frameshifts, altering the gene product and abolishing gene function 259. 
A number of genome editing tools such as zinc-finger nucleases (ZFN), transcription 
activator-like effector nucleases (TALENs) have been used extensively over the years 
however, they have remained a niche technology. ZFNs and TALENs utilise the same 
principle: fusion of a sequence-specific DNA binding domain to the nuclease domain of 
Fok1 restriction enzyme 258,259. Contrastingly, the recently developed clustered, regularly 
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interspaced, short palindromic repeat-CRISPR associated (CRISPR-Cas), has resulted 
in widespread adoption of nuclease based genome editing, owing to its simplicity, high-
throughput capabilities  and ability to target multiple genomic sites 259. CRISPR-Cas is 
an RNA-guided system, that utilises Watson-Crick base pairing between an engineered 
RNA and the target DNA sequence 258,260. CRISPR-Cas is a prokaryotic adaptive immune 
system that has been manipulated for genome editing. This technique has been 
simplified to consist of a single guide RNA (sgRNA) and a Cas9 endonuclease. The 
sgRNA directs the Cas9 endonuclease to induce DNA DSBs at homologous sites, which 
are then repaired via NHEJ or HDR leading to introduction of insertions or deletions 
(indels) or precise gene editing, respectively (Fig 1.7).  
 
 
Figure 1.7: CRISPR-Cas9 technology. A single gRNA (sgRNA) guides the Cas9 nuclease to a 
target site with a complementary DNA sequence. Cas9 then cleaves the DNA inducing a double 
strand break (DSB). The DSB is repaired via non-homologous end joining (NHEJ) leading to 
introduction of mutations, insertions or deletions. Repair can also occur through homology 
directed repair (HDR) when a short DNA sequence that is complementary to the target site is 
inserted, thus allowing precise gene editing 259.  
 
1.9.1 CRISPR-Cas9 for drug target validation 
Advances in DNA sequencing technologies have provided insight into the genetic 
variation among patients in human disease, thus enabling improvement in treatment 
strategies 261.  These advances have therefore driven the need for personalised or 
precision medicine, where a patient’s information is combined with their genetic data, to 
inform on individual treatment regimens 261. However, hypotheses generated from these 
studies require testing using specific genetic models. CRISPR-Cas technology has 
enabled the study of gene function in disease relevant cell types, through development 
Cas9 induces DNA DSB
NHEJ creates random mutations HDR inserts desired target sequence leading 
to precise gene editing
gRNA guides 
Cas9 to target 
sequence





of cell line and animal models 262. These models have been used to evaluate drug targets 
and model drug resistance. CRISPR-Cas has also been simplified for use in genome-
wide screens. CRISPR screens study phenotypes produced upon gene knockout, with 
the aim of identifying genes involved in metabolic or pathogenetic processes 261. CRISPR 
screens have been used to identify candidate drug targets in cancer and human 
pathogens 261. Thus, the adoption of CRISPR-Cas technology in cancer research for 
example, should enable acceleration of drug discovery and development of more 




















1.10 	Overview of PhD project 
	
1.10.1 Rationale 
Breast cancer is the most common cancer in women in the UK, and high incidence rates 
have been reported worldwide. Recent advances in treatment strategies owing to 
improved molecular characterisation of breast cancer, as well as, early detection of the 
disease, has increased survival rates of breast cancer patients. However, breast cancer 
still remains the second most common cause of cancer death in women, in the UK. One 
of the major factors contributing to the high mortality rate is resistance (de novo or 
acquired) to administered treatments.  
A role for epigenetics in contributing to drug resistance, stems from observing 
development of drug tolerance and the reversibility of this tolerance by epigenetic 
manipulation. The reversible nature of drug tolerance by epigenetic factors has led to the 
development of epigenetic-based therapies, some of which (e.g. histone deacetylase 
inhibitors) have been approved for cancer treatment. However, targeting the epigenome, 
can be challenging due to the wide involvement of epigenetic factors in biological 
processes 263. Recent technological advances such as gene editing, may allow further 
characterisation of these genes in specific cell-types thus, fine-tuning their function. Such 
insights will allow better drug design, thereby enabling further exploration of the utility of 
epigenetic drugs, as well as, investigating their potential in improving the effects of 
current drugs 263.  
KDM5B is a histone demethylase that is overexpressed in a majority of breast cancers, 
particularly those belonging to the ER+ and HER2+ molecular subtypes 202. KDM5B is 
considered a promising target for a number of reasons. First, KDM5B is overexpressed 
in many malignancies. Second, KDM5B promotes drug resistance in a number of 
cancers, by maintaining the growth of a sub-population of cancer cells, that serve to 
initiate therapeutic relapse. Third, since KDM5B regulates expression of genes involved 
in biological processes such as, cell cycle, DNA repair and development, its aberrant 
expression can result in dysregulation of these processes and eventually disease 
development or progression.  
Based on the above, KDM5B is a possible target for anti-cancer therapy. Although there 
have been advances towards development of small molecule inhibitors targeting 
KDM5B, these inhibitors lack specificity since they also target other members of the 
KDM5 family114,115,247,254. Thus, understanding the function of KDM5B in normal and 
cancer cells, could provide to the knowledge required to develop specific KDM5B 
inhibitors, since multiple enzymes can demethylate the H3K4me2/me3 marks, thereby 




The aim of this project was to further investigate the role of KDM5B in the normal and 
malignant mammary gland. KDM5B has been widely studied in ER+ breast cancer, with 
a few studies being done in triple negative breast cancer cells. However, the function of 
KDM5B in HER2+ breast cancer cells, has not been widely investigated. Furthermore, 
although KDM5B has been shown to promote resistance to anti-cancer drugs in various 
malignancies, its involvement in breast cancer drug resistance, particularly in HER2 
targeted therapy, has not yet been demonstrated.   
KDM5B has been shown to downregulate CAV1 in the normal mammary gland at mid 
pregnancy and in ER+ breast cancers. Thus, suggesting similar networks are operative 
in development of the normal gland and in breast cancer. However, it is not clear how 
widespread the downregulation of CAV1 by KDM5B is seen in different breast cancer 
cell lines, nor is it clear, which cell types in the developing mammary gland (luminal, 
myoepithelial and fat cells), could be responsible for the downregulation of CAV1 by 
KDM5B. Given the above, this PhD project was directed towards testing the following 
hypotheses: 
1. Since KDM5B can enhance signalling by the ERα and HER2 receptors operative 
in some cancer cells, knockout of KDM5B will reduce cell growth, increase 
efficacy of therapeutic targeting of the HER2 receptor and impede development 
of drug resistance. 
 
2. Since KDM5B can downregulate expression of CAV1, which when expressed in 
stromal tissue is inhibitory to breast cancer growth, they may be expressed in the 
same cell types and their expression could be inversely correlated. Thus, 
targeting KDM5B could restore levels of CAV1, therefore inhibiting other 








1.10.3 Aims  
	
The specific aims of this thesis were to: 
1) Develop KDM5B KOs in two HER2+ breast cancer cell lines using CRISPR-Cas9 
technology 
 
2) Investigate the molecular effect of KDM5B KO by performing transcriptomic analysis, 
in a HER2+ breast cancer cell line 
 
3) Investigate phenotypic effects of KDM5B KO on cell growth and drug resistance, in 
two HER2+ breast cancer cell lines 
 
4) Investigate KDM5B regulation of CAV1 by examining their expression levels in a) 
parental and KDM5B KO HER2+ breast cancer cells and b) normal and breast 
cancer-associated fibroblast cells. Furthermore, the cellular localisation of KDM5B 
and CAV1 will be examined in the mouse mammary gland, to decipher the cell types 












































2.1 Cell culture and conditions 
	
2.1.1 Cell culture Reagents  
	
Table 2.1: Cell culture reagents 
Reagent Supplier 
Trypsin (2.5%), no phenol red Life Technologies 
Trypan blue solution 0.4% Sigma-Aldrich 
Penicillin-Streptomycin/Glutamine 100X Life Technologies 
Insulin solution human Sigma-Aldrich 
Fetal Bovine Serum (FBS) Life Technologies 
Dulbecco’s Modified Eagle’s Medium (DMEM) VWR International 
Roswell Park Memorial Institute 1640 (RPMI) VWR International 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Trastuzumab (Herceptin) Kindly provided by the Breast 




2.1.2 Cell culture media 
 
Table 2.2 Cell culture media 
Media Reagents Concentration 
DMEM (500ml) FBS 10% (v/v) 
Penicillin-Streptomycin/Glutamine 1% (v/v) 
RPMI (500ml) FBS 10% (v/v) 





Fresh complete media 








Fresh complete media 









2.1.3 Cell culture maintenance 
The breast cancer cell lines BT- 474, HCC1143 and T47D were maintained in RPMI 
medium. MCF-7, MDA-MB-231 and SKBr3 cell lines were maintained in DMEM medium. 
BT-474 and SKBr3 Herceptin resistant cells were maintained using the same medium 
as the parental cells, with further addition of 40µg/ml Herceptin. BT-474 and SKBr3 
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KDM5B knockout cell lines were maintained using the same conditions as the parental 
cells. The normal breast fibroblast line, HMFU19 and the breast cancer-associated 
fibroblast lines, LS11-045 and LS11-088 were maintained in DMEM medium. All cells 
were incubated at 37°C with 5% CO2. The characteristics of these cell lines are shown 
in Table 2.3 264. All cell lines were authenticated using short-tandem repeat (STR) 
profiling. To maintain the cells’ authenticity a master cell bank was created. Cells were 
kept in culture for no more than 10 weeks and were regularly checked for mycoplasma 
contamination using the MycoAlert Mycoplasma Detection Kit (Lonza).  
 
Table 2.3: Description of cell lines.   
Name Immunoprofile Subtype Source 
BT-474 ER+/ PR+/-/HER2+ Luminal B CRUK Cell  
Service laboratory 
HCC1143 ER-/HER2-/PR- Basal  ATCC 
MCF-7 ER+/PR+/-/HER2- Luminal A ATCC 
MDA-MB-231 ER-/HER2-/PR- Basal ATCC 
SKBr3 ER-/PR-/HER2+ HER2+ Memorial Sloan  
Kettering Cancer Centre 




ER+/ PR+/-/HER2+ Luminal B Kindly provided by Professor 





ER-/PR-/HER2+ HER2+ Kindly provided by Professor 





  Kindly provided by Professor Valerie 






  Kindly provided by Professor Valerie 













  Table 2.4: Reagents used for CRISPR gene editing 
 
 
2.2.2 Plasmids  
  




Figure 2.1: U6-gRNA PX458 plasmid map. KDM5B gRNAs were inserted into the BbsI site. U6 
promoter is shown as a black arrow head. The gRNA scaffold (blue rectangle) is a sequence 





Reagent  Supplier 
T4 ligase buffer Thermo Fisher Scientific 
T4 DNA ligase Thermo Fisher Scientific 
Fast digestion buffer New England Biolabs 
BbsI New England Biolabs 
SOC media Thermo Fisher Scientific 
Ammonium buffer Amplicon 
MgCl2 Amplicon 
dNTP mix Amplicon 
TEMPase Hot Start DNA polymerase Amplicon 
Plasmid Name Source 
U6-gRNA PX458 Asst. Prof. Eric Bennett, Copenhagen 
Centre for Glycomics, University of 
Copenhagen 
Cas9-2A-GFP pBKS Asst. Prof. Eric Bennett, Copenhagen 




Figure 2.2: Cas9-2AGFP pBKS plasmid map. Plasmid map showing features of the Cas9-
2AGFP pBKS plasmid. Cas9 endonuclease is driven by the chicken beta actin (cba) promoter. 
The Green fluorescent protein (GFP) reporter gene was used to allow isolation of transfected 
cells. The 2A peptide sequence (2A) allows simultaneous expression of Cas9 and GFP genes.  
	
2.2.3 KDM5B PCR primers 
	
  Table 2.6: KDM5B Primers to Exons 1, 4, 5 and 6 
For – Forward; Rev – Reverse. The forward primer has a FAMF target sequence extension 
(red). 
 
2.2.4 Design of candidate KDM5B gRNAs 
gRNAs targeting four exons of KDM5B were selected (Table 2.7) using a Cas9/gRNA 
target prediction tool (https://chopchop.rc.fas.harvard.edu/).	 Chopchop ranks gRNA 
sequences according to specific parameters including 1) number of off-targets and 
mismatches 2) GC content (gRNAs are most effective when they have a GC content of 
between 40-70%) and 3) location of gRNA within the gene (5’ (best) and 3’ (worst)). 
KDM5B gRNAs were tested for their cutting efficiency, and a suitable guide was chosen 













KDM5B Exon 1 For: 5’-GAGCTGACCGGCAGCAAAATTGGTACAACTCGGACTTGCTGTTGCTC-3’ 
Rev: 5’-CTCAACTCCGACCTTCTAGGC-3’ 
KDM5B Exon 4 For: 5’-GAGCTGACCGGCAGCAAAATTGCAGAAGAAGGTGGATTTGCAGTTGT-3’ 
Rev: 5’-CAAGGTCTTCCAAACACAATCAAGG-3’ 
KDM5B Exon 5 For: 5’-GAGCTGACCGGCAGCAAAATTGGTGCAGCCTCTGGAAGTAGATCAAA-
3’ 
Rev: 5’-ACATGAGAGAAATCCAGTGCCAGAC-3’ 
KDM5B Exon 6 For: 5’-GAGCTGACCGGCAGCAAAATTGAAGGCCATGAATATTAAAATAGAAC-3’ 
Rev: 5’-CAAAGCCCAACCCAGTGACTACT-3’ 
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Table 2.7: KDM5B gRNA target sequences with corresponding target exon. 





PAM sequence is highlighted in red. 
 
2.2.5 Generation of KDM5B gRNA expression plasmid 
For each gRNA targeting one of the four exons of KDM5B, a 25-base pair (bp) sequence 
was synthesised as two complementary oligonucleotides (Table 2.8). The 
oligonucleotides were annealed and inserted into the U6-gRNA plasmid (Fig 2.1) which 
was cut with BbsI, to generate single KDM5B gRNA expression constructs, as described 
below. 
Table 2.8: KDM5B gRNA oligonucleotide sequences 
KDM5B Targeted Exon Sequence 
1 For: 5’-CACCGCGGCCCATAGCCGAGCAGAC-3’ 
Rev: 5’-AAACGTCTGCTCGGCTATGGGCCGC-3’ 
4 For: 5’-CACCGGTTTGCTCCTGGCAAAGCAG-3’ 
Rev: 5’-AAACCTGCTTTGCCAGGAGCAAACC-3’ 
5 For: 5’-CACCGAGGCTGCACAGACTGCCTCT-3’ 
Rev: 5’-AAACAGAGGCAGTCTGTGCAGCCTC-3’ 
6 For: 5’-CACCGTCATAATCTGAGACGTCGAA-3’ 
Rev: 5’-AAACTTCGACGTCTCAGATTATGAC-3’ 
For – Forward    Rev – Reverse. The selected guide RNA sequences are underlined.  
 
2.2.5.1 Oligonucleotide annealing 
Forward and reverse oligonucleotide (oligo) gRNA sequences targeting exons 1, 4, 5 or 
6 of KDM5B (Table 2.8), were first annealed together to form a double stranded DNA 
molecule. Oligonucleotides were mixed with the appropriate buffer (Table 2.9) and 
annealed in a thermocycler using the following conditions: 95°C for 5 minutes followed 





Table 2.9: Components of oligo annealing reaction 
Reagent  Final Concentration Volume 
100µM Oligonucleotide (Forward) 10µM 1µl 
100µM Oligonucleotide (Reverse) 10µM 1µl 
10X T4 ligase buffer 1X 1µl 
ddH2O Make up to 10µl 7µl 
 
 
2.2.5.2 Digestion of U6-gRNA expression plasmid 
The U6-gRNA plasmid was digested with the BbsI restriction enzyme (Table 2.10) and 
incubated for 1 hour at 37°C.  
 Table 2.10: Components of U6-gRNA expression plasmid digest 
 
 
2.2.5.3 Ligation of annealed oligonucleotides with the U6-gRNA plasmid 
The annealed KDM5B gRNA oligonucleotides were mixed directly with the digested U6-
gRNA plasmid in a ligation reaction (Table 2.11) and incubated at 16°C overnight. This 
allowed insertion of the KDM5B gRNA oligonucleotides into the BbsI site of the U6-gRNA 
plasmid (Fig 2.1).  




Reagent  Final Concentration Volume 
10X Fast digestion buffer 1X 0.8 µl 
U6-gRNA plasmid 300ng 6.7 µl 
10U BbsI 0.625U 0.5 µl 
Reagent  Final Concentration Volume 
10µM Annealed oligonucleotides 50nM 0.5µl 
BbsI digested U6-gRNA plasmid 300ng 8 µl 
10X T4 ligase buffer 1X 1 µl 
5U/µl T4 DNA ligase 0.3U 0.6µl 
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2.2.5.4 Transformation of competent cells 
15µl of Top 10 chemically competent E. coli cells (Thermo Fisher Scientific) were 
transformed with 1µl of the ligation mixture. Reaction was incubated on ice for 30 
minutes, followed by heat shock at 42°C for 60 seconds and immediate incubation on 
ice for 2 minutes. 90µl of super optimal broth with catabolite repression (SOC) media 
(Thermo Fisher Scientific) was added and cells incubated at 37°C for 30 minutes with 
shaking. Thereafter, cells were spread on Lysogeny broth (LB) agar plates containing 
ampicillin and incubated at 37°C overnight, to allow for the growth of antibiotic-resistant 
clones.  
 
2.2.6 Hot PCR Screen   
To check whether the gRNAs had been inserted correctly in the U6-gRNA plasmid, a few 
colonies were picked and lysed in 5µl of 0.5µM sodium hydroxide (NaOH) for 2 minutes, 
neutralised with 10µl of 1M Tris pH 8.0 and diluted in 100µl H2O. 1µl of the lysed cells 
was used in a 12.5µl PCR reaction utilising primers outlined in Table 2.6. 1µl of 10ng/µl 
positive (correct vector – B4GALT7; provided by Asst. Prof. Eric Benett) and negative 
(empty vector - PX458) controls were also included in the PCR reaction (Table 2.12) 
using thermocycling conditions shown in Table 2.13.  
Positive colonies containing the correct sized inserts, were identified by fragment 
analysis using the ABI3010 DNA Analyzer (ABI/Life Technologies) according to 
manufacturer’s instructions. 1µl PCR product was mixed with 0.3µl of GeneScan-LIZ600 
standard (ABI/Life Technologies) and 10µl Hi-Di Formamide (Thermo Fisher Scientific), 
incubated at 90°C for 2 minutes then subjected to fragment analysis. Analysis of raw 
data was performed on the Peak Scanner Software (ABI/Life Technologies). Positive 
colonies with correct sized inserts were purified using the Qiagen Miniprep Kit according 
to manufacturer’s instructions and DNA concentration was measured using the 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). Positive colonies were 
also validated by Sanger sequencing, which confirmed correct orientation of inserts. For 
this purpose, 5µl DNA (100ng/µl stock) and 5µl forward primer (5µM stock) were mixed 







Table 2.12: Tri-primer PCR Reaction 
  
Table 2.13: Tri-primer PCR thermocycling conditions 
*Touchdown 72°C to 1°C per cycle 
 
2.2.7 Screening of KDM5B gRNAs 
	
2.2.7.1 Transfection and fluorescence-activated cell sorting (FACS)  
To examine the cutting efficiency of the KDM5B gRNAs, positive gRNA sequences 
prepared by Miniprep were co-transfected with the Cas9-2AGFP pBKS plasmid (Fig 2.2), 
into SKBr3 cells. Plasmid DNA was delivered into the cells by nucleofection using 
AMAXA solution kit C (Lonza), and program E-09 on the AMAXA Cell Nucleofector 2b 
device. 1x106 cells were harvested and nucleofected with 2µg U6-KDM5B gRNA and 
2µg Cas9-2AGFP plasmid DNA. Cells were incubated for 72 hours at 37°C with 5% CO2 
and thereafter subjected to FACS analysis to identify cells with high GFP expression 
(intensity between >104) (Chapter 3 Section 3.2.4). 1x104 parental and bulk sorted 
PCR component Volume (µl) Final concentration 
10x Ammonium buffer 1.25 1x 
MgCl2 (25mM) 0.7 2.5mM 
dNTP (25mM) 0.1 200µM 
TEMPase Hot Start DNA 
Polymerase 
0.12 0.5 
FamF primer (25µM) 0.125 0.25µM 
Forward primer (2.5µM) 0.125 0.025µM 
Reverse primer (25µM) 0.125 0.25µM 
H2O  8.955  
Template  1  
Temperature Time  Number of cycles 
95°C 15 minutes  
95°C 30 seconds X15 
72°C 30 seconds 
72°C* 30 seconds 
95°C 30 seconds X25 
58°C 30 seconds 
72°C 30 seconds 
72°C 7 minutes  
4°C Forever  
	 67	
KDM5B KO cells were subjected to DNA extraction using the Quick Extract DNA solution 
kit (Epicentre) according to manufacturer’s instructions. The cells were centrifuged for 5 
minutes at 200 x g and supernatant discarded. Cell pellet was re-suspended in 30µl 
Quick Extract DNA solution and cells incubated at 72°C for 20 min then 90°C for 10 min. 
DNA was amplified by PCR as described below.  
 
2.2.7.2 Identification of indels using Indel detection by amplicon 
analysis (IDAA)  
For the identification of gRNAs that generated indels with Cas9, indel detection by 
amplicon analysis (IDAA) was used. This techniques was recently developed by265,266 
(Fig 2.3). Tri-primer amplification was used to fluorescently label amplicons through the 
use of a universal 6-FAM 5’-labelled primer (FamF), whose sequence was 
complementary to the 5’ overhang sequence of the forward primer and, the forward (F) 
and reverse (R) primers that flanked the gene editing target site. The assay primers are 
shown on Table 2.6. A PCR tri-primer ratio of 10:1:10 (FamF:F:R) was previously 
suggested as the ratio that produces optimal amplicon yields265. PCR was performed on 
the extracted DNA in a 12.5µl reaction using the recipe shown on Table 2.12 and a 
touchdown thermocycling profile as shown on Table 2.13. Thereafter, 1µl of the PCR 
reaction was mixed with 0.3µl of GeneScan-LIZ600 standard (ABI/Life Technologies) 
and 10µl Hi-Di Formamide (Thermo Fisher Scientific), incubated at 90°C for 2 minutes 
then subjected to fragment analysis on the 3730xl DNA Analyzer (ABI/Life Technologies) 
according to manufacturer’s instructions. Analysis of raw data was performed on the 
Peak Scanner Software (ABI/Life Technologies).  
 
2.2.8 Development of KDM5B knockout cells 
	
2.2.8.1 Selection of KDM5B gRNA 
The gRNA targeting KDM5B exon 4, was the only gRNA that produced edited cells 
(Chapter 3 section 3.2.4.2), and so was used to develop KDM5B knockout (KO) cells 
in BT-474 and SKBr3 cell lines.  
 
2.2.8.2  Transfection, FACS and cell cloning 
To generate KDM5B KO cells, cells were co-transfected with the U6-gRNA expression 
plasmid targeting KDM5B exon 4 and the Cas9-2AGFP pBKS plasmid, as described in 
	 68	
Section 2.2.7.1. 72 hours post transfection, cells with a GFP intensity of between 103-
104 were isolated by FACS (Chapter 3 Section 3.2.5.1) and either 3 cells per well or 10 
cells per well were seeded into 96 well plates. Cells were maintained with the appropriate 
media conditioned on WT cells (RPMI for BT-474 cells and DMEM for SKBr3 cells; Table 
2.2) at 37°C and 5% CO2. Only wells with single colonies were selected and expanded 
into 24 well plates and thereafter subjected to IDAA analysis to identify KDM5B KO 
clones.  
 
2.2.8.3 IDAA screening of KDM5B edited clones 
DNA from single colonies growing in 24 well plates was extracted using the Quick Extract 
DNA solution as described in Section 2.2.7.1. DNA was PCR amplified and PCR 
products were subjected to IDAA as described in Section 2.2.7.2. A total of 17 BT-474 
and 29 SKBr3 KDM5B edited clones were screened by IDAA (Chapter 3 Section 
3.2.5.2). Selected KDM5B KO clones were further validated by Sanger sequencing, 
western blot and RT-qPCR as described in the sections below.  
 
 
Figure 2.3: Schematic representation of the IDAA technique. (a) Precise gene editing creates 
DSBs that are repaired by NHEJ, thus introducing indels at the target site. (b) Amplification occurs 
through tri-primer PCR, using primers flanking the target region (Forward (F)/Reverse (R)) and a 
universal 5’-FAM labelled primer (FAMF) that is complementary to the 5’ overhang sequence 
attached to the forward primer. This results in fluorescently labelled amplicons. (c) Fragment 
analysis detects indels produced in fluorescently labelled amplicons. Y axis represents 
































Genomic target of interest
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2.2.9 Sanger sequencing of KDM5B KO clones 
	
2.2.9.1 Purification of PCR Product  
PCR products of KDM5B KO clones generated in Section 2.2.8.3, were purified using 
the ExoSAP-ITä PCR product cleanup reagent (Thermo Fisher Scientific), according to 
manufacturer’s instructions. 5µl PCR product was mixed with 2µl ExoSAP-ITä reagent 
and incubated at 37°C for 15 minutes, to degrade any remaining primers and 
nucleotides. The reaction was then incubated at 80°C for 15 minutes to inactivate the 
ExoSAP-ITä reagent. Purified PCR products were subjected to Sanger sequencing or 
stored at -20°C for later analysis.  
 
2.2.9.2 Sanger Sequencing 
DNA sequencing of KDM5B KO clones was performed using the BigDye terminator v3.1 
Cycle Sequencing kit (Thermo Fisher Scientific) with either the forward or reverse primer 
targeting KDM5B Exon 4 (Table 2.6). The sequencing reaction was set up in a 96 well 
plate as shown in Table 2.14.  
 




The plate was sealed, vortexed for 5 seconds and spun briefly for 30 seconds at 300 x 
g, to collect contents. The sequencing reaction was then run in a thermal cycler with 
conditions outlined on Table 2.15. The sequencing reaction was then purified by 
ethanol/sodium acetate (NaOAc) precipitation. 26µl of precipitation solution (50ml 100% 
ethanol and 2ml 3M NaOAc) was added to the sequencing reaction, vortexed gently for 
2-3 seconds and incubated for 10 minutes at room temperature. The plate was sealed 
and centrifuged at 600 x g for 10 minutes. The plate was then centrifuged uncovered, 
upside down, at 13 x g for 5 seconds and air-dried upright and protected from light for 
10-15 minutes at room temperature or stored at -20°C. Dried samples were re-
suspended in 10µl Hi-Di Formamide (Thermo Fisher Scientific) and incubated at 90°C 
for 2 minutes. Plate was run on the ABI3730xl DNA analyzer (ABI/Life Technologies), in 
the NIHR BRC Genomics Laboratory at Guy’s Hospital, London. Sanger sequencing 
Reagent Amount (µL) 
Sequencing buffer 1.25 
BigDye 3.1 0.25 
F or R primer 0.25-0.50  
ExoSAP-cleaned PCR product 3.5 
Total 5.25-5.5  
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analysis was performed on the CodonCode Aligner software.  Sequences of KDM5B KO 
clones were determined by the assistance of Dr Zhang Yang, Copenhagen Centre for 
Glycomics, University of Copenhagen.  
 





2.3 Copy number and Gene expression analysis of breast 
tumours 
The two largest publicly available breast cancer datasets with both genomic and 
transcriptomic data namely, Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) were used. 
METABRIC contains genomic and transcriptomic information for 2509 breast tumours 
whereas, TCGA information data for 825 breast tumours. These data were downloaded 













30 seconds 96°C 
15 seconds 50°C 
60 seconds 60°C  
Hold 4°C 
X 30 cycles 
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2.4 Protein Analysis 
	
2.4.1 Whole cell lysate extraction of proteins 
Confluent T75cm2 flask was trypsinised and cell pellet collected by centrifugation at 200 
x g for 5 minutes. The cell pellet was re-suspended in appropriate media, counted and 
1x106 cells transferred to a 1.5ml Eppendorf tube. Cells were centrifuged at 200 x g for 
5 minutes to collect the cell pellet, which was subsequently lysed in 100µl 1X Laemmli 
sample buffer (0.01% (w/v) bromophenol blue, 2% SDS, 60mM Tris-HCl pH 6.8, 10% 
(w/v) glycerol) containing 5% β-mercaptoethanol. Protein lysates were heated at 95°C 
for 3 minutes and passed through a 25-gauge needle to shear the DNA. Protein lysates 
were either stored at -20°C for later analysis or subjected immediately to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot, as described 
below.  
 
2.4.2 Histone protein extraction 
Confluent T75cm2 flask was trypsinised and cell pellet collected by centrifugation at 200 
x g for 5 minutes. The cell pellet was re-suspended in appropriate media, counted and 
2x106 cells transferred to a 1.5ml Eppendorf tube. Histone proteins were then extracted 
according to the Abcam histone extraction protocol 
http://www.abcam.com/ps/pdf/protocols/histone%20extraction%20protocol.pdf. The cell 
pellet was washed twice in ice-cold PBS by centrifugation at 200 x g for 5 minutes. Cells 
were re-suspended in 200µl Triton Extraction buffer (TEB) (PBS containing: 0.5% Triton 
X-100, 2mM phenylmethylsulfonyl fluoride (PMSF), 0.02% Sodium Azide (NaN3)) and 
lysed on ice for 10 minutes with gentle mixing. Following lysis, cells were centrifuged at 
200 x g for 10 minutes at 4°C and supernatant discarded. Cells were washed in 100µl 
TEB and centrifuged at 200 x g for 10 minutes at 4°C. Pellet was re-suspended in 50µl 
0.2M hydrochloric acid (HCl) and incubated at 4°C overnight, with gentle rotation to acid 
extract histones. The following day, samples were centrifuged at 200 x g for 10 minutes 
at 4°C and supernatant was transferred to a fresh 1.5ml Eppendorf tube. Concentration 
of histone protein lysate was determined using the Nanodrop One spectrophotometer 
(ThermoFisher Scientific) on the Protein A280 setting. Histone lysates were stored at -




2.4.3 SDS-PAGE Gel and Western blot 
10µl of protein lysate was separated on either a 7.5% or 12.5% SDS-PAGE gel according 
to their molecular weight using SDS-PAGE running buffer. 5µg of histone protein lysate 
was separated on a 15% SDS-PAGE gel. Samples were run on the Mini-PROTEAN 
Tetra Cell system (Bio-Rad) at 150V for approximately 60-75 minutes. 
Proteins were transferred onto an Amersham Protran 0.45µm nitrocellulose membrane 
(GE Healthcare Life Sciences) using the Mini-transfer blot system (Biorad) in 1X Transfer 
buffer at 30V, overnight at 4°C. Alternatively, proteins were transferred using the 
TransBlotÒ Turboä Transfer System (Bio-Rad) for 30 minutes. Membranes were 
incubated in blocking buffer (5% non-fat milk powder, 0.1% Tween-20 in TBS or 5% 
bovine serum albumin (BSA), 0.1% Tween-20 in tris-buffered saline (TBS)) for 1 hour at 
room temperature, with gentle shaking. Blots were incubated in appropriate primary 
antibodies (Table 2.16) diluted in binding buffer (1% non-fat milk powder, 0.1% Tween-
20 in TBS or 1% BSA, 0.1% Tween-20 in TBS). Following primary antibody incubation, 
membranes were washed three times in 0.1% Tween-20 in TBS at room temperature, 
for 10 minutes per wash. Membranes were then incubated with appropriate secondary 
antibody diluted in binding buffer (Table 2.17) for 1 hour at room temperature, with gentle 
shaking. Membranes were washed three times in 0.1% Tween-20 in TBS at room 
temperature, for 10 minutes per wash. Immune-complexes bound to the membrane were 
detected using enhanced chemiluminescence (ECL) (Pierce) and visualised using the 
GeneGnome XRQ chemiluminescence imaging system (SYNGENE) or, on 
autoradiography film (GE Healthcare) after developing the film on an X-ray developer. 
Blots were quantified using the ImageJ software.  
 
2.4.4 Stripping membranes 
To remove membrane bound antibodies, the stripping buffer (62.5mM Tris-HCl, pH6.7, 
2% SDS, 100mM 2-Mercaptoethanol) was heated to 50°C in a water bath or in the 
microwave for 15 seconds. Membranes were incubated in stripping buffer for 15 minutes 
with shaking, in the fume hood. Membranes were washed in several washes of PBS, 
and the removal of antibodies was confirmed by visualisation on the GeneGnome XRQ 
chemiluminescence imaging system (SYNGENE) or, on autoradiography film (GE 





2.4.5 Antibodies and Buffers used for Protein Analysis 
	















1:1000 1% non-fat milk 
powder, 0.1% 
Tween-20 in TBS 
Abcam 
KDM5A 







1:2000 1% non-fat milk 
powder, 0.1% 










aa 1283-1473  
1:1500 1% non-fat milk 
powder, 0.1% 














1:1000 1% BSA, 0.1% 










1:5000 1% BSA, 0.1% 











H3 aa 1-100 (tri 
methyl K4) 
 
1:1000 1% BSA, 0.1% 










tyrosine 1248 of 
HER2 protein 
1:1000 1% BSA, 0.1% 













1:1000 1% BSA, 0.1% 











1:10,000 1% non-fat milk 
powder, 0.1% 
Tween-20 in TBS 
Santa Cruz 
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Buffer recipes used for western blot are as listed below. All chemicals were purchased 
from Sigma Aldrich unless otherwise stated.   
1x SDS-PAGE running buffer 
1. 25mM Tris pH8.3  
2. 192mM Glycine  
3. 0.1% SDS 
1x Transfer buffer 
1. 25mM Tris pH 8.3  
2. 192mM Glycine  
3. 20% methanol (Thermo Fisher Scientific) 
1x Tris-buffered saline-Tween (TBST) buffer 
1. 20mM Tris pH 7.6 
2. 150mM NaCl 
3. 0.1% Tween-20  
Blocking buffer 
1. TBST buffer 


















2.5.1 Tissue Fixation 
Thoracic mammary glands of 12.5 day pregnant mice were dissected by Dr Gianfranco 
Picco. Once excised, mammary glands were formalin-fixed in 10% neutral buffered 
formalin (Sigma-Aldrich), overnight at room temperature. Fixed mammary glands were 
subsequently paraffin embedded by the King’s Health Partners (KHP) Cancer Biobank 
group at Guy’s Hospital, London. Paraffin-embedded glands were stored at room 
temperature until required for tissue sectioning.  
 
2.5.2 Tissue sectioning 
Paraffin-embedded mammary glands were chilled on ice block before sectioning. The 
block was first trimmed at a thickness of 10µm to expose the tissue surface. Thereafter, 
tissue sections were cut at a thickness of 3µm to produce a ribbon of sections. The ribbon 
of sections was placed on the surface of the water of a 35°C water bath to flatten them 
out. Consecutive sections were separated using tweezers and mounted onto a 
microscope slide. Mounted sections were placed on a slide rack and allowed to dry 
overnight in a 37°C oven. Sections can then be stored at 4°C or immediately subjected 
to immunohistochemistry.  
 
2.5.3 Immunohistochemistry 
Tissue sections were baked at 60°C for 2 hours and de-waxed by incubating in two 
changes of xylene for 2 minutes each. To hydrate the sections, they were incubated in 
two changes of absolute ethanol for 2 minutes per incubation and thereafter in one 
change of 70% ethanol for 2 minutes. The sections were washed in water and subjected 
to antigen retrieval for 20 minutes in 10mM sodium citrate buffer pH6.0 in the pressure 
cooker. Whilst still in the racks, sections were placed in slow running water to allow them 
to cool for 10 minutes. Sections were incubated in blocking buffer (50% FBS in 
phosphate buffered saline (PBS)) for 30 minutes. Following blocking, sections were 
incubated with appropriate primary antibody (Table 2.18) diluted in blocking buffer, for 
60 minutes at room temperature. The sections were washed in three changes of PBS for 
3 minutes per wash and incubated with the appropriate secondary antibody (Table 2.18) 
for 60 minutes at room temperature. The sections were washed in three changes of PBS 
for 3 minutes per wash and incubated in 3,3’-Diaminobenzidine (DAB) (DAKO) for 
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horseradish peroxidase (HRP) antibodies for 3 minutes or in liquid permanent red 
(DAKO) for alkaline phosphatase for 10 minutes. Sections were placed on a slide rack 
and washed once in distilled water. The sections were then counterstained with Mayer’s 
Haematoxylin (Sigma-Aldrich) for 5 minutes, placed in a tray of running water to wash 
off the haematoxylin and then incubated in 1% acid alcohol for 5 seconds. Sections were 
serially dehydrated in 70% ethanol for 5 seconds and incubated in two changes of 100% 
ethanol for 1 minute per incubation. Following dehydrations, sections were incubated in 
xylene for 2 minutes to remove the alcohol. Slides were mounted onto a coverslip and 
left to dry. Immunostaining of sections was visually inspected using the Olympus BX50 
microscope (Olympus). Slides were scanned using the Hamamatsu NanoZoomer 
(Hamamatsu Photonics) by Patryjca Gazinska from the Breast Cancer Now Unit at Guy’s 
Cancer Centre, London. Images were viewed with the Hamamatsu NDP.view2 software.   
 
Table 2.18: Antibodies and reagents used for immunohistochemistry 
 Caveolin-1 KDM5B SMA 
Primary antibody Rabbit polyclonal to 
Caveolin-1 
(ab2910) 
Rabbit 3 antibody. 
Rabbit polyclonal 
to KDM5B 
Smooth muscle actin 
monoclonal mouse 
anti-human clone 1A4 
(M0851) 







domain of human 
KDM5B 
corresponding to 
aa 1283-1473  
N-terminal synthetic 
decapeptide of α-
smooth muscle actin 
(4) 
 
Supplier Abcam In-house DAKO 
Dilution 1:100 1:700 1:500 
Primary antibody  
diluent 
2% FBS/PBS 2% FBS/PBS 2% FBS/PBS 









Supplier DAKO DAKO Abcam 
Dilution  1:100 1:100 1:300 
Secondary antibody 
diluent 
2% FBS/PBS 2% FBS/PBS 2% FBS/PBS 




Liquid permanent red 
(K064011-2) 
Supplier DAKO DAKO DAKO 
Wash buffer PBS PBS PBS 
Blocking buffer 50% FBS/PBS 50% FBS/PBS 50% FBS/PBS 
HRP: Horseradish peroxidase; PBS: phosphate buffered saline 
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2.6 Gene Expression  
	
2.6.1 RNA Extraction 
RNA was extracted from WT and KDM5B KO cells of BT-474 and SKBr3, using the 
RNeasy mini kit (Qiagen) according to manufacturer’s instructions. 2x105 WT and 
KDM5B KO cells of BT-474 or SKBr3, were seeded in a well of a 6-well plate, and 
incubated at 37°C and 5% CO2 for three days. Media was aspirated from wells and cells 
were lysed directly in the well using 350µl of lysis buffer supplied. Cells were scraped 
using a cell scraper and lysate was transferred into an Eppendorf tube and vortexed for 
a one minute to homogenize the lysate. 1 volume (350µl) of 70% ethanol was added to 
the homogenized lysate and mixed by pipetting. 700µl of the sample was transferred into 
an RNeasy spin column (made of silica membrane that binds RNA) placed inside a 2ml 
collection tube. Samples were centrifuged for 15 seconds at ³8000 x g and the flow-
through discarded. To wash the membrane of the spin column, 700µl of the supplied 
wash buffer was added to the RNeasy spin column and centrifuged for 15 seconds at 
³8000 x g and flow-through discarded. The membrane was washed again using 500µl 
of a second wash buffer, centrifuged for 15 seconds at ³8000 x g and flow-through 
discarded. The membrane was washed a second time with 500µl wash buffer and 
centrifuged for 2 minutes at ³8000 x g. The spin column was placed in a fresh collection 
tube and spun for 1 minute at full speed to prevent any carryover of wash buffer. The 
spin column was then placed in a new 1.5ml Eppendorf tube and 42µl RNase free water 
(Thermo Fisher Scientific) was added directly onto the spin column membrane. Samples 
were centrifuged for 1 minute at ³8000 x g to elute RNA. RNA was stored at -80°C. RNA 
concentration was measured using the Nanodrop One spectrophotometer (Thermo 
Fisher Scientific) on the RNA setting.  
 
2.6.2 Bioanalyzer analysis of RNA samples 
The Agilent 2100 Bioanalyzer on-chip electrophoresis platform, was used to further 
check the quality and quantity of RNA. RNA samples were run on the Agilent RNA 6000 
Nano chip according to manufacturer’s instructions. RNA integrity was expressed using 
the RNA integrity number (RIN). Good quality, non-degraded RNA was demonstrated by 
a RIN greater than 7, as well as, the presence of distinct bands of 18S and 28S rRNA in 
the gel image and their corresponding peaks on the electropherogram (Figure 2.4). RNA 




Figure 2.4: Electropherogram trace and gel image from the Agilent 2100 Bioanalyzer. An 
example of electropherogram and corresponding gel image of the SKBr3 wild-type (WT) RNA 
sample with a RIN number of 8.2.  
 
2.6.3 cDNA synthesis for RT-qPCR analysis 
Complementary DNA (cDNA) was generated from the isolated total RNA using the 
qScript cDNA Supermix kit (Quantabio), according to manufacturer’s instructions. A 20µl 
reaction consisting of 1µg of total RNA, 1X qScript cDNA supermix and RNase free water 
(where appropriate), was gently mixed by vortexing and briefly centrifuged to collect 
contents. The mixture was then incubated as follows to generate cDNA: 
• 25°C for 5 minutes 
• 42°C for 30 minutes 
• 85°C for 5 minutes 
Samples were then stored at -20°C.   
 
2.6.4 RT-qPCR analysis 
Relative quantification of genes was determined using the Precision qPCR SYBR green 
Master mix (Primer Design) and Quantitect primers (Qiagen) according to manufacturer’s 
instructions. The primers used in the RT-qPCR reactions are listed in Table 2.19. PUM1 
primer (Eurofins) was used as the reference gene. cDNA was diluted to 5ng/µl and a 
total of 25ng was used for each qPCR reaction. A master mix of each individual primer 
and the qPCR mastermix was prepared (Tables 2.20 and 2.21) and pipetted into 
triplicate wells of a 96 well plate. 5µl of cDNA (5ng/µl) was then added to each well and 
mixed well by pipetting. Plate was sealed and spun at 300 x g for 2 minutes prior to 









cycle conditions for all primers listed in Table 2.19 were: 95°C for 5 minutes, then 40 
cycles at 95°C for 15 seconds, 60°C for 30 seconds, 72°C for 30 seconds.  
Data values were averaged prior to further analysis. Cycle threshold (Ct) was set above 
the background but within the linear phase of amplification for all samples. Data was 
normalised to the PUM1 expression and subsequently analysed using the comparative 
2-DDCt method: ΔΔCT = ΔCT (target gene) − ΔCT(reference gene) 267.  
 
              Table 2.19: Primers used in RT-qPCR reactions 
Target gene ID and Source 
ABCC2 Hs_ABCC2_1_SG QuantiTect Primer Assay 
(QT00056294; Qiagen) 
EGR1 Hs_EGR1_1_SG QuantiTect Primer Assay 
(QT00218505; Qiagen) 
FOS Hs_FOS_1_SG QuantiTect Primer Assay 
(QT00007070; Qiagen) 
KDM5B Hs_KDM5B_1_SG QuantiTect Primer Assay 
(QT00060648; Qiagen) 
LCN2 Hs_LCN2_1_SG QuantiTect Primer Assay 
(QT00028098; Qiagen) 
MYC Forward: 5’- GCC ACG TCT CCA CAC ATC AG-3’ 
Reverse: 5’- TCT TGG CAG CAG GAT AGT CCT-3’ 
(Eurofins Genomics) 
PUM1 Forward: 5’- GAT TAT TCA GGC ACG CAG GT -3’ 
Reverse: 5’- AGC AGC GCT GAT GAT GTA TG -3’ 
(Eurofins Genomics) 
SLC40A1 Hs_SLC40A1_1_SG QuantiTect Primer Assay 
(QT00094843: Qiagen) 
 
            Table 2.20: RT-qPCR master mix components for each reaction using QuantiTect 
             Primers 
 
 1X Master mix  
(per reaction) 
2X Precision qPCR  
SYBR green Master mix  
(PrimerDesign) 
10µl 
10X QuantiTect primers 2µl 
cDNA (5ng/µl) 5µl 




   
     Table 2.21: RT-qPCR master mix components for each reaction using PUM1 or 
            MYC primers 
 
 1X Master mix  
(per reaction) 
2X Precision qPCR  
SYBR green Master mix  
(PrimerDesign) 
10µl 
2µM PUM1 or MYC primer 5µl 




2.7 Microarray Gene Expression analysis  
	
2.7.1 cDNA synthesis and amplification 
The Ovationâ PicoSL WTA system V2 kit (NuGEN Technologies) was used to prepare 
cDNA for gene expression analysis, following cDNA amplification with the Ribo-Single 
Isotheral Amplification (Ribo-SPIA) technology, according to manufacturer’s instructions. 
The Ribo-SPIA technology was used to amplify SKBr3 WT and KDM5B KO cDNA using 
three main steps (Fig 2.5):   
1) The first strand of cDNA is generated using reverse transcriptase producing a 
cDNA/mRNA hybrid molecule with an RNA tag sequence (SPIA tag), at the 5’ 
end of the cDNA strand. 
2) Heat induced fragmentation of mRNA within the cDNA/mRNA complex then 
creates priming sites that allow for second strand synthesis of cDNA by DNA 
polymerase. DNA complementary to the 5’ SPIA tag sequence is also 
synthesized. This generates double stranded cDNA with a DNA/RNA 
heteroduplex that corresponds to the SPIA tag. 
3) Addition of RNase H results in removal of the RNA portion of the SPIA tag 
sequence allowing binding of the SPIA primer (DNA/RNA chimeric primer). cDNA 
synthesis by DNA polymerase at the 3’ end of the SPIA primer displaces the 
forward strand, producing a DNA/RNA heteroduplex. This results in subsequent 
removal of the RNA portion of the SPIA primer by RNase H, and so initiates the 
next round of cDNA synthesis. This process results in rapid cDNA amplification 
producing 2-5µg of cDNA from 500 picograms of RNA.  
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Following amplification, cDNA purification was performed using the MinElute Reaction 
Cleanup kit (Qiagen) according to manufacturer’s instructions. Purity of the amplified 
cDNA samples were run on the 2100 Bioanalyzer platform using the Agilent RNA 6000 
Nano chip. cDNA yield was determined using the NanoDrop 1000 spectrophotometer 
(Thermo Scientific) on the single-stranded DNA setting.  
 
Figure 2.5: Ribo-SPIA process for synthesizing single stranded cDNA. Modified image 
from 268. 
 
2.7.2 Biotinylation of amplified cDNA 
Amplified cDNA was biotinylated using the Encore BiotinIL Module (NuGEN) according 
to manufacturer’s instructions. Removal of the uracil base incorporated during the 
amplification process was achieved through addition of the uracil-DNA glycosylase 
(UNG) enzyme, which resulted in creation of abasic sites in the cDNA strand. 
Subsequent chemical attachment of a biotin moiety onto the abasic site, resulted in 
labelling of the cDNA. Biotin labelled cDNA was purified using the MinElute Reaction 
Cleanup kit (Qiagen) according to manufacturer’s instructions and concentration of 
eluted cDNA (10µl) was determined using the NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific) on the single-stranded DNA setting. The labelled cDNA was 
	 82	
diluted with RNase-free water or concentrated using the Vacufuge vacuum concentrator 
(Eppendorf) to a final concentration of 150ng/µl in a total volume of 5µl.  
 
2.7.3 Hybridisation of biotin-labelled cDNA on Microarray 
One biological repeat of SKBr3 WT and KDM5B KO was analysed by microarray. The 
Illumina HumanHT-12 v4 Expression BeadChip array (Illumina) which targets more than 
47,000 genes, was used. Hybridisation of biotin labelled cDNA on to this array was 
performed by the NIHR BRC Genomics Facility at Guy’s Hospital, London. Scanning of 
the BeadChip was done on the iScan system (Illumina) using GenomeStudio software 
(Illumina). Data analysis was done by Dr Paul Lavender, who used the Partek Genomics 
Suite software (Partek Incorporated) using the 2 way-ANOVA model. Genes were 
considered to be differentially expressed if they had a ³1.5-fold difference in expression. 
Differentially expressed genes that had a fold change  ³1.5 were analysed for enriched 
biological processes using the ToppGene Suite bioinformatics tool 269. Gene Ontology 
(GO) terms were considered to be statistically significant by using the Benjamini-
















2.8 Cell Viability Assays 
	
2.8.1 MTT cell growth assay 
1x104 cells of SKBr3 parental and KDM5B KO cells, were seeded in duplicate in 24 well 
plates and cell growth determined at day 1, 4 and 7 using the thiazolyl blue tetrazolium 
bromide (MTT) (Sigma-Aldrich) assay according to manufacturer’s instructions. At the 
end of each time point, 5µg/ml MTT was added to each well and incubated for 3 hours 
at 37°C with 5% CO2. Cell viability was subsequently determined by measuring 
absorbance at 595nm on the FLUOstar Omega plate reader (BMG Labtech). All optical 
density (OD) values were corrected by subtraction of background values generated using 
the media alone control.  
 
2.8.2 Methylene Blue Assay 
1x104 cells of WT and KDM5B KO cells of BT-474 or SKBr3, were seeded in duplicate in 
24 well plates and cells left to adhere overnight at 37°C with 5% CO2. The following day, 
cells were treated with control (DMSO or PBS), Herceptin (10µg/ml), Lapatinib (100nM) 
or Herceptin/Lapatinib (10µg/ml and 100nM respectively) combination for 0,3 and 6 days. 
Media and control or drug was changed every three days. At the end of each time point, 
media was aspirated from wells and cells were fixed with 4% glutaraldehyde (Sigma-
Aldrich) for 20 minutes at room temperature. Cells were washed twice with PBS and 
subsequently stained with 0.05% Methylene Blue (Sigma-Aldrich) for 20 minutes at room 
temperature, with gentle shaking. Cells were washed three times in a tray of running 
water then air-dried upside down, overnight at room temperature. The following day, 
methylene blue dye was extracted by addition of 3% HCl and incubation for 30 minutes 
with gentle shaking, at room temperature. Cell viability was determined by measuring 
absorbance at 655nm on the FLUOstar Omega plate reader (BMG Labtech). All OD 
values were corrected by subtraction of background values generated using the media 
alone control.  
For the analysis of BT-474 parental and KDM5B KO cell growth, cells were seeded in 
duplicate in 24 well plates and cell growth was determined at day 1, 4 and 7. At the end 




2.8.3 Crystal violet assay 
2.5x103 WT and KDM5B KO cells of BT-474 or SKBr3, were seeded in duplicate onto 6-
well plates and 5µg/ml Herceptin was immediately added to the wells. Cells were 
incubated for 14 days at 37°C with 5% CO2, with media and Herceptin changes every 
three to four days. At the end of the 14-day period, media was aspirated from wells and 
cells were fixed with 4% glutaraldehyde (Sigma-Aldrich) for 20 minutes at room 
temperature. Cells were washed twice with PBS and subsequently stained with 0.05% 
Crystal Violet (Sigma-Aldrich) for 20 minutes at room temperature, with gentle shaking. 
Cells were washed three times in a tray of running water then air-dried upside down, 
overnight at room temperature. The following day, the crystal violet dye was extracted 
by addition of 10% acetic acid and incubation for 30 minutes with gentle shaking, at room 
temperature. Cell viability was determined by measuring absorbance at 570nm on the 
FLUOstar Omega plate reader (BMG Labtech). Viability was calculated as: 
 
!"#$%&'"	$)*+,)$-." = average	OD	of	treatedaverage	OD	of	control  
 
 
2.9 Statistical Analysis 
Unpaired two-sided Student t-test was used to determine whether the means of the 
parental and KDM5B KO cells were significantly different. ANOVA with Sidak multiple 
comparisons test, was used to determine whether there were any statistically significant 
differences between three or more groups. Results were considered statistically 
significant if p<0.05. All statistical analysis was performed using GraphPad Prism® 7 
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To begin studies in understanding the role of KDM5B in HER2+ breast cancer, gene 
editing was employed to knock out KDM5B. Genome editing using endonucleases that 
target specific genomic sequences, have become powerful tools for biological research, 
allowing genetic manipulation of a wide range of organisms and cell types. Here, the 
selected gene editing tool CRISPR-Cas9 was used to develop KDM5B KO cells and so 
will be discussed in more detail below.  
 
3.1.1 CRISPR-Cas system in prokaryotes 
CRISPR-Cas is a prokaryotic adaptive immune system, that uses RNA-guided 
nucleases to destroy invading nucleic acids such as viruses and plasmids 270–272. To date, 
two main classes of CRISPR-Cas systems exist, which are classified according to the 
occurrence of the CRISPR-associated (Cas) proteins. These classes are divided into six 
types (I-VI) and multiple subtypes, of which type I-III and V, have been well 
characterized.  Class 1 CRISPR-Cas systems consist of type I, III and IV and utilise a 
multi-protein effector complex whereas, class 2 systems (type II, V and VI) use one 
effector protein (Fig 3.1) (reviewed by 259. In this work, the type II CRISPR system was 
used and so will be the main system discussed hereafter. The mechanism of the 
CRISPR-Cas system can be divided into three main stages: 1) Protospacer acquisition 




Figure 3.1: CRISPR-Cas immune systems in bacteria. Upon viral or phage infection, a 
sequence of foreign DNA (protospacer), the Cas1-Cas2 complex incorporates the DNA into the 
CRISPR array. The CRISPR array consists of identical repeat sequences (black rectangles) 
interspersed by phage-derived spacers (coloured rectangles) and is flanked by the cas genes 
(blue). To acquire immunity, the CRISPR array is transcribed into a long precursor CRISPR RNA 
(pre-crRNA) which is subsequently processed into short mature CRISPR RNA (crRNA). Type II 
systems, require Cas9, RNase III and tracrRNA for pre-crRNA processing. During interference, 
Cas9, RNase III and tracrRNA:crRNA duplex target and cleave invading DNA. Red triangles 
represent cleavage sites of the interference machinery. Modified image from 259. 
 
3.1.1.1 Protospacer acquisition 
In this stage, invading DNA known as protospacers, are incorporated in-between 
CRISPR repeat sequences (20-50 base pairs), thereby generating a CRISPR array 
273,274. CRISPR arrays are flanked by cas genes that encode Cas proteins, and are 
preceded by an AT-rich leader sequence. Protospacers are usually integrated at the 
leader end of the CRISPR array and for each integrated protospacer, the first CRISPR 
repeat sequence is duplicated, to maintain the repeat-spacer-repeat architecture 273,274. 
Selection of protospacers is dependent on the protospacer adjacent motif (PAM); a short 
sequence located directly next to the protospacer 275,276. In the type II-A system, it has 
been demonstrated that protospacer selection, occurs through the PAM-recognizing 
domain of the Cas9 protein 277,278. Following protospacer selection, Cas9 is thought to 
recruit Cas1, Cas2 and possibly Csn2, for integration of the protospacer into the CRISPR 
array 259.  
Cas9 induces DNA DSB
NHEJ creates random mutations HDR inserts desired target sequence leading 
to precise gene editing
gRNA guides 
Cas9 to target 
sequence











3.1.1.2 crRNA biogenesis 
The second stage of the CRISPR-Cas adaptive immune system, involves acquisition of 
immunity. This involves the transcription of the CRISPR array into a long precursor 
crRNA (pre-crRNA), followed by processing into short guide crRNAs, which requires the 
trans activating CRISPR RNA (tracrRNA) 279. tracrRNA is a 24-nucleotide sequence that 
is complementary to the CRISPR repeat 279. tracrRNA and pre-crRNA form an RNA-
duplex, which is stabilized by Cas9 and processed by the host RNase III, resulting in an 
intermediate crRNA that is further processed to a mature small guide crRNA 279. These 
guide crRNAs contain protospacer sequences required for adaptive immune response.  
 
3.1.1.3 crRNA guided interference 
The third stage of CRISPR-Cas adaptive immunity involves crRNA guided interference 
of invading nucleic acids. crRNAs guide the Cas9 effector protein to invading nucleic 
acids, which are identified through complementary base-pairing 280. Cas9 subsequently 
cleaves the invading DNA through introduction of a DSB 280. Cleavage by Cas9 occurs if 
the invading sequence is adjacent to a PAM sequence, thus preventing self-targeting.  
 
3.1.2 Applications of CRISPR-Cas9 technology 
CRISPR-Cas9 has been exploited in different fields of biological research and medicine, 
to introduce precise gene modifications in cells or organisms. In this context, the type II 
CRISPR system from Streptococcus pyogenes has been simplified to consist of two 
components: Cas9 nuclease protein and a guide RNA (gRNA), which is a hybrid of the 
crRNA: tracrRNA duplex 280. The gRNA, a 20-nucleotide (nt) sequence, directs Cas9 to 
a specific complementary DNA sequence where Cas9 induces a DSB (see Fig 1.7 in 
Chapter 1 section 1.9). The gRNA must lie upstream of a PAM sequence to allow 
cleavage of the target DNA by Cas9. PAM sequences in S. pyogenes are in the form 5’-
NGG, thus any DNA sequence in the form N20-NGG can be targeted by Cas9, by altering 
the 20-nt gRNA sequence to correspond to a target of interest. Type II CRISPR systems 
from other bacterial species that have different crRNA and tracrRNA sequences and 
recognise different PAM sequences, have also been used 281,282. However, the S. 
pyogenes is the most commonly used and well characterised type II CRISPR system. 
Genome editing using the CRISPR-Cas9 system takes advantage of eukaryotic DNA 
repair mechanisms, to repair Cas9-induced DSB by NHEJ. NHEJ is an error-prone 
mechanism that results in the introduction of deletions, insertions, point mutations or 
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frameshifts, that can alter the gene product leading to loss of function 283. This loss of 
gene function is what is termed as genetic knockout (KO), and is the desired outcome of 
CRISPR-Cas9 targeting. For precise gene editing, homology directed repair (HDR) 
pathway is used. This is achieved by using, a DNA sequence that shares sequence 
homology with the target site, to repair the Cas9-induced DSB via homologous 
recombination. The DNA sequence can contain any alteration e.g. insertion or deletion, 
thus allowing precise editing of the target sequence 284,285. 
CRISPR-Cas9 has also been used to regulate gene transcription by mutating the 
nuclease domain of Cas9 thus resulting in a nuclease ‘dead’ protein (dCas9) (reviewed 
by 259). Targeting a gene’s promoter region or open reading frame using dCas9 prevents 
binding of RNA polymerase and inhibits mRNA elongation. Alternatively, dCas9 can be 
fused to a transcriptional activator or repressor thus allowing gene expression or 
inhibition, respectively. CRISPR-Cas9 has also been utilised in genome-wide screens 
through reverse genetics, whereby the resultant phenotype from a gene knockout, is 




In this Chapter, development of KDM5B KO in HER2+ breast cancer cell lines using 
CRISPR-Cas9, is documented. This was achieved by: 
1) Examining expression of KDM5B in breast tumours and cell lines. This was to 
enable selection of suitable cell lines for KDM5B gene editing 
2) Investigating expression of KDM5B in Herceptin sensitive and resistant cell lines 
3) Selection of suitable guide RNAs for KDM5B gene editing 
4) Co-transfection of selected gRNA and Cas9 in HER2+ breast cancer cell lines, 
followed by single cell cloning 
5) Screening and selection of KDM5B KO clones using indel analysis, followed by 









3.2.1 KDM5B expression is upregulated in Luminal A and HER2+ 
breast tumours and cell lines 
	
3.2.1.1 Copy number and gene expression analysis of KDM5B in breast 
cancer 
Upon discovery of KDM5B,183 first showed that KDM5B mRNA expression was 
upregulated in breast cancer cell lines. Later, studies using Single Nucleotide 
Polymorphism (SNP) array analysis, identified KDM5B as a gene with copy number gain 
in breast cancer 286. More recently, it was demonstrated that increased KDM5B mRNA 
expression is associated with copy number gain 202. To confirm these observations, two 
published breast cancer databases containing copy number (CN) and gene expression 
(GE) data were used.  
The first database, Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) contains CN and GE profiles of 2509 tumours 46,287. The second, The 
Cancer Genome Atlas (TCGA), contains CN and GE profiles of 825 breast tumours 288. 
These datasets were downloaded from the cBioPortal platform 289,290. Increased KDM5B 
mRNA expression was found to be associated with copy number gain or amplification in 
both datasets (Fig 3.2A). It was further investigated whether KDM5B expression was 
associated with breast cancer subtypes (luminal A, luminal B, HER2-enriched, basal-like 
and normal-like), as classified by the PAM50 gene classifier 45. KDM5B mRNA 
expression was significantly higher in the HER2+ tumours compared to the other 
subtypes in the METABRIC dataset (Fig 3.2B), thus corresponding with previous 
observations 202. In the TCGA dataset, there was no significant difference in KDM5B 
expression between HER2+ and luminal A subtypes. These findings suggest that 
KDM5B may play an important role in luminal A and HER2+ breast cancers. Indeed, 
KDM5B has been shown to be an oncogenic driver of the luminal lineage in breast cancer 







Figure 3.2: KDM5B expression is upregulated in luminal A and HER2 breast cancer. A) 
Increased KDM5B mRNA expression is associated with copy number gain or amplification in the 
METABRIC and TCGA datasets. Sample numbers are indicated below each copy number 
alteration. B) KDM5B mRNA expression is significantly upregulated in luminal A and HER2+ 
breast tumours. Sample numbers are indicated below each PAM50 subtype. METABRIC and 
TCGA data was downloaded from the cBioportal platform. Asterisks indicate significance where 
*=p£0.05, **=p£0.01, ***=p£0.001, ****=p£0.0001. n.s = not significant. Statistical significance 
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3.2.1.2 KDM5B protein expression in breast cancer cell lines 
The expression of KDM5B was then examined in a panel of breast cancer cell lines. 
These cell lines are representative of the PAM50 breast cancer subtypes. KDM5B 
protein levels were high in ER+ (luminal) and HER2+ (HER2-enriched) cell lines, and 
low in the triple negative (TN; basal-like) cells (Fig 3.3), agreeing with the gene 
expression analysis in primary breast tumours (Fig 3.2B). BT-474 and SKBr3 were the 
two chosen HER2+ breast cancer cell lines used in this project.  
 
     
 
 
                  
Figure 3.3: Protein expression of KDM5B in breast cancer cell lines. A) Whole cell lysates of 
six breast cancer cell lines were subjected to western blot and probed with KDM5B antibody. 
HSC70 was used as a loading control. B) Blots were quantified using ImageJ. Values represent 












































































































































































































































































































































































































































































































































































































































































































3.2.2 Expression of KDM5B in Herceptin resistance breast cancer 
cell lines 
To begin studies in understanding the role of KDM5B in resistance of HER2+ breast 
cancer, protein expression of KDM5B was examined in Herceptin sensitive and 
Herceptin resistant cell lines.  
Treatment of SKBr3 cells with 20nM Herceptin for 48 hours, resulted in down-regulation 
of KDM5B expression (Fig 3.4). Similarly, a 48-hour treatment with 100nM Lapatinib, a 
dual EGFR/HER2 tyrosine kinase inhibitor, also down-regulated KDM5B expression (Fig 
3.4). These findings confirm observations by 183, who showed that KDM5B is 
downregulated by Herceptin treatment, suggesting involvement of KDM5B in HER2 
signalling. Interestingly, phosphorylated HER2 (pHER2) was downregulated by 
Lapatinib, but not by Herceptin (Fig 3.4). This corresponds with previous data showing 
no effect on HER2 phosphorylation following Herceptin treatment, in SKBr3 cells 291.  
Next, KDM5B expression was examined in Herceptin resistant cells, that had been 
developed by weekly treatment with 40µg/ml Herceptin, for 8 months 109. KDM5B protein 
levels in both BT-474 and SKBr3 Herceptin resistant cell lines (BT-474-HR and SKBr3-
HR respectively) did not change, in comparison to WT cells (Fig 3.5), suggesting that 
KDM5B may play a role in Herceptin resistance.  
Interestingly, SKBr3-HR cells did not express detectable pHER2 (Fig 3.5) and HER2 
(data not shown). Loss of HER2 amplification and overexpression has been observed in 
a BT-474 Herceptin resistant clone, and in patients who have undergone Herceptin-
based neoadjuvant therapy 103, suggesting a mechanism of resistance operating through 
enhancement of other signalling pathways. HER2 protein expression was undetected in 
3 out of 4 independent experiments and because of this inconsistency, this result could 
be an effect of culturing conditions. Therefore, it is important to regularly assess HER2 









Figure 3.4: Herceptin and Lapatinib treatment reduces KDM5B expression in SKBr3 cells. 
Whole cell lysates of SKBr3 cells treated with vehicle, 100nM Lapatinib or 20nM Herceptin were 
subjected to western blot and probed with KDM5B and pHER2 antibodies. Lamin B was used as 
a loading control. Blots were quantified on image J software. Values show relative expression to 
vehicle control after normalising to Lamin B. Blots represent one experiment.  





Figure 3.5: KDM5B expression in Herceptin resistant breast cancer cell lines. Whole cell 
lysates of parental and Herceptin resistant BT-474 and SKBr3 cells were subjected to western 
blot and probed with KDM5B and pHER2 antibodies. HSC70 was used as a loading control. Blots 

































































































3.2.3 Generating KDM5B knockout breast cancer cell lines using the 
CRISPR-Cas9 gene editing technique 
 
3.2.3.1 CRISPR Workflow 
To examine the function of KDM5B in HER2+ breast cancer, KDM5B was knocked out 
in BT-474 and SKBr3 HER2+ cell lines, using CRISPR-Cas9 technology. The CRISPR 
workflow used to develop KDM5B KO cell lines is shown in Figure 3.6, with each being 
illustrated in more detail. 
 
 
Figure 3.6: CRISPR workflow. Cells are transfected with Cas9 and KDM5B gRNAs, the day 
after seeding. Three days post transfection, cells are subjected to FACS to sort for cells with a 
specific GFP intensity. Sorted cells are single cell cloned into 96-well plates for approximately 5-
8 weeks. Single cell clones are identified, picked and expanded in 24-well plates. Once confluent, 
DNA is extracted from cells using the Quick extract DNA solution. DNA samples are subsequently 
amplified by tri-primer PCR using forward (F) and reverse (R) primers that flank the targeted 
gRNA site, and a FAM labelled primer. Fluorescently labelled amplicons are analysed by capillary 
electrophoresis to identify indels produced. KO clones are selected, expanded and confirmed by 





















































3.2.3.2 Design and construction of CRISPR-Cas9 KDM5B gRNAs 
Four gRNA sequences targeting KDM5B (Table 3.1) were selected using the CRISPR-
Cas9 target site selection tool CHOPCHOP (https://chopchop.rc.fas.harvard.edu/). 
gRNAs were targeted to exons 1, 4, 5 and 6 of KDM5B as shown in Figure 3.7. The 
gRNA sequences were cloned into the PX458 vector which was co-transfected with the 
Cas9 vector into breast cancer cell lines as described in Chapter 2.  
Table 3.1: KDM5B gRNA target sequence.  
gRNA Target sequence PAM Exon Strand 
1 CGGCCCATAGCCGAGCAGAC TGG 1 + 
2 GTTTGCTCCTGGCAAAGCAG TGG 4 + 
3 AGGCTGCACAGACTGCCTCT GGG 5 - 
4 TCATAATCTGAGACGTCGAA TGG 6 + 
List of KDM5B target sequences, PAM sequences, targeted exons and strand orientation of 
gRNAs. gRNA 1 (green) targets exon 1, gRNA 2 (blue) targets exon 4, gRNA 3 (red) targets exon 
5 and gRNA 4 (purple) targets exon 6. 
 
 
Figure 3.7: Schematic structure of KDM5B showing gRNA targeted exons and the corresponding 
position of the exons on the KDM5B protein. 
 
 
3.2.4 Experimental selection of KDM5B gRNA 
	
3.2.4.1 FACS Analysis of Cas9 and KDM5B gRNAs transfected in SKBr3 
cells 
Plasmids containing the four gRNAs targeting KDM5B, were individually co-transfected 
with the Cas9 plasmid into SKBr3 cells by nucleofection. 72 hours post transfection, cells 
were subjected to fluorescence activated cell sorting (FACS), to select fluorescent GFP 
expressing cells. All of the gRNAs tested had a transfection efficiency of approximately 
50-60% of the total population, as detected by GFP expression in the Cas9 plasmid. 12-
15% of these cells had a high GFP intensity (>104) (Fig 3.8) and were therefore sorted 
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Figure 3.8: FACS analysis of SKBr3 cells transfected with KDM5B gRNAs and Cas9. 
Transfection efficiency of all gRNAs was approximately 60%, of which 12-15% of this population 
was selected for sorting as they had a high GFP intensity. A) gRNA targeting exon 1 B) gRNA 
targeting exon 4 C) gRNA targeting exon 5 and D) gRNA targeting exon 6. 
 
 
3.2.4.2 Screening of KDM5B gRNAs cutting efficiency using indel 
detection by amplicon analysis (IDAA) 
Bulk sorted SKBr3 cells were validated by IDAA as described in Chapter 2. DNA was 
extracted from cells and amplified by tri-primer PCR. Fluorescently labelled PCR 
amplicons were subsequently analysed by capillary electrophoresis. Fragment analysis 
showed induction of indels with gRNA 2, that was targeting exon 4 (Fig 3.9A). This gRNA 
produced various indels i.e. 1, 2, 3, 4, 5, 6 and 7bp deletions and a 1bp insertion. gRNAs 
3 and 4 that were targeting exons 5 and 6 respectively, did not produce any indels (Fig 
3.9B and C). No data was available for samples targeted with gRNA 1, due to technical 





















Figure 3.9: IDAA screening of KDM5B gRNAs cutting efficiency. SKBr3 cells transfected with 
Cas9 and KDM5B gRNA targeting exons 1, 4, 5 and 6 were bulk sorted and analysed by Indel 
Detection by Amplicon Analysis (IDAA). A) gRNA 2 targeting exon 4 successfully induced indels 
in the KDM5B gene. Deletions denoted as -1, -2, -3, -4, -5, -6 and -7 correspond to the number 
of deleted base pairs. Insertions are denoted as +1, corresponding to the number of base pairs 
inserted. B) gRNA 3 and C) gRNA 4 targeting exon 5 and 6 respectively, did not induce any indels 
in the KDM5B gene. Analysis was done on the Peak Scanner Software. 
 
3.2.5 Development of KDM5B Knockout cell lines 
	
3.2.5.1 FACS analysis of CRISPR targeted KDM5B in BT-474 and SKBr3 
cells 
The selected gRNA 2 (targeting exon 4 of KDM5B) and Cas9 plasmids were co-
transfected into BT-474 and SKBr3 cells, by nucleofection. 72 hours post transfection, 
cells were subjected to FACS analysis. For this experiment, cells with a GFP intensity of 
between 103-104 were selected, to reduce the selection of clones with potential off target 
site, which can occur with high Cas9 transfection. The sorted population was 1% and 
13.3% for BT-474 and SKBr3 cells, respectively (Fig 3.10). These cells were 














































































































































































































































































































































































































































































































Figure 3.10: FACS analysis of BT-474 and SKBr3 cells transfected with KDM5B gRNA 2 
and Cas9 plasmids. Gating of transfected cells with specific GFP fluorescent intensity levels. 




3.2.5.2 IDAA screening of CRISPR-Cas9 targeted KDM5B single cell 
clones in BT-474 and SKBr3 cells  
CRISPR-Cas9 targeted KDM5B single cell clones were cultured for approximately 8 
weeks prior to IDAA, to obtain sufficient number of cells to split allowing half to be used 
for IDAA. In total, 17 single cell clones were analysed in BT-474 cells (Fig 3.11) and 29 
















                  
                  
                                               Amplicon size (bp) 
Figure 3.11: IDAA screening of CRISPR targeted KDM5B single cell clones in BT-474 cells. 
DNA was extracted from single cell clones and amplified by tri-primer PCR. Fluorescently labelled 
amplicons were run on a capillary electrophoresis sequencer and thereafter data was analysed 
on the Peak Scanner software. The selected KDM5B KO clones, B113C and G113C are shown 
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Figure 3.12: IDAA screening of CRISPR targeted KDM5B single cell clones in SKBr3 cells. 
DNA was extracted from single cell colonies and amplified by tri-primer PCR. Fluorescently 
labelled amplicons were run on a capillary electrophoresis sequencer and thereafter data was 
analysed on the Peak Scanner software. The selected KDM5B KO clone, F113E, is shown in a 
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Clones were selected as potential KOs if they did not have the parental allele or in-frame 
indels. Furthermore, the growth rate was also a determining factor in selecting KDM5B 
KO clones, as clones that did not grow very well were not selected. In BT-474, this 
resulted in 10 clones being selected as potential KOs. These clones were subsequently 
screened by western blot for KDM5B expression, which identified B113C and G113C 
clones as KDM5B KOs, since they did not have any detectable KDM5B protein (Fig 
3.13). In SKBr3 cells, 2 clones (D910B and F113E) were selected as potential KOs and 
screened by western blot. The D910B clone showed expression of KDM5B, whereas the 




Figure 3.13: Screening of KDM5B CRISPR targeted clones in BT-474. Whole cell lysates of 
BT-474 WT and KDM5B CRISPR targeted clones were subjected to western blot and probed with 





Figure 3.14: Screening of KDM5B CRISPR targeted clones in SKBr3. Whole cell lysates of 
SKBr3 WT and KDM5B CRISPR targeted clones were subjected to western blot and probed with 






















3.2.5.3 Validation of CRISPR-Cas9 targeted KDM5B KO clones by Sanger 
Sequencing 
To confirm the presence of the indels identified in the CRISPR targeted KDM5B clones 
(BT-474 B113C, BT-474 G113C and SKBr3 F113E), DNA of the targeted site (Exon 4) 
was PCR amplified and sequenced. Sanger sequencing data was analysed using the 
CodonCode Aligner software and was in agreement with IDAA, as the sequences 
identified in each of the clones had the exact indels shown by IDAA. Two sequences 
were identified in the BT-474 B113C clone, 3 sequences in the BT-474 G113C clone and 
4 sequences in the SKBr3 F113E clone. The sequences and their corresponding indels 
are shown in (Fig 3.15), and were identified with the assistance of Dr. Zhang Yang, 
University of Copenhagen. Furthermore, the number of sequences identified in BT-474 
G113C and in SKBr3 F113E correspond to KDM5B copy number in these cell lines, 
where the copy number of KDM5B is three in BT-474 and four in SKBr3, as analysed in 
the cancer cell line encyclopedia (CCLE) 292. However, since only two sequences were 
























Figure 3.15: Sanger sequencing of CRISPR targeted KDM5B clones. A) Sequencing traces 
of Parental and CRISPR targeted KDM5B clones showing KDM5B gene disruption in the clones. 
B) Sequences of CRISPR targeted KDM5B clones with their respective indels. Red: gRNA 2 
target sequence and PAM sequence; Bold red uppercase: Inserted bases; dashed line: deleted 
bases. The position of Cas9 cutting site is indicated with an orange arrow. Sequences were 





























CCAAGATGGGgtttgctcc_ _ _ _ _ _ _ _ _ _ _tggGCTCACATATCAGAGGGATTATGAACGAATTCTCAACCCCTA
CCAAGATGGGgtttgctcctggcaaagcagtggGCTCACATATCAGAGGGATTATGAACGAATTCTCAACCCCTA
CCAAGATGGGgtttgctcctggcaaagGcagtggGCTCACATATCAGAGGGATTATGAACGAATTCTCAACCCCTA 














3.2.5.4 Validation of CRISPR-Cas9 targeted KDM5B clones by western 
blot and RT-qPCR 
KDM5B KO clones were further validated by western blot and RT-qPCR. KDM5B protein 
was not detected in the BT-474 and SKBr3 KO clones by western blot analysis (Fig 3.16 
and 3.17). Protein expression of KDM5A and KDM5C were also examined to determine 
whether they compensated for KDM5B KO. Expression levels of KDM5A and KDM5C 
did not change in the KDM5B KO clones in comparison to parental cells (Fig 3.16 and 
Fig 3.17). KDM5D was not examined as being located on the Y chromosome168 it is not 
expressed in females.  
KDM5B mRNA expression by RT-qPCR in the KO clones showed a fold change of 0.28 
in BT-474 B113C, 0.07 in BT-474 G113C and 0.13 in the SKBr3 F113E clones (Fig 
3.18A and 3.18B). Taken together, these findings confirm complete KDM5B KO in the 
SKBr3 F113E clone and BT-474 G113C clone. Whereas, the low KDM5B mRNA 
expression in the BT-474 B113C clone, suggests a partial/incomplete KO. Thus, further 
studies utilizing this clone needs to consider this low mRNA expression, when making 
conclusions on any molecular and/or phenotypic observations. These clones will 





Figure 3.16: Validation of KDM5B KO in BT-474 cells by western blot. A) Western blot 
analysis showing no detectable KDM5B protein in the KO clones. Expression of KDM5A and 
KDM5C was not changed in the KDM5B KO clones. HSC70 was used as a loading control. Blots 
are representative of 3 independent experiments. B) Quantification of blots on imageJ software. 
Error bars indicate s.e.m of 3 independent experiments. Asterisks show significance where **** = 























































































Figure 3.17: Validation of KDM5B KO in SKBr3 cells by western blot. A) Western blot analysis 
showing no detectable KDM5B protein in the KO clones. Expression of KDM5A and KDM5C was 
not changed in the KDM5B KO clones. HSC70 was used as a loading control. Blots are 
representative of 3 independent experiments. B) Quantification of blots on imageJ software. Error 
bars indicate s.e.m of 3 independent experiments. Asterisks show significance where **** = 






Figure 3.18: Validation of KDM5B KO clones by RT-qPCR. Expression of KDM5B in the KO 
clones was quantitated relative to parental cells. Cells were normalised to expression of the 
housekeeping gene PUM1. Values are fold changes ± s.e.m. of 3 independent experiments. 
Asterisks show significance where * = p£0.05, *** = p£0.001 and **** = p£0.0001. Statistical 


































































































































































































In this Chapter, upregulation of KDM5B in breast tumours is shown and this increased 
expression was found to be associated with copy number gain and/or amplification. 
Furthermore, KDM5B was found to be particularly increased in HER2+ and ER+ breast 
tumours and cell lines, suggesting it may play an important role in these tumours. Since 
KDM5B has been implicated in drug resistance of various cancers 204,212, its expression 
was examined in Herceptin resistant HER2+ breast cancer cells. KDM5B protein levels 
in BT-474 and SKBr3 Herceptin resistant cells was similar to WT cells. This is in contrast 
to its downregulation in SKBr3 Herceptin sensitive cells, thus suggesting that KDM5B 
may play a role in Herceptin resistance in these cells.  
The study of gene function in various biological processes, has been accelerated by the 
development of genome editing tools such as CRISPR-Cas9. To understand the role of 
KDM5B in HER2+ breast cancer cells including drug resistance, CRISPR-Cas9 was 
employed to develop KDM5B KO breast cancer cell lines. KDM5B KO was successfully 
achieved in BT-474 and SKBr3 cells. Confirmation of gene inactivation by RT-qPCR 
revealed substantial reduction of KDM5B in the KO cell lines, which could be due to 
degradation of nonsense mRNAs via the nonsense-mediated decay (NMD) pathway 293. 
However, in the BT-474 KO1* cells there is still some mRNA expression. The difference 
between BT-474 KO1* and BT-474 KO2 cells could relate to the number of targeted 
alleles, i.e. two versus three alleles, respectively, as observed by IDAA. Since KDM5B 
has a copy number of three in BT-474 cells, it suggests that one of the alleles was not 
targeted in the BT-474 KO1* cells. Since KDM5B protein in the BT-474 KO1* cells was 
not detected on western blot, this may be a reflection on the sensitivity of the assay 
therefore, it is important to consider the mRNA expression in any differences observed 
between the two clones in future experiments.  
In this first round of targeting KDM5B using CRISPR-Cas9, only one KDM5B KO clone 
was developed in SKBr3 cells. It would have been ideal to have a second KDM5B KO 
clone, to enable validation of any phenotypes observed in these cells. Although the 
D910B was a potential KO as visualised by IDAA, western blot analysis showed the 
presence of KDM5B protein. Re-targeting of nuclease edited cells has been shown to 
increase editing efficiency 294. Thus, this clone could be re-targeted to assess whether 
complete KDM5B KO can eventually be achieved. Unfortunately, the other potential KO 
clones B63A, D33B, E43D, E113D and G53B were discarded as it was initially thought 
that they were not KOs, therefore they cannot be further analysed or re-targeted. These 
KDM5B KO cell lines will now be used to study the function of KDM5B in gene expression 
and response to HER2 targeted therapies in HER2+ breast cancer cell lines.   
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4 : KDM5B regulation of Caveolin1 in the 
































Genome-wide analyses looking at KDM5B occupancy, have revealed its association with 
transcriptional start sites, where it binds at the regions containing the H3K4me3 mark on 
promoters of target genes 146,202. Clearly demonstrating that KDM5B can repress target 
genes via its demethylase activity. One of the target genes that was found to have 
increased expression upon KDM5B KD which correlated with increased H3K4me3 levels 
in the MCF-7 breast cancer cell line, is CAV1 146. Understanding KDM5B regulation of 
CAV1 is of particular interest because, recent data from our laboratory using a mouse 
model suggests that CAV1 may normally be downregulated by KDM5B, during normal 
mammary gland development. 
In the mouse mammary gland, CAV1 negatively regulates STAT5a expression since its 
knockout resulted in hyperactivation of JAK2/STAT5 signalling 231. Interestingly, in the 
mid-pregnant mammary gland of the ΔARID mouse which lacks KDM5B demethylase 
activity, pSTAT5 is downregulated 196 and this correlates with upregulation of CAV1 
(Steven Catchpole personal communication). Therefore, KDM5B could play a role in 
downregulating CAV1 expression, thus enabling activation of the JAK2/STAT5 signalling 
pathway and in turn alveologenesis.  
CAV1 expression is generally downregulated in breast cancer 232,233, where it may act as 
a tumour suppressor 234. However, in the aggressive basal-like and triple negative breast 
cancers CAV1 expression has been reported to be upregulated 233,236. In contrast, high 
expression of CAV1 in breast cancer associated fibroblasts has been found to be 
associated with good prognosis 239,242. More recently, stromal CAV1 expression in TNBC 
was shown to predict better overall survival in Asian women 238. Taken together, these 










Data from previous studies, suggest a possible role for KDM5B in repression of CAV1 
expression, during normal mammary gland development and in some breast cancer cell 
lines. However, it is not clear how widespread the downregulation of CAV1 by KDM5B 
is seen in different breast cancer cell lines, nor is it clear, which cell types in the 
developing mammary gland (luminal, myoepithelial and fat cells), could be responsible 
for downregulation of CAV1 by KDM5B. This chapter aims to further understand KDM5B 
regulation of CAV1 in mammary gland development and breast cancer by examining:  
1) Expression and copy number of CAV1 in breast tumours  
2) Expression of CAV1 and KDM5B in breast tumours and cell lines 
3) CAV1 expression in KDM5B KO breast cancer cell lines 
4) Expression of CAV1 and KDM5B in normal breast fibroblasts and breast 
cancer-associated fibroblasts 




















4.2.1 CAV1 expression in breast tumours and cell lines 
	
4.2.1.1 Copy number and gene expression analysis of CAV1 in breast 
tumours 
CAV1 is downregulated in a majority of breast cancers and cell lines 232,237, with the 
exception of aggressive subtypes such as basal-like and triple negative 233,236. To confirm 
these observations and to determine whether CAV1 expression was driven by copy 
number aberrations, the METABRIC breast cancer database was used. Decreased 
CAV1 mRNA expression was found to be associated with copy number deletion in a 
fraction of breast cancers (186 out of 1903) (Fig 4.1A). However, since a majority of the 
tumours were diploid (1478 out of 1903), it suggests that other factors may be driving 
downregulation of CAV1. It was further investigated whether CAV1 expression was 
associated with breast cancer molecular subtypes (luminal A (LumA), luminal B (LumB), 
HER2+ (HER2+), basal-like and normal-like), as classified by the PAM50 gene classifier 
45. CAV1 expression was found to be downregulated in all breast cancer subtypes, in 
comparison to the normal-like subtype (Fig 4.1B). CAV1 expression was however 
significantly lower in the basal-like, HER2+ and LumB subtypes in comparison to the 
LumA subtype (Fig 4.1B).  
 
 
Figure 4.1: CAV1 expression is downregulated in breast cancers. A) Decreased CAV1 mRNA 
expression is associated with copy number deletion in the METABRIC dataset. Sample numbers 
are indicated below each copy number alteration. B) CAV1 mRNA expression is significantly 
downregulated in breast cancer tumours. Sample numbers are indicated below each PAM50 
subtype. METABRIC data was downloaded from the cBioportal platform. Asterisks indicate 
significance where, ****=p£0.0001. ns=not significant. Statistical significance was calculated 
using One-way ANOVA with Sidak correction. 
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4.2.1.2 CAV1 and KDM5B expression in breast cancer 
 
In order to determine whether CAV1 and KDM5B expression correlate in breast cancer, 
their expression was examined in breast tumours and a panel of breast cancer cell lines. 
Further analysis using the METABRIC dataset to validate whether CAV1 and KDM5B 
genes are inversely correlated in breast cancers, showed a weak negative correlation 
between the two proteins (Fig 4.2A). CAV1 expression was examined in six breast 
cancer cell lines that were representative of the breast cancer molecular subtypes. CAV1 
was abundantly expressed in the triple negative cells (TN; most TN are associated with 
the basal-like subtype) (MDA-MB-231 and HCC1143), moderately expressed in the ER+ 
(luminal) cell line (MCF-7), but not in the ER+ T47D cell line (Fig 4.2B). Very low 
expression was observed in the HER2+ cell lines (BT-474 and SKBr3) (Fig 4.2B). 
Interestingly, expression of CAV1 was generally inversely correlated with KDM5B 
expression in these cells lines. In particular, the TN cells had very low levels of KDM5B, 
whereas the HER2+ cells had moderate to high levels of KDM5B expression (Figure 
3.3A section 3.2.1.2). The difference in the level of CAV1 expression in the two ER+ cell 
lines, indicates that even within a subtype, phenotypic variation is seen.  
 
 
Figure 4.2: KDM5B and CAV1 expression in breast cancer. A) Correlation between CAV1 and 
KDM5B mRNA expression in breast tumours from the METABRIC dataset. N=1904 pairs. B) 
Whole cell lysates of breast cancer cell lines were subjected to western blot and probed for CAV1. 
HSC70 was used as a loading control. Blots are representative of two independent experiments 



























































































































































































































































































































































































4.2.2 Global H3K4me3 expression in KDM5B KO breast cancer cell 
lines 
Transcriptional repression by KDM5B on its target genes, has been shown to occur 
through its demethylase activity acting on the active H3K4me3 mark, found on the 
promoters of these genes 146. Thus, prior to examining CAV1 expression in the KDM5B 
KO cells, global H3K4me3 levels were examined in these cells.  H3K4me3 levels was 
high in BT-474 KO2 cells and moderately increased in the BT-474 KO1* cells, in 
comparison to WT cells (Fig 4.3A). Contrastingly, KDM5B KO in SKBr3 cells did not alter 
global H3K4me3 levels (Fig 4.3B). Lack of increased global H3K4me3 levels upon 
KDM5B silencing has previously been observed in MCF-7 cells 146. The authors did 
however observe increased H3K4me3 levels on the promoters of KDM5B target genes 




Figure 4.3: Global H3K4me3 expression in KDM5B KO cells. Acid extracted histone proteins 
from wildtype (WT) and KDM5B KO cells of A) BT-474 and B) SKBr3 cells, were subjected to 
western blot and probed with the H3K4me3 antibody. Histone H3 was used as a loading control.  
C) and D) Quantification of blots was done on imageJ software. Blots were normalised to histone 
H3 and thereafter to WT cells. Error bars indicate s.e.m of two independent experiments. Blots 














































































4.2.3 KDM5B transcriptionally represses CAV1 expression in SKBr3 
cells 
Since silencing of KDM5B activates CAV1 expression in MCF-7 breast cancer cells 
146,156, CAV1 expression was examined in the BT-474 and SKBr3 KDM5B KO cells, to 
determine whether KDM5B regulates its expression in these cell lines. CAV1 was 
markedly upregulated upon KDM5B KO in SKBr3 cells (Fig 4.4A). Interestingly, KDM5B 
KO did not alter CAV1 expression in BT-474 cells (Fig 4.4B). This data demonstrates 
that KDM5B regulates CAV1 in a cell phenotype dependent manner since, BT-474 being 
an ER+/HER2+ cell line, has different signalling pathways in comparison to SKBr3, an 





Fig 4.4: CAV1 expression upon KDM5B KO in SKBr3 and BT-474 cells. Whole cell lysates of 
A) BT-474 WT KO1* and KO2 cells and B) SKBr3 WT and KO cells were subjected to western 




4.2.4 KDM5B and CAV1 expression in normal breast fibroblast and 
breast cancer-associated fibroblasts 
Studies have shown that high CAV1 expression in breast cancer-associated fibroblasts 
(CAFs), is associated with good clinical outcome 239. However, the mechanism of CAV1 
downregulation in the stroma, is still poorly understood. Since KDM5B can repress CAV1 
expression in some cell types (Fig 4.4), and this can be reflected as an inverse 
correlation between CAV1 and KDM5B expression, the level of expression in two strains 
of breast CAFs was examined. Levels of these proteins were compared to levels found 
in the cell line derived from a normal breast fibroblast. KDM5B expression in breast CAFs 
(LS11-045 and LS11-088) was downregulated in comparison to the normal breast 
fibroblast line (HMFU19). Conversely, CAV1 expression was upregulated in these breast 
CAFs in comparison to the normal breast fibroblast line (Fig 4.5). Clearly the levels of 
CAV1 in these two CAFs are high and so would predict a good clinical outcome. The 












could be involved in downregulation of CAV1 expression in breast fibroblasts. Thus, 
inhibiting KDM5B in breast CAFs that have a low CAV1 expression, could potentially be 
beneficial in the clinic.  
 
Figure 4.5: Expression of CAV1 and KDM5B in the normal breast fibroblast and breast 
cancer-associated fibroblasts. Whole cell lysates of the normal breast fibroblast line HMFU19 
and breast CAFs were subjected to western blot and probed with KDM5B and CAV1 antibodies. 
HSC70 was used as a loading control. Blots are from one experiment. 
	
4.2.5 Cellular distribution of KDM5B and CAV1 in the mouse 
mammary gland  
At mid-pregnancy, data from our laboratory has shown that deletion of the demethylase 
activity of KDM5B, activates CAV1 expression (Steven Catchpole personal 
communication) and downregulates pSTAT5 196 in the mouse mammary gland. Since 
KDM5B represses CAV1 expression by demethylating the H3K4me3 active mark found 
on the CAV1 promoter, it requires that KDM5B and CAV1 are expressed in the same 
cells. Therefore, to investigate the cellular distribution of these proteins, 
immunohistochemical staining was performed on the mid-pregnant (day 12.5) mammary 
glands of WT mice.  
Serial sections were stained with antibodies to CAV1, KDM5B and smooth muscle actin 
(a-SMA), which was used to identify myoepithelial cells. Fig 4.6A shows strong KDM5B 
expression in the nuclei of luminal epithelial cells of alveoli, but a moderate and 
heterogeneous expression of the same, in the ducts (Fig 4.6D). KDM5B was also 
expressed in the myoepithelial and fat cells (Fig 4.6A and D). A strong CAV1 expression 
was observed in the myoepithelial and fat cells, but was completely absent in the luminal 
cells (Fig 4.6G). The adjacent serial sections show a-SMA staining in myoepithelial cells 
(Fig 4.6B, E, H). This data demonstrates that KDM5B could regulate CAV1 in 
myoepithelial and/or fat cells, in the mid-pregnant mammary gland. However, 























subsequent production of milk at lactation. It follows therefore that signals from CAV1, 
which controls the JAK/STAT5 pathway, occurs in a paracrine fashion.  
 
Figure 4.6: Cellular distribution of CAV1 and KDM5B in the mouse mammary gland at 
pregnancy day 12.5. (A-C) Consecutive sections showing staining of lobules. A) KDM5B 
expression in luminal (arrow heads), myoepithelial and fat cells (black arrows). B) a-SMA 
expression in myoepithelial cells (black arrow) and C) Secondary antibody control. (D-F) 
Consecutive sections showing staining of ducts. D) KDM5B expression in luminal (arrow heads), 
myoepithelial and fat cells (black arrows). E) a-SMA expression in myoepithelial cells (black 
arrow) and F) Secondary antibody control. (G-I) Consecutive sections showing G) CAV1 
expression in myoepithelial and fat cells (black arrows) and lack of staining in luminal cells (arrow 
heads). H) a-SMA expression in myoepithelial cells (black arrow) and I) Secondary antibody 













CAV1 ⍺- SMA Control
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4.3 Discussion 
The aim of this chapter was to further understand KDM5B regulation of CAV1 in the 
normal and malignant mammary gland, by looking at their cellular distribution in the mid-
pregnant mammary gland and their expression in different breast cancer cell types (i.e. 
epithelial and fibroblasts), respectively.  
 
4.3.1 CAV1 expression in breast tumours 
Studies on the expression of CAV1 and KDM5B in breast tumours using the METABRIC 
dataset revealed that, CAV1 gene expression is downregulated in HER2+ and luminal B 
breast cancer subtypes (see Fig 4.1). However, CAV1 mRNA expression in the 
METABRIC dataset was unexpectedly low in the basal-like subtype, which can also 
include triple negative breast cancers. However, it has previously been suggested that 
analysis using expression arrays such as METABRIC, should be interpreted with caution. 
This is because, samples constituting the normal-like subtype may have been derived 
from cell types expressing high CAV1 (adipocytes, fibroblasts and endothelial cells), and 
so may distort analysis 233. Therefore, to precisely measure CAV1 mRNA, Elsheikh and 
colleagues, suggested the use of microdissection or in situ methods 233. It was observed 
that expression of CAV1 in the luminal A subtype, was not as downregulated as in the 
other subtypes. This difference particularly between luminal A (ER+/HER2-) and, HER2+ 
(ER-/HER2+) and luminal B (ER+/HER2+ or ER+/HER2-) subtypes, may be attributed 
to HER2 expression, as CAV1 has been shown to negatively associate with HER2 232.  
Given that CAV1 is located in a region that is frequently deleted in many malignancies 
including breast cancer 295, it was investigated whether CAV1 gene deletion was the 
underlying mechanism driving CAV1 downregulation. CAV1 was significantly deleted in 
186 out of 1903 (9.8%) breast tumours, suggesting that CAV1 expression is driven by 
copy number deletion in a fraction of breast cancers. Since the majority of breast cancers 
were diploid for CAV1 expression, it suggests that other factors such as epigenetics as 
discussed below, may be driving CAV1 expression in breast cancer.  
 
4.3.2 CAV1 expression in breast cancer cell lines is subtype specific 
CAV1 expression in breast cancer cell lines, appeared to be subtype specific. These 
differences in CAV1 expression between different breast cancer subtypes (high in TN 
and moderate to low in ER+ and HER2+ cells), has previously been explained to be due 
to methylation of CpG Islands (CGI) shores on the CAV1 promoter 237. CGI shores are 
regions that flank CGI with less CG-density. The authors demonstrated that 
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hypermethylation of CAV1 CGI shores, is mostly observed in cell lines that have low 
CAV1 expression and is characteristic of some luminal breast cancer cell lines. 
Contrastingly, hypomethylation of CAV1 CGI shore is characteristic of the basal-like 
subtype and is hypothesized as contributing to the enhanced aggressiveness of some 
cancers in this subtype. To investigate whether the CGI and CGI shores chromatin 
environment influenced CAV1 gene expression, the authors performed chromatin 
immunoprecipitation sequencing (ChIP-seq) analysis of histone modifications in MCF-7 
cells. Although the H3K4me2 active mark, a substrate of KDM5B was tested, only 
minimal enrichment at CGI shores was observed and so it was concluded that this mark 
was not sufficient to activate CAV1 expression. This is in agreement with the observation 
that CAV1 expression is controlled by the H3K4me3 mark and not H3K4me2 or H3Kme1 
146. Thus, it is not known whether the H3K4me3 mark is enriched at these CGI shores 
thereby regulating CAV1 expression. If so, this may also implicate KDM5B at these 
regions, since KDM5B and H3K4me3 bind at the same regions 146,202.   
 
4.3.3 KDM5B regulates CAV1 in SKBr3 cells 
In breast tumours, there was a weak inverse correlation between CAV1 and KDM5B 
expression. However, in breast cancer cell lines, there was an indication that KDM5B 
may regulate CAV1, since cell lines with a high KDM5B expression, had a very low CAV1 
expression. Indeed, I now find that KDM5B regulates CAV1 expression in SKBr3 cells, 
as demonstrated by its increased expression upon KDM5B KO. This is the first study to 
show that KDM5B can regulate CAV1 in a HER2+ breast cancer cell line, since previous 
studies have used the ER+ cell line, MCF-7 146,156. Although global H3K4me3 levels did 
not change in SKBr3 KO cells, the increased CAV1 expression implies increased 
H3K4me3 levels on the CAV1 promoter, due to the absence of KDM5B. Further work 
using ChIP-PCR assays should confirm this.  
Surprisingly, CAV1 expression did not change in BT-474 KDM5B KO cells. BT-474 cells 
have a high KDM5B expression, and so its KO is expected to result in gene expression 
changes of target genes. Thus, the lack of a change in CAV1 expression in BT-474 cells, 
reflects the cell phenotype. Being an ER+/HER2+ cell line, BT-474 has both the ER and 
HER2 pathways active, and this allows for molecular cross-talk between the two 
pathways, which in turn influences gene expression amongst other cellular behaviours 
296. In contrast, in the ER-/HER2+ SKBr3 cell line, the HER2 signalling pathway may 




4.3.4 KDM5B may regulate CAV1 in normal and breast cancer-
associated fibroblasts 
In breast cancer-associated fibroblasts, CAV1 upregulation is often associated with good 
clinical outcome 239,242. However, the underlying mechanism of CAV1 expression is not 
known. Similar to breast cancer epithelial cells, an inverse correlation between CAV1 
and KDM5B expression was observed in the breast fibroblast and CAF lines. This 
suggests that CAV1 in breast cancer fibroblasts, may be epigenetically regulated by 
KDM5B. Therefore, targeting KDM5B in breast CAFS that have low CAV1 expression, 
could improve clinical outcome of patients. Given more time, I would have confirmed this 
hypothesis by gene editing of KDM5B in breast fibroblast lines. 
 
4.3.5 KDM5B may regulate CAV1 in myoepithelial and/or fat cells in 
the mouse mammary gland 
To elucidate the CAV1 and KDM5B axis in breast cancer, an understanding of their 
association in the normal mammary gland needs to be examined. A mouse model lacking 
KDM5B demethylase activity, showed upregulation of CAV1 in the mammary gland 
during mid-pregnancy (Steven Catchpole personal communication). Investigations into 
the cellular distribution of CAV1 and KDM5B in the mouse mammary gland, revealed 
expression of both proteins in fat and myoepithelial cells at mid pregnancy. This suggests 
that KDM5B regulates CAV1 through its demethylase activity, in one or both of these cell 
types. The fact that CAV1 is not expressed in the luminal epithelial cells is in agreement 
with previous data 220, and coincides with the notion that CAV1 may be regulating 
signalling pathways in mammary epithelial cells through the stroma, in a paracrine 
fashion. Indeed, observations in our laboratory show that phosphorylation of STAT5, 
which is inhibited by CAV1 231, is expressed in the luminal epithelial cells 196, which are 
involved in alveologenesis and lactation. Therefore, during mid-pregnancy KDM5B may 
be downregulating CAV1 expression in the fat and/or myoepithelial cells, which in turn 
results in activation of the STAT5a signalling pathway, in luminal cells. The importance 
of this pathway has been demonstrated by accelerated mammary gland development 
and premature lactation during pregnancy, as a result of CAV1 knockout 231.  
 
4.3.6 Conclusion 
In conclusion, the data presented here suggests that, downregulation of CAV1 in breast 
cancer cell lines can be mediated by KDM5B in a cell phenotype dependent manner. It 
is also possible that this regulation is extended to normal fibroblast and breast cancer-
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associated fibroblasts. Furthermore, during normal mammary gland development as 
demonstrated in the mouse, KDM5B could regulate CAV1 in the myoepithelial and fat 
cells. Thus, the regulation of CAV1 by KDM5B seems to span across different cell types, 
in the normal and malignant mammary gland. Elucidating this molecular axis may enable 
us to understand the opposite roles of CAV1 in different breast cancer phenotypes and 






















5 : Molecular Effects of KDM5B KO in 

























Previous studies looking at KDM5B-induced gene expression changes in ER+ or triple 
negative breast cancer cell lines, have used knockdown (KD) cells for their analysis 
146,156,159,202. These functional studies which aimed to identify KDM5B target genes in 
breast cancer cells, have shown that KDM5B regulates genes involved in various 
processes such as proliferation, mitotic cell cycle and immune response 146,156,159. Some 
of KDM5B target genes identified in the ER+ breast cancer cell line MCF-7, include 
BRCA1, CAV1 and HOXA5 146,156. These studies have shown that KDM5B regulates 
these target genes, through its demethylase activity. Furthermore, global gene 
expression analysis of KDM5B knockdown in luminal and basal-like breast cancer cells, 
resulted in specific gene expression changes associated with the luminal lineage 
showing that KDM5B can drive specific lineage-associated gene expression patterns 202. 
To date, global gene expression changes induced by KDM5B in HER2+ breast cancer 
cells, has not yet been reported.  
 
5.1.1 Aims 
KDM5B was first identified as a gene that was downregulated upon inhibition of HER2 
signalling 183. This suggests that KDM5B is positively regulated by HER2 signalling and 
may therefore be involved in HER2 tumorigenesis in the breast. It is therefore 
hypothesized that, loss of KDM5B function in HER2+ breast cancer cells will result in 
global gene expression changes. These gene expression changes may in turn lead to 
inhibition of hallmarks of cancer such as, uncontrolled cell growth.  
In Chapter 4, it was shown that KDM5B regulates its target gene CAV1, in the HER2+ 
breast cancer cell line SKBr3, but not in BT-474 cells. This demonstrates that KDM5B 
may regulate target genes in a cell phenotype dependent manner, even within HER2+ 
cell lines, possibly by forming different biological complexes. This chapter aimed to 1) 
identify KDM5B target genes in HER2+ breast cancer cells and 2) determine whether 
HER2+ breast cancer cell lines have common genes regulated by KDM5B. These aims 
were investigated by: 
1) Performing transcriptomic analysis on SKBr3 WT and KDM5B KO cells 
2) Validating expression array analysis in selected KDM5B target genes by RT-qPCR 
3) Examining expression of selected target genes in BT-474 WT and KDM5B KO cells 
by RT-qPCR 
4) Performing gene ontology analysis in SKBr3 KDM5B KO cells to identify enriched 





5.2.1 Genome wide expression profiling of KDM5B KO cells by 
microarray analysis 
	
5.2.1.1 KDM5B-induced gene expression changes in SKBr3 cells 
Whole genome expression profile was assessed in one biological repeat of SKBr3 
parental and KDM5B KO cells, using the Illumina Human HT-12 v4 Expression BeadChip 
array, as described in Chapter 2. Comparison of SKBr3 parental and KDM5B KO cells, 
identified 99 upregulated genes and 105 downregulated genes, that showed expression 
differences of 1.5-fold or greater (Fig 5.1) in the KO cells. These findings show that 
KDM5B is involved in both gene activation and repression, in SKBr3 cells. Importantly, 
these differentially expressed genes are constitutive changes, since KDM5B is 




        
Figure 5.1: Differentially expressed genes upon KDM5B KO in SKBr3 cells. Differentially 
expressed genes with their respective fold changes (only fold changes ³1.5 or ³-1.5 are shown). 
Comparison of SKBr3 WT cells with KDM5B KO cells (n=1 per group) identified 99 upregulated 
genes (red) and 105 downregulated genes (blue). Data analysis was performed in Partek 






5.2.1.2 RT-qPCR validation of microarray analysis 
To confirm the microarray analysis, RT-qPCR was performed on three upregulated 
genes, EGR1 (fold change = 3), FOS (fold change = 1.27) and MYC (fold change = 1.5) 
and one downregulated gene, SLC40A1 (fold change = -1.8). Early response gene 1 
(EGR1) was selected as it was the top upregulated gene, and has previously been shown 
to be a KDM5B target gene in mouse embryonic stem cells (mESCs) 190. FOS was 
selected since it is also an early response gene and is co-regulated with EGR1 297, 
although its fold change was below 1.5. MYC was selected as it has previously been 
shown to exist in a transcriptional repressor complex with KDM5B 298. Solute carrier 
family 40 member 1 (SLC40A1) was one of the downregulated genes chosen to confirm 
results.  
Total RNA was isolated from cells and processed as described in Chapter 2. RT-qPCR 
analysis of the genes confirmed upregulation of EGR1, FOS and MYC (Fig 5.2A, B, C) 
however, due to large variations between experiments, particularly in the two early 
response genes (EGR1 and FOS), the upregulation was not statistically significant (Fig 
5.2A, B). SLC40A1 showed a trend towards downregulation by RT-qPCR (Fig 5.2D). 











   
Figure 5.2: RT-qPCR validation of microarray analysis. RNA extracted from SKBr3 WT and 
KO cells was reverse transcribed, and A) EGR1, B) FOS, C) MYC, D) SLC40A1 and E) KDM5B 
genes examined using Qiagen Quantitect primers. Samples were run in triplicate in each 
experiment. Data represents three independent experiments. Errors bars denote standard error 
of the mean (s.e.m). Asterisks show significance where ****= p£0.0001. Statistical significance 



























































































































































































5.2.1.3 Expression of selected microarray genes in BT-474 cells 
To determine whether the genes selected above (i.e. EGR1, FOS, MYC and SLC40A1) 
are regulated by KDM5B in another HER2+ cell line, their expression in BT-474 WT and 
KDM5B KO cells was examined by RT-qPCR.  
EGR1, FOS and MYC expression were upregulated in the BT-474 KO2 cells, in 
comparison to WT cells (Fig 5.3A, B, C), with EGR1 and MYC showing statistical 
significance. However, due to large variations between experiments, the increased 
expression in FOS was not statistically significant, although a clear trend can be 
observed. These genes were however not upregulated in the BT-474 KO1* cells, in 
comparison to WT cells (Fig 5.3A, B, C). Comparison of SKBr3 KO and BT-474 KO2 
cells, suggest that KDM5B can be a transcriptional repressor of EGR1, FOS and MYC, 
in these two phenotypically different cell types. 
SLC40A1 was downregulated in both BT-474 KO cells in comparison to WT cells 
however, downregulation was only significant in the BT-474 KO1* cells (Fig 5.3D). This 
data suggests that KDM5B can be a transcriptional activator of SLC40A1 in BT-474 and 
SKBr3 cells. KDM5B KO was confirmed in the BT-474 KO cell lines (Fig 5.3E). 
The differences observed between BT-474 KO1* and KO2 are likely to be due to the 
higher KDM5B mRNA expression in the former. For genes where KDM5B appears to be 
acting as an activator (i.e. they are downregulated in the knockouts), the influence of the 
low level of KDM5B mRNA still present in the BT-474 KO1* cells, could be expanded 
through indirect activation or repression of other factors influencing SLC40A1 
expression. However, it cannot be ruled out that these differences may also be attributed 
to a clonal effect. Taken together, these data suggest that KDM5B can regulate EGR1, 
FOS, MYC and SLC40A1 in BT-474 and SKBr3 cells. However, further validation using 













    
Figure 5.3: Expression of selected microarray genes in BT-474 cells. RNA extracted from 
BT-474 WT, KO1* and KO2 cells was reverse transcribed and A) EGR1, B) FOS, C) MYC, D) 
SLC40A1 and E) KDM5B genes examined, using Qiagen Quantitect primers. Samples were run 
in triplicate in each experiment. Data represents three independent experiments. Errors bars 
denote standard error of the mean (s.e.m). Only significant differences are shown. Asterisks show 
significance where *= p£0.05, ***= p£0.001, ****= p£0.0001. Statistical significance was 





























































































































































































5.2.2 Cell culture methods can affect expression of early response 
genes  
EGR1 and FOS are early response genes that are normally expressed in response to 
stress stimuli 299. Since large variations were observed particularly in EGR1 and/or FOS 
expression in SKBr3 KO and BT-474 KO2 cells, it suggested that cell culture methods 
could be affecting their expression. Indeed, a previous study by Yang and colleagues, 
found that EGR1 expression was rapidly induced when cells were rinsed with PBS or 
media, prior to cell lysis 300. Upon closer observation of EGR1 expression from two 
independent RT-qPCR experiments of BT-474 WT cells for example, it was noticed that 
the cycle threshold (Ct) values differed (i.e. 19.3 and 24.2 in experiment 1 and 
experiment 2 respectively). Ct values are inversely correlated to the amount of RNA in 
the sample. Lower Ct values indicate high amounts of targeted gene, whereas higher Ct 
values indicate low amounts of targeted gene. It was thus hypothesized that these 
differences in Ct values, may be attributed to the method of cell lysis used for RNA 
preparation. This is because in experiment 1, cell lysis was performed on a cell pellet 
after trypsinisation, whereas in experiment 2, cells were directly lysed on the plate by 
scraping. Therefore, these two methods of cell lysis (trypsin and scraping), were re-
examined in BT-474 WT cells, to validate the initial observations. Figure 5.4 shows the 
Ct values of EGR1 and the control gene PUM1 in the two experiments. 
EGR1 was detected at lower cycles in the trypsinised samples (Fig 5.4). Contrastingly, 
in the scraped samples, EGR1 expression was detected at higher cycles (Fig 5.4). Thus, 
demonstrating induction of EGR1 expression when cells are trypsinised. Expression of 
the housekeeping gene PUM1 was detected at relatively similar cycles in both the 
trypsinised and scraped samples (Fig 5.4). This suggests that, trypsinising cells prior to 
lysis, can induce expression of early response genes such as EGR1. Therefore, care 
should be taken in manipulating cells when working with early response genes. The 
microarray and RT-qPCR data shown in Figures 5.1, 5.2 and 5.3, were performed on 
samples that were lysed using the cell scraping method. Thus, the reported gene 








Figure 5.4: Cell culture methods can affect expression of early response genes. 
Comparison of two cell lysis methods (trypsin or scraping) on EGR1 expression in BT-474 WT 
cells. Graph shows detection of EGR1 in lower cycle numbers in trypsinised samples, in 
comparison to scraped samples. In contrast, PUM1 was detected at similar cycle numbers in 
trypsinised and scraped samples. Data represents two independent experiments. Errors bars 
denote standard error of the mean (s.e.m). 
 
 
5.2.3 Gene ontology of differentially expressed genes in SKBr3 KDM5B 
KO cells 
Further analysis on the differentially expressed genes (Fig 5.1) was performed using the 
ToppGene Suite tool to identify enriched biological processes. Interestingly, gene 
ontology showed that upregulated genes were enriched for the biological process 
‘response to drug’ (Fig 5.5). Closer examination of the 12 genes identified in this group, 
revealed that 5 of the genes i.e. ATP binding cassette (ABC) transporter (ABCC2), 
Annexin A1 (ANXA1), CAV1, MYC and Lipocalin 2 (LCN2), promote resistance to 
Herceptin or Lapatinib 240,301–303.  
The downregulated genes in the SKBr3 KDM5B KO cells were enriched for various 
biological processes including mammary gland epithelial cell proliferation (Fig 5.6). 
These genes included inhibitor of differentiation 2 (ID2) and STAT6, which belong to the 
transforming growth factor-beta (TGFb) and JAK/STAT pathways respectively. A full list 
of biological processes enriched in differentially expressed genes in SKBr3 KO cells is 
















Fig 5.5: Gene ontology of upregulated genes in SKBr3 KDM5B KO cells. Representative 
enriched biological processes in upregulated genes upon KDM5B KO in SKBr3 cells, as reported 
by ToppGene. P-values are log transformed (−log10(p value)) and were corrected by the 




Figure 5.6: Gene ontology of downregulated genes in SKBr3 KDM5B KO cells. 
Representative enriched biological processes in upregulated genes upon KDM5B KO in SKBr3 
cells, as reported by ToppGene. P-values are log transformed (−log10(p value)) and were 

























Since its discovery, studies have shown that KDM5B is a transcriptional regulator that is 
overexpressed in breast cancers. To further understand its function in this disease, 
different studies have aimed to identify genes that are regulated by KDM5B. Identification 
of KDM5B target genes and their specific roles, has enabled identification of biological 
processes involving this enzyme. To date, KDM5B target genes have been identified in 
either ER+ or triple negative breast cancer cell lines 146,156,159,202. These studies have 
mainly used RNAi to silence KDM5B expression and subsequently study its function. 
This is the first study to my knowledge, to use KDM5B KO cells to identify KDM5B target 
genes on a whole genome level, in the SKBr3 HER2+ breast cancer cells. 
 
5.3.1 KDM5B-induced gene expression changes in SKBr3 and BT-
474 HER2+ breast cancer cells 
A total of 204 genes were differentially expressed upon KDM5B KO (99 upregulated and 
105 downregulated genes) in the SKBr3 HER2+ cells. From the selected genes used to 
validate the microarray, EGR1, FOS, and MYC have previously been associated with 
KDM5B in different cell types 146,156,190,195,298. Furthermore, assessment of these genes in 
BT-474 KO cells, revealed a similar expression pattern to SKBr3 KO cells for BT-474 
KO2 cells, but not BT-474 KO1* cells. The difference between the two BT-474 KO cells 
supports the interpretation that the BT-474 KO1* cells are not a complete KO, retaining 
expression of a low amount of KDM5B mRNA.  
EGR1 is an early response gene encoding for a zinc finger transcription factor, and is 
expressed in response to various stimuli 297. EGR1 is transcriptionally repressed by 
KDM5B through its demethylase activity, in mESCs 190. The authors demonstrated that 
by overexpressing KDM5B or silencing by siRNA, KDM5B directly inhibits EGR1 
expression. They showed that binding of KDM5B led to decreased levels of H3K4me3 
at the EGR1 promoter, thereby decreasing EGR1 expression. Furthermore, of the three 
cell lineage markers examined (EGR1, p27 and BMI1), EGR1 was the only gene found 
to be affected by inhibition of KDM5B, emphasising a crucial role for KDM5B in 
downregulating this gene 190.  
In breast cancer, expression of EGR1 is decreased at the RNA and protein levels 
compared to normal mammary epithelial cells, as well as, in breast tumours 304,305. 
Overexpression of EGR1 suppresses breast cancer cell proliferation, by arresting cell 
cycle progression at the G0/G1 phase 304. The data reported in this chapter indicates that 
KDM5B normally represses EGR1 expression in SKBr3 cells, and so contributes to their 
proliferation (See Chapter 6).  
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FOS is an immediate early response gene and is co-regulated with EGR1 during growth 
and differentiation 297. FOS is part of the activator protein 1 (AP-1) complex and acts as 
a transcription factor. Knockout of KDM5b in mouse mammary epithelial cells (MECs), 
showed that fos expression did not change in comparison to wildtype MECs 195. This 
suggests that the function of KDM5B in regulating FOS may differ in normal and tumour 
cells, since FOS was upregulated upon KDM5B KO in BT-474 and SKBr3 breast cancer 
cells. Furthermore, regulation of FOS by KDM5B in human and mouse mammary cells 
may also differ.  
MYC is a protooncogene involved in many signal transduction pathways that promote 
cell growth, cell cycle and adhesion 306. Not surprisingly, abnormal expression of MYC is 
often observed in cancers, including breast cancer 307. Using the MCF-7 breast cancer 
cell line, MYC was found to exist in a complex with KDM5B and the transcription factor 
AP-2 gamma (TFAP2C)  298. This KDM5B-MYC-TFAP2C complex was shown to repress 
the cell cycle inhibitor p21, and it was proposed that this complex might promote cell 
cycle progression in breast cancer. In glioblastoma cells, MYC expression was found to 
correlate with H3K4me3 abundance on its locus, suggesting epigenetic regulation of 
MYC 308. An RT-PCR screen showed a moderate association between KDM5B and 
H3K4me3 expression on the Myc locus. Thus, the upregulation of MYC observed here 
in SKBr3 KO and BT-474 KO2 cells, suggests that KDM5B could regulate MYC 
expression via its demethylase activity.  
An association of KDM5B with SLC40A1 has not yet been documented. SLC40A1 
(Ferroportin) is an iron exporter that is decreased in some breast cancer cells and tissues 
309,310. Since SLC40A1 was downregulated in KDM5B KO cells, it implies that it is 
normally upregulated in BT-474 and SKBr3 cells. The expression of SLC40A1 still needs 
validating, as the RT-qPCR only showed a slight trend in reduction in BT-474 and SKBr3 
KO cells. 
 
5.3.2 KDM5B normally represses genes associated with Herceptin 
or Lapatinib resistance in SKBr3 cells 
Knock out of KDM5B in SKBr3 cells resulted in upregulation of CAV1, ABCC2, ANXA1, 
LCN2 and MYC, all of which have been implicated in Herceptin or Lapatinib resistance. 
This suggests that KDM5B normally represses these genes and so knocking out KDM5B 
in SKBr3 cells, may not be a good therapeutic target in these cells since expression of 
these genes upon loss of KDM5B function may not enhance sensitivity to HER2 targeted 
therapies (see Chapter 6). 
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CAV1 was recently identified as a gene that promotes Herceptin resistance 240. Sekhaar 
and colleagues, had previously shown that CAV1 contributes to Herceptin resistance by 
mediating endocytosis of HER2241. The authors proposed that endocytosis of HER2 
contributed to Herceptin resistance by attenuating antibody dependent cellular 
cytotoxicity (ADCC). Increased ABCC2 expression promotes resistance of gastric cancer 
cells to Trastuzumab emtansine (TDM1), since its inhibition sensitized cells to TDM1 and 
reduced cell viability 301. LCN2, a chaperone protein, was identified as a gene 
upregulated in the Herceptin resistant cell line HCC1954, and so is associated with 
Herceptin resistance 240. Upregulation of ANXA1 was found to confer resistance to 
Herceptin in HER2+ breast cancer cells as well as, HER2+ breast cancer patients who 
had received adjuvant Herceptin-based therapy 303. Thus, ANXA1 was identified as a 
predictive marker of Herceptin treatment response.  
MYC has previously been implicated in Lapatinib resistance since activation of the 
FOXO/c-Myc axis via the MLL2 protein, reduced sensitivity to Lapatinib302. Indeed, 
inhibition of this axis using an inhibitor to the chromatin associating protein BRD4, re-
sensitized cells to Lapatinib302.  
 
5.3.3 KDM5B normally activates genes associated with the TGFb 
and JAK/STAT pathways in SKBr3 cells 
The JAK/STAT and TGFb pathways consists of diverse proteins that regulate cell 
proliferation and differentiation. Constitutive activation of these pathways is correlated 
with tumour development and/or progression including breast cancer. Downregulation of 
STAT6 and ID2 which belong to the JAK/STAT and TGFb pathways, respectively, in 
SKBr3 KO cells, suggests that KDM5B normally activates their expression. This 
corresponds to data showing decreased TGFb pathway activity in siKDM5B basal-like 
breast cancer cells 202. Therefore, downregulation of members of the JAK/STAT and 
TGFb could result in reduced proliferation of SKBr3 cells (See Chapter 6). Contrastingly 
however, KDM5B knockdown in luminal breast cancer cells, led to upregulation of genes 
associated with the TGFb pathway 202. These findings show the importance of cell 
phenotype on KDM5B function.   
 
5.3.4 Conclusion 
Global gene expression profiling in SKBr3 parental and KDM5B KO cells has revealed 
that, KDM5B may contribute to proliferation of SKBr3 cells. It is possible that these 
functions of KDM5B extends to BT-474 cells, since at least EGR1, FOS and MYC were 
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also upregulated upon KDM5B KO in this cell line. Thus, the effect of KDM5B KO in 
proliferation in BT-474 and SKBr3 cells, was examined (see Chapter 6). Furthermore, 
KDM5B may mediate proliferation of SKBr3 cells through activation of the JAK/STAT 
and TGFb pathways however, the underlying mechanisms need to be experimentally 
determined. Additionally, knocking out KDM5B in SKBr3 revealed that KDM5B normally 
represses genes implicated in Herceptin or Lapatinib resistance and so suggests that 
this loss of KDM5B function may not increase sensitivity to HER2 targeted therapies in 
SKBr3 cells (see chapter 6).  
In order to understand whether KDM5B regulates similar genes in HER2+ breast cancer 
cells, genome wide expression analysis needs to be performed in WT and KDM5B KO 
of BT-474 and other HER2+ breast cancer cell lines. Additionally, it would be important 
to determine whether KDM5B regulates its target genes via its demethylase activity. 
Such information will enable us to determine whether the demethylase activity is the 
prominent mechanism through which KDM5B downregulates gene expression. This 
information will have bearing on the use of KDM5B small molecule inhibitors in the clinic, 
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The KDM5 family of histone demethylases have increasingly gained the spotlight as 
novel targets for anti-cancer therapy. Their attractiveness comes from studies showing 
their genetic amplification, aberrant expression, promotion of tumour growth and of drug 
resistance in various cancers. Since the KDM5 proteins are well characterised for their 
H3K4me3 demethylase activity, there are currently major efforts aimed at developing 
small molecules which inhibit their enzymatic activity for application to cancer therapy. 
These inhibitors can also be used to study the biological function of this activity. 
Identifying whether these proteins are involved in drug resistance could lead to the 
development of novel therapeutic strategies.  
 
6.1.1 Role of KDM5B in promoting cell proliferation of cancers 
Studies have shown that KDM5B promotes proliferation of various cancers, since its 
downregulation can lead to reduced cell growth. For example, silencing of KDM5B has 
been shown to reduce cell growth of bladder and lung cancer cell lines 208. The authors 
proposed that KDM5B silencing may be inducing apoptosis of bladder and lung cancer 
cells, since most of the cells were in the sub-G1 phase. Further analysis using microarray 
expression data, showed that KDM5B could be regulating cell cycle progression of 
bladder and lung cancer cell lines via activation of the E2F/RB pathway 208. Similarly, 
knockdown of KDM5B in hepatocellular carcinoma cells (HCC) inhibited cell proliferation 
and colony formation 210. Reduced tumour growth of HCC upon KDM5B knockdown was 
also observed in vivo 210. In melanoma cells, KDM5B expression in a sub-population of 
slow-cycling cells was found to be necessary for maintenance of tumour growth 204.  
In breast cancer, KDM5B has been shown to promote proliferation of the MCF-7 ER+ 
cells 146,188,202. Yamamoto and colleagues demonstrated that reduction of cell proliferation 
in KDM5B knockdown MCF-7 cells, was due to activation of the TGFb signalling 
pathway202. KDM5B knockdown in the ER-/HER2+ breast cancer cell line, UACC812, 
has also been shown to result in reduced cell growth 253.  
 
6.1.2 KDM5B and drug resistance in cancer 
A role for epigenetic factors in promoting drug resistance is emerging, implicating various 
epigenetic modifiers including KDM5B. High KDM5B expression in a subpopulation of 
melanoma cells was found to confer resistance to various anti-cancer drugs 246. Similarly, 
MYCN amplified neuroblastoma cells with a high KDM5B expression, were resistant to 
chemotherapy drugs 212. Although a role for KDM5B in breast cancer drug resistance has 
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not yet been determined experimentally, using gene expression and copy number data 
from public databases, it has been shown that positive KDM5B activity in patients with 
ER+ tumours, was associated with poor outcome and endocrine resistance202.  
 
6.1.3 Aims 
In Chapter 5 (Section 5.2.3), gene expression analysis in SKBr3 KO cells revealed that 
downregulated genes were enriched for genes associated with cell proliferation. 
Whereas upregulated genes were enriched for genes involved in Herceptin or Lapatinib 
resistance. The aim of this chapter was therefore to investigate the effect of KDM5B KO 
on cell proliferation of SKBr3 and BT-474 cells. Furthermore, it was also determined 
whether KDM5B KO affected drug sensitivity to HER2 targeted therapies (Herceptin and 
Lapatinib) in SKBr3, as well as, BT-474 cells. These aims were achieved by examining: 
1) Cell proliferation of BT-474 and SKBr3 WT and KDM5B KO cells, at different time 
points  
2) Cell viability of BT-474 and SKBr3 WT and KDM5B KO cells, following treatment with 
Herceptin or Lapatinib alone, or in combination, at different time points. The effect of 
KDM5B KO on the emergence of drug tolerant cells following long-term treatment 
















6.2.1 Effect of KDM5B KO on cell proliferation of BT-474 and SKBr3 cells 
Studies utilising RNA interference (RNAi) technology, have shown that KDM5B promotes 
cell proliferation of the ER+ breast cancer cells, MCF-7 146,188,202. In the experiment 
described below, KDM5B KO cell lines that were developed using CRISPR (Chapter 3 
Section 3.2.5), were used to investigate the role of KDM5B in proliferation of HER2+ 
breast cancer cells. It was observed that KDM5B KO did not compromise cell 
proliferation of BT-474 cells (Fig 6.1A). In contrast, KDM5B KO significantly reduced 
proliferation of SKBr3 cells (Fig 6.1B). Thus, suggesting that KDM5B can promote 
proliferation of some but not all, HER2+ breast cancer cell lines. It is should be noted 
however, the differences observed in cell proliferation between the two cell lines, may be 
a reflection of the different methodologies used and so requires further validation using 




Figure 6.1: Effect of KDM5B KO on cell proliferation of BT-474 and SKBr3 HER2+ breast 
cancer cells. A) Methylene blue cell viability assay of BT-474 WT, KDM5B KO1* and KO2 cells 
and B) MTT cell viability assay of SKBr3 WT and KDM5B KO cells. Cell viability was assessed at 
days 1, 4 and 7. Absorbance was read at 595nm for the MTT assay and 655nm for the methylene 
blue assay. Data shows the mean from three independent experiments and error bars standard 
error of the mean (± s.e.m). Asterisks indicate significance where **P=0.01 and ****P=0.0001. 




















































































6.2.2 Effect of KDM5B KO on response to HER2 targeted therapies  
The effect of KDM5B KO on response to the HER2 targeted therapies Herceptin and 
Lapatinib, was examined. 1x104 WT and KDM5B KO cells of BT-474 or SKBr3, were 
seeded in 24-well plates and 24 hours later after adhesion to the wells, cells were treated 
with control (PBS or DMSO), Herceptin (10µg/ml) or Lapatinib (100nM) alone, or in 
combination. Cell viability was then examined using the methylene blue assay at day 0, 
3 and 6.  
BT-474 KO2 cells were significantly more sensitive to Herceptin in comparison to WT 
cells, as seen at day 6 (Fig 6.2A). However, BT-474 KO1* cells did not show enhanced 
Herceptin sensitivity at the dose and time tested, in comparison to WT cells (Fig 6.2A). 
Interestingly, KDM5B KO did not enhance sensitivity to Lapatinib alone in BT-474 cells 
(Fig 6.2B). However, enhanced sensitivity was observed in BT-474 KO2 cells in 
comparison to WT cells, upon combined Herceptin and Lapatinib treatment (Fig 6.2C), 
probably because of the increased sensitivity observed with Herceptin treatment. BT-
474 KO1* cells did not show enhanced sensitivity upon combined Herceptin and 
Lapatinib treatment, in comparison to WT cells (Fig 6.2C), supporting the suggestion 
that KDM5B is not completely knocked out in these cells. 
In contrast, KDM5B KO in SKBr3 cells did not show enhanced sensitivity to either 
Herceptin (Fig 6.3A) or Lapatinib (Fig 6.3B) alone, or in combination (Fig 6.3C), at the 
dose and time tested. These data suggest that features of the cell phenotype other than 
HER2 expression, are determining factors in response to Herceptin treatment, in the 




















Figure 6.2: KDM5B KO increases sensitivity to HER2 targeted therapies in BT-474 cells. 
BT-474 parental, KDM5B KO1* and KDM5B KO2 cells were treated with A) 10µg/ml Herceptin B) 
100nM Lapatinib or C) 10µg/ml Herceptin and 100nM Lapatinib for 0, 3 and 6 days. PBS and 
DMSO were used as controls. Bars denote mean from three independent experiments and errors 
bars standard error of the mean (± s.e.m.). Statistical significance was calculated using unpaired 
Student’s t-test. Asterisks indicate significance where, *=p<0.05 and ns=not significant. 





















































































Figure 6.3: KDM5B KO does not affect response to HER2 targeted therapies in SKBr3 
cells. SKBr3 parental and KDM5B KO cells were treated with A) 10µg/ml Herceptin B) 100nM 
Lapatinib or C) 10ug/ml Herceptin and 100nM Lapatinib for 0, 3 and 6 days. PBS and DMSO 
were used as controls. Bars denote mean from three independent experiments and errors bars 





































































6.2.3 Effect of KDM5B KO on emergence of drug tolerant cells in BT-474 
and SKBr3 cells 
Since increased sensitivity to Herceptin was observed in BT-474 KO2 cells and not 
SKBr3 KO cells, it suggested that KDM5B may be contributing to the survival of drug 
tolerant cells in BT-474 cells. To evaluate this observation, low numbers (2.5x103) of WT 
and KDM5B KO cells of BT-474 or SKBr3, were seeded onto 6-well plates and 
immediately treated with a low dose of Herceptin (5µg/ml) for 14 days. Media and 
Herceptin or PBS control, was changed every three to four days. After 14 days, cells 
were fixed and stained with crystal violet and absorbance read at 595nm, following 
extraction of the dye with 10% acetic acid. 
BT-474 KO2 cells were significantly more sensitive to Herceptin after the 14-day 
treatment, in comparison to WT cells (Fig 6.4A). In contrast, there was no difference in 
Herceptin sensitivity between BT-474 WT and KO1* cells (Fig 6.4A). Similarly, no 
difference in Herceptin sensitivity was observed between SKBr3 WT and KO cells (Fig 
6.4B). These experiments provide the first evidence that KDM5B can contribute to 
emergence of drug tolerance to Herceptin in BT-474 cells.  
 
Figure 6.4: Effect of KDM5B KO on emergence of drug tolerant cells in BT-474 and SKBr3 
cells. A) 2.5x103 BT-474 WT, KDM5B KO1* and KDM5B KO2 cells and B) 2.5x103 SKBr3 WT 
and KDM5B KO cells, were seeded in 6-well plates and treated with PBS (blue bars) or 5µg/ml 
Herceptin (red bars) for 14 days. Bars denote mean from three independent experiments and 
errors bars show standard error of the mean (± s.e.m.). Asterisks indicate significance where 

































































2-way ANOVA, Sidak Correction
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6.2.4 Dosage effect of Herceptin on cell viability of SKBr3 WT and KDM5B 
KO cells 
As enhanced sensitivity was not observed in SKBr3 KDM5B KO cells treated with either 
5µg/ml or 10µg/ml Herceptin, it was determined whether increasing Herceptin 
concentration would increase sensitivity. To this end, both SKBr3 WT and KO cells were 
treated with control (PBS), 40µg/ml, 100µg/ml or 200µg/ml Herceptin for 3 and 6 days. 
As shown in figure 6.5, treatment with Herceptin at the indicated doses did not enhance 
sensitivity in SKBr3 KO cells, in comparison to WT cells. Thus, suggesting that the 
maximum dose that induced a response had been reached.  
 
 
Figure 6.5: Dosage effect of Herceptin on cell viability of SKBr3 WT and KDM5B KO cells. 
SKBr3 parental and KO cells were treated with PBS control or Herceptin at the indicated doses 
for 3 and 6 days. Bars denote mean from three independent experiments and errors bars 



































6.2.5 KDM5B represses genes associated with drug response in SKBr3 
cells  
Gene expression studies have shown association between expression of particular 
genes and Herceptin response 240. In Chapter 5, gene ontology analysis revealed that 
some upregulated genes (CAV1, ABCC2, ANXA1, LCN2 and MYC) are involved in 
resistance to Herceptin or Lapatinib (Chapter 5 Section 5.2.3). To determine whether 
gene expression profile could explain the differences observed in Herceptin sensitivity 
between SKBr3 KO and BT-474 KO2 cells, mRNA expression of these genes was 
examined in these cells.  
Upregulation of ABCC2 and LCN2 mRNA expression in SKBr3 KO cells was confirmed 
by RT-qPCR (Fig 6.6A and B). Upregulation of CAV1 and MYC in SKBr3 KO cells has 
previously been confirmed by western blot and RT-qPCR, as shown in Chapters 4 
Section 4.2.3 and Chapter 5 Section 5.2.1.2, respectively.  
In BT-474 KO2 cells, LCN2 mRNA expression (Fig 6.6B) and CAV1 protein expression 
(Chapter 4 Section 4.2.3) did not change in comparison to WT cells. However, ABCC2 
(Fig 6.6A) and MYC mRNA expression (Chapter 5 Section 5.2.1.3) were upregulated 
in BT-474 KO2 cells but to a lesser extent than in SKBr3 KO cells. These results suggest 
that gene expression/cell phenotype could determine KDM5B function in conferring 
Herceptin resistance in HER2+ breast cancer cell lines. Further functional experiments 
are required to test this hypothesis.  
 
 
Figure 6.6: Expression of ABCC2 and LCN2 in SKBr3 and BT-474 WT and KDM5B KO cells. 
RNA extracted from SKBr3 WT and KO cells and BT-474 WT and KO2 cells was reverse 
transcribed and ABCC2 and LCN2 genes examined, using Qiagen Quantitect primers. Samples 
were run in triplicate in each experiment. Data represents three independent experiments. Errors 




























































































In this chapter, the phenotypic effects of KDM5B KO on 1) cell proliferation and 2) 
sensitivity to the HER2 targeted therapies, Herceptin and Lapatinib was investigated. 
The findings show that KO of KDM5B inhibits cell growth of the ER-/HER2+ SKBr3 cells 
and reveals a potential novel role for KDM5B in promoting resistance to Herceptin, in the 
ER+/HER2+ BT-474 cells. These results demonstrate that KDM5B functions in a 
phenotypic specific manner.  
 
6.3.1 KDM5B promotes cell proliferation of SKBr3 cells 
The finding that KDM5B KO results in reduced proliferation of SKBr3 cells, confirms 
Gene Ontology analysis showing involvement of some of the downregulated genes in 
mammary epithelial cell proliferation (Chapter 5 Section 5.2.3). These genes included 
ID2 and STAT6 which are part of the TGFb and JAK-STAT signalling pathways, 
respectively. Both of these pathways are involved in promoting cell proliferation, 
suggesting that KDM5B normally activates these genes potentially leading to increased 
cell growth. This is in contrast to the finding that KDM5B knockdown activated the TGF 
pathway in the ER+ cell line, MCF-7202. Thus, these data demonstrate that KDM5B 
function is dependent on cell phenotype.  
Furthermore, the result that KDM5B KO reduces cell proliferation of SKBr3 cells, 
demonstrates the advantages of the CRISPR/Cas9 gene editing technology in functional 
studies. A KDM5B shRNA screen for cellular viability in a panel of breast cancer cell 
lines, that included BT-474 and SKBr3, showed that the growth of these cells was not 
inhibited by KDM5B knockdown 202. Using CRISPR it is now evident that KDM5B KO 
reduces the growth of SKBr3 cells, and thus shows the limitations of RNAi technology, 
which only partially silences genes that may still therefore have residual functionality. 
This observation however, needs to be validated using another clone or by performing 
rescue experiments to confirm that observations are not a clonal effect. 
Although KDM5B is highly expressed in BT-474 cells, it was surprising that its knockout 
did not have an effect on cell growth. Furthermore, since BT-474 is an ER+/HER2+ cell 
line and KDM5B has been shown to control cell growth of ER+ cells 188,202, this lack of 
reduced cell growth was surprising. However, these results are in agreement with those 
of Gale and colleagues who found that treatment of BT-474 cells with a small molecule 
inhibitor to KDM5A and KDM5C, did not affect cell proliferation114. Thus, taken together 
these findings suggest that KDM5B and indeed other KDM5 family members, may not 
have a direct role in controlling the growth of BT-474 cells.  
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6.3.2 A role for KDM5B in Herceptin resistance of BT-474 cells 
This is the first study to demonstrate a role for KDM5B in Herceptin resistance of BT-474 
breast cancer cells. Increased sensitivity to Herceptin in BT-474 KO2 cells was also 
observed in a long-term assay (Fig 6.4), where fewer drug tolerant cells were seen after 
14-day Herceptin treatment. Herceptin has previously been shown to enhance apoptotic 
cell death induced by Lapatinib 311,312. The data shown here is in agreement with these 
studies, since cell viability was further reduced when BT-474 KO2 cells were treated with 
a combination of Herceptin and Lapatinib. Taken together it is clear that multiple targeting 
is important in achieving enhanced therapeutic response and that determination of 
tumour phenotype is vital. 
Surprisingly, KDM5B KO did not increase efficacy to Herceptin in SKBr3 cells but gene 
ontology analysis revealed that upregulated genes in SKBr3 KO cells, were enriched for 
genes involved in Herceptin resistance (see Chapter 5 Section 5.2.3), thus 
demonstrating that KDM5B normally represses expression of these genes. Interestingly, 
expression of CAV1 and LCN2 which have previously been associated with Herceptin 
resistance, were not upregulated in BT-474 KO2 cells, whereas ABCC2 was marginally 
upregulated in these cells. Therefore, the difference in Herceptin sensitivity observed 
between BT-474 and SKBr3 KDM5B KO cells could be explained by cell phenotype, 
since KDM5B represses some resistance associated genes in SKBr3 cells but not in BT-
474 cells. 
 
6.3.3 KDM5B KO does not enhance sensitivity to Lapatinib 
KDM5B KO in both BT-474 and SKBr3 cells did not enhance sensitivity to Lapatinib. 
Lapatinib influences cell proliferation by 1) slowing down cycling cells and 2) driving cells 
into quiescence through apoptosis 312. This phenomenon was observed here, where 
Lapatinib had an initial cytotoxic effect at day 3 resulting in reduced cell viability, which 
was later cytostatic by day 6, in both BT-474 and SKBr3 cells. Although BT-474 KO2 
cells seemed to be slightly more sensitive to Lapatinib, this response was not significant. 
Thus, other factors which could include other KDM5 family members, may be influencing 
Lapatinib sensitivity. Indeed, a recent study has shown that treatment of SKBr3 cells with 
Lapatinib in combination with a pan-KDM5 small molecule inhibitor significantly reduced 
survival of drug tolerant cells 115. Thus, inhibition of other KDM5 enzymes, perhaps 
coupled with other therapies, may be required to overcome drug tolerance to Lapatinib 
in this cell line. 
Furthermore, the lack of increased sensitivity to Lapatinib could be explained by 
upregulation of MYC which has been shown to confer resistance to Lapatinib 302. Since 
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MYC expression was also upregulated in both SKBr3 KO and BT-474 KO2 cells, this 
could explain why both cell lines did not show enhanced sensitivity to Lapatinib. 
Therefore, this increased expression of MYC upon KDM5B KO, may be contributing to 
the maintenance of Lapatinib resistance at day 6, in BT-474 and SKBr3 cells (Fig 6.2 
and 6.3 respectively). Inhibition of MYC may therefore re-sensitise these cells to 
Lapatinib however, this needs to be experimentally tested.  
 
6.3.4 Conclusion 
The data shown here, demonstrate a novel observation that KDM5B promotes 
proliferation of SKBr3 cells which had not been previously shown using RNAi. This effect 
in proliferation is not universal in HER2+ breast cancer cells, since BT-474 cell growth 
was not affected by KDM5B KO. Gene expression profiling of SKBr3 KO cells, showed 
that KDM5B normally activates genes involved in the TGFb (i.e. ID2) and JAK-STAT (i.e. 
STAT6) pathways, in this ER-/HER2+ cell line. Thus, it remains to be experimentally 
tested whether KDM5B may be promoting cell proliferation of SKBr3 cells through these 
signalling pathways. Furthermore, it remains to be determined whether KDM5B 
regulation of these genes depends on its demethylase activity, since in contrast to gene 
repression which has been shown to occur mainly via KDM5B demethylase function, the 
mechanism through which KDM5B activates gene expression is not known.  
One of the hypotheses of this PhD was that, loss of KDM5B could increase efficacy to 
HER2 targeted therapies. This is the first study to show that KDM5B can promote 
resistance to Herceptin in BT-474 cells, and thus this finding warrants further validation 
by testing KDM5B KO in other HER2+/ER+ cell lines. Surprisingly, in SKBr3 cells, 
KDM5B appears to have the opposite effect in that, it represses genes associated with 
drug resistance and so KO does not therefore increase efficacy to HER2 targeted 
therapies, and could in fact increase drug resistance. Given the increasing interest in the 
clinical potential of KDM5 small molecule inhibitors, it is crucial that these results be 
validated. The findings demonstrate the importance of cell phenotype when investigating 
function of KDM5B. As discussed in the introduction, considerable effort is being focused 
on the development of small molecule inhibitors of KDM5B as cancer therapeutics. If 
these are to be translated into the clinic, the data here suggests that patient stratification 
would be vital. Therefore, pending in vivo validation, it is possible that the recently 
developed KDM5B small molecule inhibitor, KDOAM-25 254 can indeed find utility in the 
clinical setting, for the treatment of some HER2+ breast cancers, providing careful 
patient selection is carried out. 
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7.1 Overview of PhD project 
KDM5B is regulated by HER2 signalling 183 however, its function in HER2+ breast cancer 
has not been widely studied. One of the aims of this PhD thesis, was to investigate the 
role of KDM5B in HER2+ breast cancer cells by developing KDM5B KO cells and 
examining their effect on, 1) gene expression levels 2) cell proliferation and 3) response 
to Herceptin or Lapatinib, alone or in combination. The second aim was to investigate 
CAV1 regulation by KDM5B in normal and malignant breast cancer cells, as well as the 
cellular distribution of CAV1 and KDM5B in the developing mammary gland. Beyond ER+ 
cells it is not known how widespread KDM5B downregulation of CAV1 is in breast cancer. 
This is of importance as CAV1 expression in the stroma of breast cancers is associated 
with a good prognosis 238,239,242. Additionally, in the normal gland it is not clear in which 
cells downregulation of CAV1 by KDM5B can occur. 
During this PhD, I have: 
• Developed the first reported KDM5B knockout cell lines produced by gene 
editing. 
• Shown that the early response genes EGR1 and FOS are down-regulated by 
KDM5B. 
• Demonstrated that KDM5B enhances the growth of the HER2+ SKBr3 cell line. 
• Shown for the first time that KDM5B can promote resistance to Herceptin, adding 
to the evidence that KDM5B may be a suitable therapeutic target. However, this 
effect was cell phenotype dependent and in the SKBr3 cell line where KDM5B 
knockout did not increase Herceptin sensitivity, KDM5B appears to downregulate 
genes involved in drug resistance in the parental SKBr3 cells. It is crucial that 
these results be extended and validated in other cell lines, if inhibitors of KDM5B 
are to enter the clinic.  
•  Shown that the down-regulation of CAV1 by KDM5B in breast cancer cells lines 
is phenotype dependent.  
• Identified in the mouse mammary gland the cellular distribution of KDM5b and 
CAV1. 
The specific phenotypes of the KDM5B KO cells in BT-474 and SKBr3 are shown in 








Table 7.1: Summary of observed phenotypes in KDM5B KO cells 






Global H3K4me3 levels Not changed Not changed Increased 
Gene Expression 
1. CAV1 





1. Not changed 
2. Not changed 
 
3. Not changed 
 
 










Cell growth Not changed Not changed Reduced growth 
Drug resistance No increase in 
sensitivity to 
Herceptin or 




Herceptin alone or 
in combination 
with Lapatinib, but 
not to Lapatinib 
alone.  




or in combination. 
Herceptin resistant genes 
(i.e. ABCC2 and LCN2) 






7.2 Genes controlled by KDM5B 
Disruption of KDM5B function was achieved by using a gRNA targeting exon 4 of 
KDM5B. This resulted in development of KDM5B KO cell lines in BT-474 and SKBr3. An 
additional cell line BT-474 KO1* did express low levels of KDM5B mRNA as determined 
by RT-qPCR. As discussed in chapter 3, in the IDAA analysis only two indels were 
detected for this clone in contrast to BT474 KO2 that showed three indels, and this was 
confirmed by sequencing. As BT474 has three copies of KDM5B this may suggest that 
a single copy of KDM5B is being transcribed. This may explain the differing results 
obtained with BT474 KO1* and BT474 KO2 in the sensitivity of these cells to Herceptin, 
and its contribution to resistance where BT474 KO1* is acting more like wild-type cells. 
Although the possibility of the effects being due to clonal variation cannot be ruled out, 
given that EGR1, FOS and MYC are upregulated in both the SKBr3 KO and BT474 KO2 
but not in BT473 KO1*, the most likely explanation for the phenotype of the BT474 KO1* 
is that it is not a full knockout.  
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7.2.1 KDM5B regulation of early response genes 
The global gene expression analysis of the SKBr3 KO showed that KDM5B down 
regulates the early response genes EGR1 and FOS. This was also observed in BT474 
KO2. Early response genes are typically induced transiently and rapidly when cells are 
exposed to external stimuli 299 such as mitogens, for example EGF and platelet-derived 
growth factor (PDGF). Using 14 breast cancer datasets Li and colleagues showed that 
EGR1 and FOS are down-regulated in breast cancer 313. It is tempting to speculate that 
this is the result of KDM5B expression by these breast cancers.  
Analyses of published papers looking at global gene expression analysis after 
knockdown of KDM5B in breast cancer cell lines do not reveal EGR1 to be a target of 
KDM5B 156,159,202. However, the work of Dey and colleagues in mouse embryonic stem 
cells also shows that KDM5B suppresses the expression of EGR1, thus inhibiting 
differentiation 190. It is interesting to note the discordance between gene expression 
profiles of KDM5B knock-downs which is seen between different groups of investigators 
using the same breast cancer cell line (in many cases MCF-7). While this could be due 
to a drift in the cell phenotype it may also be due to the variation in levels of KDM5B that 
are seen in RNAi or short hairpin RNA (shRNA) knockdowns and illustrates the 
advantage of using a gene editing technique such as CRISPR/Cas9. 
 
7.2.2 KDM5B regulation of CAV1 expression  
The precise role of CAV1 in breast cancer is currently under much debate. Although 
there have been numerous reports examining CAV1 expression in breast cancer tissues 
and cell lines, there is no consensus regarding how CAV1 expression in tumour cells 
relates to prognosis 314. Furthermore, whilst some studies suggest that CAV1 is a tumour 
suppressor in breast cancer, others report an oncogenic function of CAV1 in breast 
cancer 232,315,236,295. Taken together with controversial reports on the CAV1 P132L 
mutation316–318, progress in understanding the specific role of CAV1 in different breast 
cancer subtypes has been confounded. There is however consensus that expression of 
CAV1 in breast cancer stromal fibroblasts is associated with a good prognosis 238,239,242. 
Thus, CAV1 function is highly dependent on the context of the cell. 
The data obtained from the KO clones of two HER2+ cell lines, and on CAV1 and KDM5B 
expression in breast cancer fibroblasts, are relevant to these issues. CAV1 protein 
expression varied in cell lines obtained from different breast cancer subtypes, and 
regulation of CAV1 expression by KDM5B was seen in SKBr3 KO cells but not, BT-474 
KO cells. These data demonstrate that KDM5B regulates CAV1 expression in a cell 
phenotype dependent manner, in HER2+ breast cancer cells. Others have shown that 
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CAV1 is also transcriptionally repressed by KDM5B in ER+ breast cancer cells 146,156, 
indicating that regulation of CAV1 is operating in different pathways in different breast 
cancer subtypes.  
In the two strains of cancer associated fibroblasts that were examined here, high CAV1 
and low KDM5B expression was observed in comparison to normal breast fibroblast 
cells. An inverse correlation was also observed in breast cancer cell lines. Nevertheless, 
the inverse ratio does not necessarily indicate that KDM5B is regulating gene expression 
as the knockouts of BT474 and SKBr3 showed. Indeed, although both wild-type cells 
show low levels of CAV1, knocking out KDM5B increased CAV1 expression only in the 
SKBr3KO cells.  
Studies in mice have provided data relating to the role of CAV1 in normal mammary 
gland. CAV1 has been found to inhibit the proliferation and extension of the mouse 
luminal epithelial cells in pregnancy, and this inhibition relates to CAV1 inhibition of 
phosphorylated STAT5 signalling231. Data from an analysis of mice that are null for 
KDM5b demethylase activity showed an increase in CAV1 expression in the mid-
pregnant mammary gland (Steven Catchpole personal communication). The data 
reported here showed that in the mouse mammary gland at mid-pregnancy, CAV1 and 
KDM5B are both expressed in the myoepithelial and fat cells, allowing the interpretation 
that KDM5B may be regulating CAV1 in one or both of these cells. However, the 
increased proliferation of the mammary luminal epithelial cells (where CAV1 is not 
expressed) at mid pregnancy is driven by the STAT5 signalling pathway 231, and 
activation of STAT5 was found to be inhibited in the KDM5B demethylase null mouse at 
mid pregnancy 196. Thus, if CAV1 is normally downregulated by KDM5B in stromal or 
myoepithelial cells, any effects of CAV1 on mammary epithelial cell proliferation driven 
by pSTAT5, would have to be regulated in a paracrine fashion.  
These findings in the normal mouse mammary gland could relate to the effect of high 
levels of CAV1 expression in breast cancer fibroblasts correlating with good prognosis. 
Thus, CAV1 effects on tumour proliferation may also be operating through a paracrine 
mechanism. Constitutive activation of STAT5a has been reported in many malignancies 
including breast cancer, and this could be due to KDM5B down-regulation of CAV1. 
However, this hypothesis needs to be tested. Using the gRNA we have identified for 
CRISPR gene editing, it should be possible to develop KDM5B KOs from strains of 
breast cancer fibroblasts, to determine whether KDM5B regulates CAV1 expression in 
these cells. Demonstration of downregulation of CAV1 by KDM5B would add to the 
argument for inhibitor targeting of this demethylase.    
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7.2.3 KDM5B regulation of MYC expression  
In Drosophila the homologue of KDM5- Lid, was found to interact with dmyc and was 
required for activation of mitochondrial genes by Myc; a function which was independent 
of KDM5 demethylase activity 319. This connection with Myc has not been reported in 
mammalian KDM5 proteins. However, upregulation in enzymes of mitochondrial 
oxidative-ATP-synthesis (oxidative phosphorylation) have been found in long-term 
tumor-maintaining melanoma cells with high KDM5B expression 246. Moreover, using the 
MCF-7 breast cancer cell line, MYC was found to exist in a complex with KDM5B and 
TFAP2C 298. This KDM5B-MYC-TFAP2C complex was shown to repress the cell cycle 
inhibitor p21, and it was proposed that this complex might promote cell cycle progression 
in breast cancer. In this thesis, knocking out KDM5B in two HER2 expressing breast 
cancer cell lines, induced increased expression of MYC (Chapter 5), suggesting that 
KDM5B normally downregulates MYC in these cells. It will be important to investigate 
the relevance of effects of KDM5 proteins and the role of MYC on mitochondrial gene 
expression in the context of targeting KDM5 demethylases.  
 
7.3 The role of KDM5B in sensitivity to HER2 targeted 
therapies  
The epigenetic changes that are induced by HER2 signalling are dramatic 320 altering the 
chromatin state and changing the global profile of genes expressed. Thus, targeting 
elements of epigenetic change, for example the methyl mark (H3K4me3) removed by 
KDM5B, could affect multiple pathways including those reported to be involved in the 
development of resistance to HER2 targeting. In order to examine the phenotypic effects 
of KDM5B KO, its role in cell proliferation and drug resistance was investigated. KDM5B 
KO in SKBr3 cells reduced cell proliferation, but did not increase sensitivity to Herceptin 
or Lapatinib alone or in combination. In contrast, whereas KDM5B KO in BT-474 cells 
did not compromise their proliferation, sensitivity to Herceptin alone or in combination 
with Lapatinib, was increased in BT-474 KO2 cells. Furthermore, treatment of BT-474 
KO2 cells with Herceptin in a long-term assay, resulted in reduction of drug tolerant cells. 
To my knowledge, this is the first report showing a role of KDM5B in drug resistance of 
BT-474 cells.  
Interestingly, in SKBr3, knockout of KDM5B increased the expression of some genes 
involved in drug resistance including ABCC2, CAV1 and LCN2. ABCC2, CAV1 and LCN2 
were validated by qPCR or western blot and shown to be elevated in SKBr3 KO. 
Although, ABCC2 was elevated to a much lesser extent in BT474 KO2 knockout, CAV1 
and LCN2 levels did not change in this cell line. ABCC2 is involved in the efflux of 
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chemicals from the cells such as the chemotherapeutics doxorubicin and cisplatin. While 
it is hard to see an association with the ABCC2 expression and resistance to Herceptin, 
LCN2 has been associated with resistance to Herceptin. LCN2 is a chaperone protein 
that is upregulated during the unfolded protein response (UPR). It has been associated 
with drug resistance in a number of systems and is highly expressed in the intrinsically 
Herceptin resistant line HCC1954 240, and there is evidence to suggest that LCN2 can 
override Herceptin inhibition of HER2 321. The upregulation of ABCC2, CAV1 and LCN2 
in the SKBr3 KO but not in the BT474 KO2, correlates with the observation that KDM5B 
silencing does not enhance sensitivity to Herceptin in SKBr3, but does in BT474. 
Owing to its various reported roles in tumorigenesis and drug resistance, KDM5B has 
been proposed to be a suitable target for cancer therapy. Although considerable effort 
has been made to develop small molecule inhibitors to KDM5B to study its clinical utility, 
currently none of these inhibitors are specific to KDM5B. To enable validation and 
application of these inhibitors, a proper understanding of the tumorigenic function of 
KDM5B is required. The knockout lines developed in this thesis can now be used to 
further characterise and fine-tune the function of KDM5B in HER2+ breast cancer. 
Furthermore, they can be used to complement work using small molecule inhibitors, to 
investigate the importance of the KDM5B demethylase activity in drug resistance. 
Indeed, this strategy has been used to validate the effect of a KDM5A/C inhibitor on cell 
proliferation 114. The authors compared the effect of inhibiting the demethylase activity of 
KDM5A with knockout of KDM5A. Both strategies showed reduced proliferation of HeLa 
cells but minimal effect on MCF-7 cells, thus demonstrating that KDM5A promotes 
proliferation of KDM5A-dependent cells, through its demethylase activity 114. Adopting 
similar strategies will therefore enable better drug design and thus improve success of 
these inhibitors in the clinic. The unexpected result that in SKBr3 cells KDM5B appears 
to downregulate genes encoding proteins involved in drug resistance needs to be 
extended and validated to other HER2+/ER- cell lines, if small molecule inhibitors of 
KDM5B are to be introduced to the clinic. Moreover, the involvement of the demethylase 
activity of KDM5B in repressing these genes needs to be established. These results 
emphasise the importance of performing extensive preclinical studies before phase I 
trials are initiated. 
 
7.4 Future work 
The interest in developing small molecular weight inhibitors of the demethylase activity 
of KDM5B proteins, stems from the fact that these proteins are often elevated in many 
cancers, and that they can change the profile of genes transcribed by a cell by 
demethylating the active H3K4me3/2 marks. Although some inhibitors have been 
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developed that specifically inhibit the KDM5 family of demethylases, as yet inhibitors 
showing reliable specificity for inhibiting a specific KDM5 member have yet to be 
developed, although inhibitors with some preferences for individual family members have 
been reported 114,254. Without such inhibitor specificity, investigating the effects of an 
individual KDM5 protein on the phenotype of cells from different tissues and cancers and 
the role of the demethylase activity can be approached through gene editing.  
 
7.4.1 KDM5B  
In this thesis, we have taken the first step in examining how deleting the KDM5B gene in 
two cell lines from the subtype of HER2+ breast cancers, affects cell phenotype. To 
pursue the validation of KDM5B affecting cell proliferation and upregulation of genes 
associated with drug resistance, in the HER2+/ER- cell line SKBr3, another KO clone 
should be developed. KDM5B KO in other HER2+/ER- cell lines should also be 
developed with the gRNA used here, to investigate the extent of these observations.  A 
similar approach should be taken to validate the increased Herceptin sensitivity induced 
by knocking out KDM5B in BT474 cells (i.e. isolate another KO clone and delete KDM5B 
in other HER2+/ER+ cell lines). Furthermore, RNA-seq can be performed to analyse 
global gene expression changes induced upon KDM5B KO. The importance of the 
demethylase activity in these effects can be addressed by gene mutation, rather than 
deleting the KDM5B gene, for example replacing the WT gene with a demethylase null 
mutant. Additionally, rescue experiments should be performed to demonstrate that the 
phenotype of the knockout clones is dependent on KDM5B loss. Furthermore, functional 
testing through knockdown of genes involved in Herceptin resistance (e.g. ABC22 and 
LCN2), is required to make conclusions about the mechanisms behind any effects of 
KDM5B.  
 
To further understand the role of KDM5B in drug resistance, the effect of KDM5B loss 
with and without HER2 targeted therapies, on apoptosis, metastasis, migration, stem cell 
activities and in vivo tumour growth, should be examined. These studies will enable 
identification of specific mechanisms and in turn, genetic targets that can be further 
explored for therapy. To make these observations more clinically relevant, similar 
experiments should be performed using patient-derived organoids/xenografts.  
 
 
7.4.2 Other Cell types and other KDM5 family members  
The epigenome defines cell phenotype and specific epigenetic factors are expressed 
and regulated differently in different cell types. The KDM5 family members form 
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complexes regulating transcription which can vary with cell phenotype. We have focused 
on the effects of one KDM5 protein in two cell lines which represent two HER2+ subtypes 
of breast cancer. With the guide RNA already established, the effects of silencing 
KDM5B can readily be examined in cell lines derived from different cancers and different 
breast cancer subtypes. It will be important to knockout KDM5B in strains of breast 
cancer fibroblasts to determine whether CAV1 expression is regulated by KDM5B. These 
studies would give a picture of the importance of this family member in regulating 
phenotype in different cancers and could guide the choice of cancers to be targeted in 
the clinic- should specific inhibitors become available. However, in many cells of female 
origin KDM5 A, B and C can be expressed, and all four members can be expressed in 
males. Depending on which family members are expressed, gene editing can be used 
to silence the other family members both individually and consecutively if necessary. 
Thus, extensive pre-clinical testing of the importance of the individual family members in 
regulation of cell phenotype in different cancers should ideally be carried out before 
moving to the clinic.  
 
7.4.3 Use of current inhibitors  
It is not clear whether KDM5B promotes cell proliferation in SKBr3 cells or Herceptin 
resistance in BT-474 cells through its demethylase activity. While knocking in DJmjC 
KDM5B into the KO cells, could resolve this issue, comparing the effect of total KDM5B 
KO with the effect of the inhibitor KDOAM-25 (has higher potency for inhibiting KDM5B 
demethylase activity but is not completely specific for KDM5B) 254 on cell phenotype 
would also be informative. The KDM5B KO cells will lose any important functions 
governed by other domains and unrelated to the demethylase activity, and these could 
be important for the phenotypic changes seen in the KO. This should indicate whether 
the effect on increased sensitivity seen in the KO is dependent or independent of the 
demethylase activity. Moreover, to investigate whether KDM5B is the prominent KDM5 
protein in SKBr3 and/or BT474 cells, the KDM5A/C inhibitor, YUKA1 114, can be used to 
study the effects on cell proliferation, regulation of target genes and drug resistance.  
These findings can then be compared to the effects seen with the KDM5B KO and the 
pan-KDM5 inhibitor, KDOAM-25. Taken together, these investigations could provide an 
analysis of KDM5B function in the two breast cancer cell lines and the utility of the 
currently available small molecule inhibitors. Gathering information on the effects of 
silencing individual KDM5 family members in different cell types (using gene editing 
techniques) and analysing whether the effects on phenotype are attributable to, or 
independent of, the demethylase activity will be a crucial and necessary preclinical 
activity. These studies will also expand the basic knowledge relating to the regulatory 
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activity of this family of demethylases, which may relate to the potential importance of 
other domains in the proteins.    
 
7.5 Conclusion  
The results presented in this PhD thesis demonstrate a cell phenotype dependent 
function of KDM5B in HER2+ breast cancer cell lines, where KDM5B KO can result in 
either reduced proliferation in HER2+/ER- cells or increased sensitivity to Herceptin in 
HER2+/ER+ cells. Thus, it is very important to investigate whether this data will predict 
the same phenotypes in other HER2+/ER- and HER2+/ER+ breast cancer cell lines. The 
data shown in this thesis suggests that KDM5B could be a potential therapeutic target in 
HER2+ breast cancers however, patient stratification would be vital and ER positivity 
could be used as a predictive marker for response to HER2 targeted therapies. 
Therefore, it is imperative to investigate further and validate the function of KDM5B in 









































DNA sequence of U6-gRNA (PX458) and Cas9-2AGFP-pBKS 
plasmids 
 


























































Cas9-2AGFP-pBKS plasmid sequence 
ORIGIN 
        1 gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt atttttctaa atacattcaa 
       61 atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga 
      121 agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc 
      181 ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg 
      241 gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc 
      301 gccccgaaga acgttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat 
      361 tatcccgtat tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg 
      421 acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag 
      481 aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa 
      541 cgatcggagg accgaaggag ctaaccgctt ttttgcacaa catgggggat catgtaactc 
      601 gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca 
      661 cgatgcctgt agcaatggca acaacgttgc gcaaactatt aactggcgaa ctacttactc 
      721 tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc 
      781 tgcgctcggc ccttccggct ggctggttta ttgctgataa atctggagcc ggtgagcgtg 
      841 ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgt atcgtagtta 
      901 tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag 
      961 gtgcctcact gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga 
     1021 ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc 
     1081 tcatgaccaa aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa 
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     1141 agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa 
     1201 aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca actctttttc 
     1261 cgaaggtaac tggcttcagc agagcgcaga taccaaatac tgtccttcta gtgtagccgt 
     1321 agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaatcc 
     1381 tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac 
     1441 gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc acacagccca 
     1501 gcttggagcg aacgacctac accgaactga gatacctaca gcgtgagcta tgagaaagcg 
     1561 ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg gtcggaacag 
     1621 gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt cctgtcgggt 
     1681 ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg cggagcctat 
     1741 ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg ccttttgctc 
     1801 acatgttctt tcctgcgtta tcccctgatt ctgtggataa ccgtattacc gcctttgagt 
     1861 gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg agcgaggaag 
     1921 cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt cattaatgca 
     1981 gctggcacga caggtttccc gactggaaag cgggcagtga gcgcaacgca attaatgtga 
     2041 gttagctcac tcattaggca ccccaggctt tacactttat gcttccggct cgtatgttgt 
     2101 gtggaattgt gagcggataa caatttcaca caggaaacag ctatgaccat gattacgcca 
     2161 agctcgaaat taaccctcac taaagggaac aaaagctggg tacccgttac ataacttacg 
     2221 gtaaatggcc cgcctggctg accgcccaac gacccccgcc cattgacgtc aatagtaacg 
     2281 ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg 
     2341 gcagtacatc aagtgtatca tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa 
     2401 tggcccgcct ggcattgtgc ccagtacatg accttatggg actttcctac ttggcagtac 
     2461 atctacgtat tagtcatcgc tattaccatg gtcgaggtga gccccacgtt ctgcttcact 
     2521 ctccccatct cccccccctc cccaccccca attttgtatt tatttatttt ttaattattt 
     2581 tgtgcagcga tgggggcggg gggggggggg gggcgcgcgc caggcggggc ggggcggggc 
     2641 gaggggcggg gcggggcgag gcggagaggt gcggcggcag ccaatcagag cggcgcgctc 
     2701 cgaaagtttc cttttatggc gaggcggcgg cggcggcggc cctataaaaa gcgaagcgcg 
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     2761 cggcgggcgg gagtcgctgc gacgctgcct tcgccccgtg ccccgctccg ccgccgcctc 
     2821 gcgccgcccg ccccggctct gactgaccgc gttactccca caggtgagcg ggcgggacgg 
     2881 cccttctcct ccgggctgta attagctgag caagaggtaa gggtttaagg gatggttggt 
     2941 tggtggggta ttaatgttta attacctgga gcacctgcct gaaatcactt tttttcaggt 
     3001 tggaccggtg ccaccatgga ctataaggac cacgacggag actacaagga tcatgatatt 
     3061 gattacaaag acgatgacga taagatggcc ccaaagaaga agcggaaggt cggtatccac 
     3121 ggagtcccag cagccgacaa gaagtacagc atcggcctgg acatcggcac caactctgtg 
     3181 ggctgggccg tgatcaccga cgagtacaag gtgcccagca agaaattcaa ggtgctgggc 
     3241 aacaccgacc ggcacagcat caagaagaac ctgatcggag ccctgctgtt cgacagcggc 
     3301 gaaacagccg aggccacccg gctgaagaga accgccagaa gaagatacac cagacggaag 
     3361 aaccggatct gctatctgca agagatcttc agcaacgaga tggccaaggt ggacgacagc 
     3421 ttcttccaca gactggaaga gtccttcctg gtggaagagg ataagaagca cgagcggcac 
     3481 cccatcttcg gcaacatcgt ggacgaggtg gcctaccacg agaagtaccc caccatctac 
     3541 cacctgagaa agaaactggt ggacagcacc gacaaggccg acctgcggct gatctatctg 
     3601 gccctggccc acatgatcaa gttccggggc cacttcctga tcgagggcga cctgaacccc 
     3661 gacaacagcg acgtggacaa gctgttcatc cagctggtgc agacctacaa ccagctgttc 
     3721 gaggaaaacc ccatcaacgc cagcggcgtg gacgccaagg ccatcctgtc tgccagactg 
     3781 agcaagagca gacggctgga aaatctgatc gcccagctgc ccggcgagaa gaagaatggc 
     3841 ctgttcggaa acctgattgc cctgagcctg ggcctgaccc ccaacttcaa gagcaacttc 
     3901 gacctggccg aggatgccaa actgcagctg agcaaggaca cctacgacga cgacctggac 
     3961 aacctgctgg cccagatcgg cgaccagtac gccgacctgt ttctggccgc caagaacctg 
     4021 tccgacgcca tcctgctgag cgacatcctg agagtgaaca ccgagatcac caaggccccc 
     4081 ctgagcgcct ctatgatcaa gagatacgac gagcaccacc aggacctgac cctgctgaaa 
     4141 gctctcgtgc ggcagcagct gcctgagaag tacaaagaga ttttcttcga ccagagcaag 
     4201 aacggctacg ccggctacat tgacggcgga gccagccagg aagagttcta caagttcatc 
     4261 aagcccatcc tggaaaagat ggacggcacc gaggaactgc tcgtgaagct gaacagagag 
     4321 gacctgctgc ggaagcagcg gaccttcgac aacggcagca tcccccacca gatccacctg 
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     4381 ggagagctgc acgccattct gcggcggcag gaagattttt acccattcct gaaggacaac 
     4441 cgggaaaaga tcgagaagat cctgaccttc cgcatcccct actacgtggg ccctctggcc 
     4501 aggggaaaca gcagattcgc ctggatgacc agaaagagcg aggaaaccat caccccctgg 
     4561 aacttcgagg aagtggtgga caagggcgct tccgcccaga gcttcatcga gcggatgacc 
     4621 aacttcgata agaacctgcc caacgagaag gtgctgccca agcacagcct gctgtacgag 
     4681 tacttcaccg tgtataacga gctgaccaaa gtgaaatacg tgaccgaggg aatgagaaag 
     4741 cccgccttcc tgagcggcga gcagaaaaag gccatcgtgg acctgctgtt caagaccaac 
     4801 cggaaagtga ccgtgaagca gctgaaagag gactacttca agaaaatcga gtgcttcgac 
     4861 tccgtggaaa tctccggcgt ggaagatcgg ttcaacgcct ccctgggcac ataccacgat 
     4921 ctgctgaaaa ttatcaagga caaggacttc ctggacaatg aggaaaacga ggacattctg 
     4981 gaagatatcg tgctgaccct gacactgttt gaggacagag agatgatcga ggaacggctg 
     5041 aaaacctatg cccacctgtt cgacgacaaa gtgatgaagc agctgaagcg gcggagatac 
     5101 accggctggg gcaggctgag ccggaagctg atcaacggca tccgggacaa gcagtccggc 
     5161 aagacaatcc tggatttcct gaagtccgac ggcttcgcca acagaaactt catgcagctg 
     5221 atccacgacg acagcctgac ctttaaagag gacatccaga aagcccaggt gtccggccag 
     5281 ggcgatagcc tgcacgagca cattgccaat ctggccggca gccccgccat taagaagggc 
     5341 atcctgcaga cagtgaaggt ggtggacgag ctcgtgaaag tgatgggccg gcacaagccc 
     5401 gagaacatcg tgatcgaaat ggccagagag aaccagacca cccagaaggg acagaagaac 
     5461 agccgcgaga gaatgaagcg gatcgaagag ggcatcaaag agctgggcag ccagatcctg 
     5521 aaagaacacc ccgtggaaaa cacccagctg cagaacgaga agctgtacct gtactacctg 
     5581 cagaatgggc gggatatgta cgtggaccag gaactggaca tcaaccggct gtccgactac 
     5641 gatgtggacc atatcgtgcc tcagagcttt ctgaaggacg actccatcga caacaaggtg 
     5701 ctgaccagaa gcgacaagaa ccggggcaag agcgacaacg tgccctccga agaggtcgtg 
     5761 aagaagatga agaactactg gcggcagctg ctgaacgcca agctgattac ccagagaaag 
     5821 ttcgacaatc tgaccaaggc cgagagaggc ggcctgagcg aactggataa ggccggcttc 
     5881 atcaagagac agctggtgga aacccggcag atcacaaagc acgtggcaca gatcctggac 
     5941 tcccggatga acactaagta cgacgagaat gacaagctga tccgggaagt gaaagtgatc 
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     6001 accctgaagt ccaagctggt gtccgatttc cggaaggatt tccagtttta caaagtgcgc 
     6061 gagatcaaca actaccacca cgcccacgac gcctacctga acgccgtcgt gggaaccgcc 
     6121 ctgatcaaaa agtaccctaa gctggaaagc gagttcgtgt acggcgacta caaggtgtac 
     6181 gacgtgcgga agatgatcgc caagagcgag caggaaatcg gcaaggctac cgccaagtac 
     6241 ttcttctaca gcaacatcat gaactttttc aagaccgaga ttaccctggc caacggcgag 
     6301 atccggaagc ggcctctgat cgagacaaac ggcgaaaccg gggagatcgt gtgggataag 
     6361 ggccgggatt ttgccaccgt gcggaaagtg ctgagcatgc cccaagtgaa tatcgtgaaa 
     6421 aagaccgagg tgcagacagg cggcttcagc aaagagtcta tcctgcccaa gaggaacagc 
     6481 gataagctga tcgccagaaa gaaggactgg gaccctaaga agtacggcgg cttcgacagc 
     6541 cccaccgtgg cctattctgt gctggtggtg gccaaagtgg aaaagggcaa gtccaagaaa 
     6601 ctgaagagtg tgaaagagct gctggggatc accatcatgg aaagaagcag cttcgagaag 
     6661 aatcccatcg actttctgga agccaagggc tacaaagaag tgaaaaagga cctgatcatc 
     6721 aagctgccta agtactccct gttcgagctg gaaaacggcc ggaagagaat gctggcctct 
     6781 gccggcgaac tgcagaaggg aaacgaactg gccctgccct ccaaatatgt gaacttcctg 
     6841 tacctggcca gccactatga gaagctgaag ggctcccccg aggataatga gcagaaacag 
     6901 ctgtttgtgg aacagcacaa gcactacctg gacgagatca tcgagcagat cagcgagttc 
     6961 tccaagagag tgatcctggc cgacgctaat ctggacaaag tgctgtccgc ctacaacaag 
     7021 caccgggata agcccatcag agagcaggcc gagaatatca tccacctgtt taccctgacc 
     7081 aatctgggag cccctgccgc cttcaagtac tttgacacca ccatcgaccg gaagaggtac 
     7141 accagcacca aagaggtgct ggacgccacc ctgatccacc agagcatcac cggcctgtac 
     7201 gagacacgga tcgacctgtc tcagctggga ggcgacaaaa ggccggcggc cacgaaaaag 
     7261 gccggccagg caaaaaagaa aaaggaattc ggcagtggag agggcagagg aagtctgcta 
     7321 acatgcggtg acgtcgagga gaatcctggc ccagtgagca agggcgagga gctgttcacc 
     7381 ggggtggtgc ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg 
     7441 tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 
     7501 accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca ccctgaccta cggcgtgcag 
     7561 tgcttcagcc gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc 
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     7621 gaaggctacg tccaggagcg caccatcttc ttcaaggacg acggcaacta caagacccgc 
     7681 gccgaggtga agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac 
     7741 ttcaaggagg acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac 
     7801 gtctatatca tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac 
     7861 aacatcgagg acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc 
     7921 gacggccccg tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa 
     7981 gaccccaacg agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc 
     8041 actctcggca tggacgagct gtacaaggaa ttctaactag agctcgctga tcagcctcga 
     8101 ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 
     8161 tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 
     8221 tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 
     8281 gggaagagaa tagcaggcat gctggggagc ggccgccacc gcggtggagc tccaattcgc 
     8341 cctatagtga gtcgtattac aattcactgg ccgtcgtttt acaacgtcgt gactgggaaa 
     8401 accctggcgt tacccaactt aatcgccttg cagcacatcc ccctttcgcc agctggcgta 
     8461 atagcgaaga ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat 
     8521 gggacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga 
     8581 ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg 
     8641 ccacgttcgc cggctttccc cgtcaagctc taaatcgggg gctcccttta gggttccgat 
     8701 ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg 
     8761 ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 
     8821 gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt 
     8881 tataagggat tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat 





              Table 8.1: ToppGene Gene Ontology analysis of upregulated genes in SKBr3 KDM5B KO cells  
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GO:0042493 response to 
drug 





GO:0009636 response to 
toxic substance 















GO:0009611 response to 
wounding 





GO:0043207 response to 
external biotic 
stimulus 





GO:0051707 response to 
other organism 





GO:0009617 response to 
bacterium 





GO:0010243 response to 
organonitrogen 
compound 





GO:0009607 response to 
biotic stimulus 






























GO:1901698 response to 
nitrogen 
compound 






















GO:0042981 regulation of 
apoptotic 
process 







GO:0010212 response to 
ionizing 
radiation 




GO:0043067 regulation of 
programmed 
cell death 














GO:1903034 regulation of 
response to 
wounding 





GO:0014070 response to 
organic cyclic 
compound 





GO:0006873 cellular ion 
homeostasis 





GO:0051384 response to 
glucocorticoid 
















Table 8.2: Table ToppGene Gene Ontology analysis of downregulated genes in SKBr3 KDM5B KO cells  







































GO:0034340 response to 
type I 
interferon 













GO:0045069 regulation of 
viral genome 
replication 






viral life cycle 




















GO:0019079 viral genome 
replication 




GO:0009615 response to 
virus 





GO:0035455 response to 
interferon-
alpha 





















GO:0034341 response to 
interferon-
gamma 














GO:1903900 regulation of 
viral life cycle 




GO:0050792 regulation of 
viral process 








































GO:0032606 type I 
interferon 
production 




GO:0034097 response to 
cytokine 






GO:0060700 regulation of 
ribonuclease 
activity 




GO:0035456 response to 
interferon-
beta 





























GO:0045646 regulation of 
erythrocyte 
differentiation 
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